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Abstract
The piperidine moiety is found in a vast number of bioactive natural products as
well as numerous marketed drugs and is therefore an interesting target for synthetic
modifications. Synthetic piperidines currently in the clinic are predominantly limited
to 1,4-disubstitution on the piperidine ring, hence it is important to develop strategies
to access new drug candidates with diverse substitution configurations on the ring. For
this purpose, the aza-Michael reaction can be used as an atom-efficient method to access
biologically important piperidines.
An initial study into the utility of divinyl ketone as the substrate for a double aza-
Michael addition has led to the development of a facile, manganese dioxide mediated,
one-pot oxidation-cyclisation method for the preparation of a diverse range of N -
substituted 4-piperidones in moderate to good yield over two steps. Substituted divinyl
ketones were prepared from their corresponding alcohols and used in a subsequent aza-
Michael cyclisation with benzylamine for the synthesis of racemic, aromatically and
aliphatically 2-substituted N -benzylic 4-piperidones. Employing S -α-phenylethylamine
as the primary amine substrate in this protocol afforded separable, diastereomeric 4-
piperidone products with resolved stereochemistry in position 2 on the piperidine ring.
The suitability of such 2-substituted 4-piperidones for the synthesis of biologically
relevant compounds was demonstrated by employing these building blocks in the
synthesis of analogues of the acetylcholinesterase inhibiting drug donepezil. Access
to the important 4-formyl piperidines was accomplished through a concise and high
yielding route via a Wittig reaction followed by acidic hydrolysis to the desired
aldehydes. Further synthetic steps afforded the final donepezil analogues as inseparable
diastereomeric mixtures with resolved stereochemistry in position two on the piperidine
ring. Evaluating the acetylcholinesterase inhibiting potency of these analogues compared
to donepezil provided information about the sensitivity of donepezil’s piperidine moiety
towards stereoselective substitution in position two on the ring.
A detailed investigation of the manganese dioxide mediated side reaction, which is
observed in the one-pot oxidation-cyclisation reaction, led to the finding that under the
same reaction conditions the oxidation of primary benzylic amines proceeds smoothly
to the corresponding amides. The interconversion of all intermediates in this process
was demonstrated experimentally and the vital role of both manganese dioxide and the
molecular sieves explored. A range of benzylic amides was prepared in good to excellent
yield using the developed methodology.
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Introduction
1.1 Introduction to Biologically Important Piperidines
The piperidine moiety 1 (Figure 1.1) is found in a vast number of natural products and
is often associated with their distinct pharmacological or toxic properties.1 Naturally
occurring piperidine compounds constitute an important group of alkaloids originating





Figure 1.1: The piperidine structural motif.
Due to their bioactive nature, many natural products have the potential to function as
templates for synthetically prepared analogues for the development of new pharmaceu-
ticals.4,5
Natural Piperidine Products
Examples from the pool of natural piperidines originating from plants, illustrated in
Figure 1.2, demonstrate the high pharmacological potential of the simple piperidine
1
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ring structure. The bioactive alkaloid piperine 2 was isolated from black pepper (Piper
nigrum) by Hans Christian Ørsted in 1820. The French chemist Auguste Cahours further
investigated piperine and found that upon treatment with aqueous alkali, a basic product
was formed. Due to its origin, he named this unknown compound piperidine. The cyclic



















Figure 1.2: Biologically active piperidine alkaloids originating from plants.
Today it is known that the piperidine containing alkaloid piperine 2 possesses several
pharmacologically important properties. Not only is it responsible for the spiciness
of black pepper, but it has been shown to positively influence the bioavailability
of many other substances, for example curcumin,7 theophylline and propranolol.8
In vitro and in vivo studies have shown that piperine 2 inhibits a range of drug-
metabolizing enzymes, such as the arylhydrocarbon hydroxylase and the ethylmorphine-
N -demethylase9 and enhances the activity of multiple enzymes involved in digestive
processes, such as trypsin, lipases and disaccharidases.10,11 Another pharmaceutically
interesting piperidine alkaloid is lobeline 3 (Figure 1.2), which is isolated from the Indian
Tabacco (Lobelia inflata).12 Due to its stimulating effects on the respiratory system it
has been successfully used to support the treatment of conditions including bronchitis,
asthma and pneumonia.13 Lobeline acts as an antagonist at nicotinic acetylcholine
receptors in the central nervous system (CNS) and as this ultimately results in lowered
concentrations of dopamine in the synaptic cleft, it has also been investigated for the
treatment of psychostimulant abuse.14
Coniine 4 (Figure 1.2), a simple piperidine molecule and potent neurotoxin, is the chief
alkaloid isolated from hemlock (Conium maculatum). It can cause death by respiratory
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failure and has been used as a poison for centuries.15 (-)-Spectaline 5, an alkaloid from
Cassia leptophylla, bears a more complex substitution pattern on the piperidine ring,
possessing stereocentres at position 2, 5 and 6. This natural product has been found
to exhibit anticancer potential based on a yeast assay16 and antinociceptive effects in
mice.17 The major alkaloid found in the betel nut (Areca catechu) is arecoline 6 and
is responsible for the stimulating and addictive effects evoked when chewing the nut
and leaves of this plant.18 The tradition of chewing parts of the betel nut has spread
widely across the globe and has been associated with various types or pharyngeal and
oral cancer19 and neurotoxicity via the increased formation of reactive oxygen species.20
Pharmaceuticals Bearing a Piperidine Substructure
In addition to being encountered in naturally occurring compounds, the piperidine ring
is also an important substructure found in many pharmaceuticals (Figure 1.3). The
piperidine moiety is one of the most common nitrogen heterocycles in synthetic drugs
and is often relevant for their pharmacokinetic and pharmacodynamic profile.21
Piperidine containing pharmaceuticals cover a wide range of indications and are currently
used extensively in the clinic. Most of these drugs are limited to a simple 1,4-
disubstitution on the piperidine ring, for example the antidiarrheal loperamide 7. This
drug is a strong µ-receptor agonist, acting exclusively peripherally,22 and has been listed
on the WHO Model List of Essential Medicines.23 Sertindole 8, risperidone 9 as well
as its active metabolite 10 are classified as atypical antipsychotics and are used in
the treatment of schizophrenia and bipolar disorders with the therapeutic advantage of
causing less extrapyramidal side effects than other available drugs.24
Another widely used piperidine containing pharmaceutical is raloxifene 11, a selective
estrogen receptor modulator. By acting as an estrogen receptor agonist in bones it re-
duces the risk of fractures in postmenopausal women with osteoporosis.25 Simultaneously
raloxifene acts as an estrogen receptor antagonist in the uterus and breast and is therefore
an important drug in the prevention of breast cancer in postmenopausal women.26
Donepezil 12, used in the treatment of Alzheimer’s disease, is an acetylcholinesterase
inhibitor which prevents the degradation of the important neurotransmitter acetylcholine







































Figure 1.3: A selection of important pharmaceutical agents bearing the piperidine
ring substructure.
in the brain.27 The selective histamine H1 receptor antagonist fexofenadine 13 is used
for the treatment of allergic symptoms, such as allergic rhinitis and idiopathic urticaria.
As it does not cross the brain-barrier like most first-generation antihistamines, it causes
reduced drowsiness in patients.28
Modifications on the Piperidine Ring
Another example of a drug which possesses the classical 1,4-disubstitution pattern on
the piperidine ring is the selective µ-receptor agonist fentanyl 14 (Figure 1.4). This
drug is widely used for pain management and as anaesthetic and is about 100 times
more potent than morphine.29 Despite the fact that fentanyl and other µ-opiates are
used extensively in the clinic and their pharmacological properties are well explored,
it is not fully understood which of their structural features are responsible for the
ligand recognition that results in such high-affinity binding. Until recently30 the crystal
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structure of the complex membrane-bound µ-receptor was not available and models on
a molecular level were difficult to establish.
During structure-activity relationship (SAR) studies it has been shown that substitution
on the fentanyl piperidine ring can have a significant impact on the drug’s activity
profile.31–33 Analogues possessing an additional methoxymethyl group 15 or a methyl
ester 16 in position 433 as well as analogues bearing a methyl group in position 3

















14 15 16 17
Figure 1.4: Analogues of fentanyl 14.
In vivo studies in mice and rats have shown that the four possible methyl substituted
stereoisomers 17-20 exhibit different activities (Figure 1.5). 3R,4S -cis-3-Methylfentanyl
17 has been found to be approximately 20 times more potent than fentanyl, while its
enantiomer 18 is approximately 5 times less potent.31,32
In an attempt to explain the different activities of these close fentanyl analogues, Dosen-
Micovic34 conducted a detailed molecular modelling study. The binding pocket for
fentanyl 14 within the receptor was shown to lie close to the extracellular region and
between two transmembrane helices (TM3 and TM7) (Figure 1.6). The fentanyl-ligand’s
N -phenylpropanamide group protrudes towards the extracellular side of this pocket
while the N -phenethyl group is buried inside the cavity. Fentanyl is protonated and
maintains a stable salt-bridge to an aspartate residue in close proximity. While the




















Figure 1.5: Fentanyl 14 and its 3-methyl-substituted analogues 17-20.
geometries of the methyl-substituted analogues 18-20 are similar to the best fentanyl
orientation, the position and orientation of the more potent analogue 17 is different.
This analogue occupies the same binding pocket and maintains the salt bridge as the
other isomers, but is rotated and shifted in a way that the methyl group points into
a small hydrophobic pocket of the cavity (Figure 1.6). Through this difference in
overall orientation it connects the surrounding transmembrane helices TM3 and TM6
and reaches a closer proximity to TM7, ultimately resulting in a higher binding affinity.34
Figure 1.6: On the Left: Fentanyl 14 in its best orientation in the binding pocket.
On the Right: 3R,4S -analogue 17 in the binding pocket.
This example demonstrates how a small additional substituent on the 1,4-disubstituted
piperidine moiety of a drug can have a significant influence on binding behaviour and
activity. SAR studies of this type are rarely reported in the literature, possibly due
to the increased number of synthetic steps and the complication of purification and
separation caused by the introduction of additional stereocentres.
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1.2 Methods for the Synthesis of 1,2,4-Trisubstituted
Piperidines
Since substituted piperidines ring systems are found in a diverse range of bioactive
natural products, the pharmaceutical industry has developed great interest in obtaining
such compounds in a stereoselective manner. Currently, the N (1),C (4)-disubstitution
pattern prevails amongst drugs in the clinic and therefore the easy access to steroselec-
tively substituted piperidines, such as N (1),C (2),C (4)-trisubstituted building blocks, is
highly desirable in order to gain further structure-activity related information on existing
and new pharmaceuticals.
Many different approaches towards the synthesis of a multi-substituted piperidine core
exist, and review literature illustrates the current interest in this important area of
organic chemistry.35–40 Out of this large amount of different strategies available for the
synthesis of substituted piperidines, examples specifically for the stereoselective synthesis
of 1,2,4-trisubstituted piperidines will be presented in the following section, emphasising
the key steps of these routes.
Nucleophilic 1,4-Addition to Dihydropyridones
Shintani reported an enantioselective preparation of 2-aryl-substituted 4-piperidones
via rhodium catalysis (Scheme 1.1).41 Nucleophilic 1,4-addition of aromatic organozinc
reagents 22 to 2,3-dihydro-4-pyridone 21 utilising [RhCl(R-binap)]2 as a catalyst leads
to the target compounds. The reaction proceeds under mild conditions and furnishes
2-substituted 4-piperidones 23 with excellent enantioselectivity (>99% ee) and in high
yields (87-100%).










i)   Ar= Ph, 4-Ph-C6H4, 4-F-C6H4






Scheme 1.1: Reaction conditions: i) 22 (1.5 equiv.), 3 mol% [RhCl(R-binap)]2, THF,
20 ◦C, 2 h, then H2O quench; ii) 22 (3.0 equiv.), 6 mol% [RhCl(R-binap)]2, THF, 20◦C, 2 h, then H2O quench.
This protocol was applied to the synthesis of piperidone 26, an important interme-
diate for the further synthesis of potent tachykinin NK1 receptor antagonist 2742
(Scheme 1.2). In the first step, the rhodium catalysed 1,4-addition yielded desired
2-aryl substituted 25, which was hydrogenated over a palladium catalyst to remove
the benzyloxycarbonyl moiety and obtain building block R-26 in high yield and























21 24 25 26
27
Scheme 1.2: Reaction conditions: i) 8 mol% [RhCl(R-binap)]2, THF, 20
◦C, 9 h, then
H2O quench; ii) 9 mol% Pd/C, H2, 1 atm, MeOH, 20
◦C, 4 h.
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Nucleophilic Addition to N -Acylpyridinium Salts
Starting from simple, commercially available 4-methoxypyridine 28, Comins achieved
the diastereoselective synthesis of 2-aryl substituted dihydropyridones (Scheme 1.3).43
Chiral chloroformate 32, derived from (-)-menthol, was utilised to generate optically
active 1-acylpyridinium salt 29 in situ. A subsequent Grignard addition and aqueous
workup provided the diastereomeric dihydropyridone products 30 and 31 in a combined



















28 29 30 31
32
33
Scheme 1.3: Reaction conditions: i) 32, toluene, -23 ◦C, 15 min; ii) PhMgCl,
toluene/THF (24:1), -78 ◦C, 1 h; iii) 10% HCl (aqu.), 23 ◦C, 10 min.
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A similar route towards the diastereoselective synthesis of 2-substituted 4-piperidones
via nucleophilic addition to an N -acylpyridinium salt was described by Watson
(Scheme 1.4).44 The origin of the diastereoselectivity in this synthetic approach is due





























Figure 1.7: N -Acylpiperidines and their resonance hybrids.
Resonance hybrids 34 and 35 exist due to the delocalisation of the nitrogen’s lone
pair of electrons. The result is a pseudo-allylic system which causes an A1,3-strain
on the C2 carbon of the piperidine ring. If a substituent in position 2 on the ring
is large enough, it is forced into an axial position (37 and 38) due to minimized steric
hindrance. As the conformation where the substituent adopts an equatorial position (36
and 39) is disfavoured because of steric interference, it becomes possible to influence the
diastereoselectivity of the reaction.
In the first step of Watson’s synthesis,44 4-methoxypyridine 28 is reacted with phenyl
chloroformate to give an N -acylpyridinium salt as the intermediate (Scheme 1.4).
The Grignard reagent is then added to position two on the ring and generates the
unstable intermediate 40. Acidic aqueous workup yields dihydropyridone 4145 which is
subsequently subjected to a deprotection and reprotection step to obtain Boc protected
dihydropyridone 42 in a yield of 41-73% over three steps. Reduction of 42 to 2-
substituted piperidone 43 is followed by a Wittig olefination to provide styrene 44
in high overall yield (89-95%). Reduction of the double bond and deprotection on the
nitrogen afforded piperidine 45 in good diastereoselectivity (trans:cis 88:1 for 45a, 4:1
for 45b and 18:1 for 45c) in yields of 97-100%.

























               
a:  R= allyl     
b:  R= i-Pr        








Scheme 1.4: Reaction conditions: i) PhOC(O)Cl, THF, -20 ◦C, 15 min; ii) RMgCl,
-78 ◦C, 1 h; iii) 10% HCl (aqu.), 23 ◦C, 10 min; iv) NaOMe, MeOH, 23 ◦C, 2 h;
v) Boc2O, DMAP, MeCN, 23
◦C, 12 h; vi) Zn, HOAc, 50 ◦C, 12 h; vii) t-BuOK,
PhCH2P(Ph)3Cl, THF, 23
◦C, 24 h; viii) Li, NH3, THF, -78
◦C, to -28 ◦C, 1 h; ix)
75% TFA/CH2Cl2, 2 h.
Imino Diels-Alder Reactions
The imino Diels-Alder reaction has been frequently employed as a convenient approach
to access substituted piperidines in an asymmetric manner.46,47 Typically, an electron
rich diene, for example Danishefsky’s diene (1-methoxy-3-trimethylsiloxy-1,3-butadiene),
reacts with an electrophilic imine and affords the desired piperidone with good
enantioselectivity.
Manchen˜o applied this methodolody to the synthesis of N -sulfonyl 2,3-dihydropyridone
48 as part of the formal synthesis of the quinolizidine alkaloid (+)-lasubine I 49
(Scheme 1.5).48 Danishefsky’s diene 46, catalysed by copper-fesulphos bromo dimer
catalyst 50,49 reacts with N -tosyl aldimine 47 to afford 2R-aryl-substituted piperidone
48 in good yield (71%) and excellent enantioselectivity (94% ee). Dihydropyridone 48
is then converted to (+)-lasubine I 49 in a further 5 steps.





























46 47 48 49
50
Scheme 1.5: Reaction conditions: i) 5.1 mol% 50, 10 mol% AgClO4, then TFA,
CH2Cl2, -20
◦C, 12 h.
Bailey also explored the aza-Diels-Alder reaction for the synthesis of 2,4-substituted
piperidines (Scheme 1.6).50 Imine 52, a dienophile with a tethered chiral auxiliary, was













52 53 54 55
Scheme 1.6: Reaction conditions: i) DMF/TFA (6:1), H2O (cat.), rt, 30 h; ii) H2,
3% Pt-C, EtOAc, rt, 16 h; iii) H2, Pd(OH)2, EtOH, rt, 8 h.
A catalytic amount of water was found to greatly improve the yield of the reaction
and suggested that there is hydrogen bond formation taking place between imine 52
and water (Figure 1.8). This cyclic intermediate promotes the reaction, as it helps to
stabilise the 6-membered transition state of the subsequent aza-Diels-Alder reaction. In
their model, the use of R-phenylethylamine as chiral auxiliary leads to an endo attack
of diene 51 on the si face of imine 52, resulting in a major product bearing S -chirality
in position 2 on the ring.
























Figure 1.8: Water coordinating chiral imine intermediate 52 leading to an endo
product bearing S -chirality in position 2 on the ring.
Chiral imine 52 reacts with diene 51 to give 2S -53 as the major product and 2R-53
as the minor product (2S :2R 81:19). The diastereomers can be conveniently separated
by flash chromatography and when 2S -53 is subjected to reduction over a platinum
catalyst, cis disubstituted 54 is obtained as the major product (cis:trans 88:12). In
a second reduction step removal of the chiral auxiliary is achieved using Pearlman’s
catalyst to give deprotected piperidine 55 as final product in 72% yield.
Aza-Prins-Type Reactions
Murty’s approach shows an example for the stereoselective preparation of 2,4-substituted
piperidines via an aza-Prins type reaction (Scheme 1.7).51 Reacting N -tosyl protected
amine 56 in the presence of bismuth(III) chloride with various aliphatic or aromatic
epoxides 57 delivers N -tosyl protected 2-substituted 4-chloropiperidines 58 in high yields









R= Ph, Me, 4-MeO-C6H4, i-Pr
56 57 58
Scheme 1.7: Reaction conditions: i) BiCl3, CH2Cl2, 0
◦C-rt, 30 min.
This aza-Prins cyclisation reaction is promoted by bismuth(III) chloride, which is acting
as a Lewis acid and facilitates the ring-opening of the epoxide substrate 59 to 60
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(Figure 1.9). A hydride shift gives intermediate 61 which is subsequently attacked by
nucleophilic amine 56. The resulting iminium ion 64 is stabilised by the tosyl protecting
group and cyclises to piperidine 66. The addition of chloride to the carbocation results





































64 65 66 67
Figure 1.9: Reaction pathway for the aza-Prins type reaction.
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An aza-Prins type cyclisation reaction can furthermore be employed for the construction
of heterotricycles, such as shown in the protocol described by Reddy (Scheme 1.8).52
Benzo[f ]isoquinoline products 72 are dopamine congeners53 and can be decorated with
aromatic or aliphatic substituents adjacent to the nitrogen on the ring. In this reaction
the Brønsted acid p-toluenesulfonic acid and the Lewis acid Sc(OTf)3 act synerigistically
and achieve an initial addition of the tosyl-protected amine substrate 68 to aldehyde 69,
followed by the formation of iminium intermediate 71. The nucleophilic aryl-moiety of
71 then attacks the resulting carbocation equatorially and thereby furnishes exclusively
the trans-diastereomeric product 72. This aza-Prins/Friedel-Crafts reaction proceeds
with good yield (75-88%) and allows easy access to potential dopamine analogues 73





































Scheme 1.8: Reaction conditions: i) TsOH, Sc(OTf)3, CH2Cl2, 80
◦C, 4-8 h; ii)
Li/naphthalene, THF, 40 ◦C, 30 min.
Rutjes developed a protocol for the synthesis of 2,4-disubstituted pipecolic acid
derivative 80, using non-natural amino acids as starting material (Scheme 1.9).54
Enantiopure amino acid derivatives such as 74 are prepared using enzymatic resolution of
the corresponding amino acid amides and subsequent protection. In the presence of the
Lewis acid SnCl4 and 1,3,5-trioxane, a source of C1, N -acyliminium 77 is generated. This
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intermediate cyclises readily to give secondary carbocation 78, which can be trapped by
chloride from the less hindered equatorial position to yield the trans product. Another
possibility is that the ester group stabilises the positive charge and leads to the formation
of dioxycarbenium ion intermediate 79, which can be further hydrolysed during workup
to yield the cis product. In this reaction, the 4-hydroxy-cis-isomer 76 is obtained as






























Scheme 1.9: Reaction conditions: i) 1,3,5-trioxane, SnCl4, CH2Cl2, rt, 20 h.
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1.3 The Aza-Michael Addition for the Construction of
Substituted Piperidines
The Aza-Michael Reaction
The classical carbon Michael addition involves the base-catalysed attack of a nucleophilic
enolate (Michael donor) to an activated, α,β-unsaturated carbonyl compound (Michael
acceptor).55 An example therefore is the reaction of ethyl acetoacetate 81, a Michael
donor, with methyl acrylate 84, a Michael acceptor (Figure 1.10).55 Upon deprotonation
of acetoacetate 81, a nucleophilic enolate anion is formed. This anion reacts with the
double bond of acrylate 84 and forms a new carbon-carbon bond. The carbonyl group
of the Michael acceptor stabilises the resulting anion 85 until protonation occurs. The
addition of enolate anion 81 to the alkene is the rate determining step. According to


































Figure 1.10: Mechanism for the addition of ethyl acetoacetate to methyl acrylate.55
If the nucleophile in the reaction is not a carbanion, but a heteroatom, the reaction is
called a hetero-Michael addition (Scheme 1.10). Those heteroatom-nucleophiles, such
as amines,39,56 thiols and alcohols57 can react with activated electrophilic olefins in a
Michael-like manner. As it is the case in the carbon-Michael addition, it is important
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that the alkene bears an electron-withdrawing substituent in order to facilitate the
nucleophilic attack on the β-carbon of the Michael acceptor. If the nucleophile is a




EWG= CO2R, C(O)NR2, C(O)R, CN, SO2R, P(O)R2
Nu= NHR, NR2, PR2, OR, SR (R= Alk, Ar)
87 88 89
Scheme 1.10: Schematic depiction of a hetero-Michael addition.56
Sokoloff and Latschinoff 58 were the first to describe such a reaction when they observed
the addition of ammonia 91 to mesityl oxide 90 (Scheme 1.11). The aza-Michael addition
is a powerful tool for the formation of new C-N bonds and widely used for accessing






Scheme 1.11: Formation of diacetonamine 92.
Since amines are both nucleophilic and basic, there is in general no need for additional
base catalysis to achieve the addition to an activated olefin. The higher the
nucleophilicity of the amine and the more electrophilic and sterically accessible the
Michael acceptor, the more efficient the reaction will be. Secondary amines, especially
if they are cyclic, are more nucleophilic and therefore react readily and in high yield
with simple Michael acceptors. Conversely, primary amines are less reactive towards
nucleophilic attack and often require harsher reaction conditions, such as increased
temperatures and long reaction times.56
The choice of solvent for a Michael reaction depends on the solubility of the reagents
and the chemical sensitivity of other functional groups present. In general, polar protic
solvents including methanol, ethanol, and water and polar aprotic solvents including
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acetonitrile and dichloromethane are preferred. These solvents can stabilise the charged
reaction intermediates and in the case of protic solvents also facilitate proton transfer.55
In water, an aliphatic, secondary amine such as piperidine 93 reacts with ethyl acrylate
94 without the need for any further catalyst and affords addition product 95 in high
yield (85%) (Scheme 1.12),62 whereas a primary amine substrate like benzylamine 96
gives a mixture of mono- and di-substituted products 97 and 98 in low yield (20%)
when reacting with methyl acrylate Michael acceptor 94 (Scheme 1.13).63 This contrast
in reactivity of piperidine and benzylamine towards an activated Michael acceptor can be
explained by their differences in nucleophilicity. A secondary amine, such as piperidine
is more nucleophilic in water than benzylamine, hence reacting with a Michael acceptor









R=  OEt     i)
       OMe   ii)
93 94 95












96 94 97 98
Scheme 1.13: Reaction conditions: i) H2O, rt, 6 h, 20% (97:98 35:65); ii) MeCN, rt,
48 h, 70% (97:98 100:0).
Although the addition of benzylamine 96 to methyl acrylate 94 in water is low yielding,
these conditions promote the mono-subsituted product 97 to ungergo a second aza-
Michael addition, therefore forming disubstituted product 98 as the major product.
Acetonitrile facilitates the addition of benzylamine 96 to the Michael acceptor and
increases the yield to 70%, but gives exclusively the mono-substituted product 97
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(Scheme 1.13).65 On the contrary, piperidine 93 is less reactive in acetonitrile and gives
95 in only 40% yield (Scheme 1.12).65 These observations suggest that using acetonitrile
as the solvent promotes the reaction of a primary amine with an acitivated Michael
acceptor, but is less suitable for aza-Michael additions with secondary amine substrates.
Less reactive aza-Michael substrates can be activated using a range of catalysts.38,66
Catalysts enhance either the nucleophilicity of the amine or the electrophilicity of the
Michael acceptor. In cases where sterically hindered, α or β-substituted olefins or
less reactive primary amines are involved, Lewis acid catalysts have been successfully
employed. Lewis acids such as copper and nickel salts, triflates67 and transition and
main-group metal chlorides63,66,68 have been shown to improve the yields for various aza-
Michael reactions (Scheme 1.14, Table 1.1). Commonly, 5-20 mol%56 of these catalysts
are used to accelerate the reaction by coordination to the carbonyl function of the











Scheme 1.14: Lewis-acid catalysed conjugate additions. Reagents and conditions: i)
various.
Table 1.1: Lewis-acid catalysed conjugate addition of various aliphatic amines 99.
Entry Catalyst R3 EWG Amine 99 Solvent Yield of 101 (%)
1 CdCl2
a H CO2Et BnNH2 CH2Cl2 93
68
2 CdCl2
a H CO2Et BnCH2NH2 CH2Cl2 87
68
3 - Me CO2Et BnNH2 THF 0
67
4 Yb(OTf)3
b Me CO2Et BnNH2 THF 92
67
5 Yb(OTf)3
b Me CO2Et pyrrolidine THF 95
67
6 InCl3
a Me CO2Me BnNH2 H2O 70
c , 63
7 InCl3
a Me CO2Me Me2NH H2O 85
63
a 20 mol% of catalyst used.
b 10 mol% of catalyst used.
c Ratio of mono-substituted to disubstituted product 33:67.
Many more catalytic systems, such as Brønsted acids,57 silica gel69 and lipases70 have
been developed for enhancing the reactivity of the aza-Michael components and it should
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be noted that their application can be highly specific. However, the results obtained
depend on the steric properties of the reactants as well as the solvent system and other
reaction conditions.
Intramolecular Aza-Michael Additions
An asymmetric synthesis of 4-oxo-L-pipecolic acid 106a, starting from L-aspartic acid,
has been developed by Golubev (Scheme 1.15).71 The uncommon amino acid 106a is a
structural component of the cyclic peptide virginiamycin S1 which has been shown to
possess antibiotic properties.72 Protected amino acid 102 was prepared by the reaction
of L-aspartic acid with hexafluoroacetone (HFA). Acid chloride formation yields 103
and is followed by Stille coupling using vinyltrimethyltin and a palladium catalyst to
give enone 104a. A Lewis acid catalysed intramolecular aza-Michael addition leads to
the formation of protected piperidone 105a in a yield of 50-55%. 4-Oxo-L-pipecolic acid







































R=    H     a   ii)
         Me   b  iii)
102 103 104a,b
105a,b 106a
Scheme 1.15: Reaction conditions: i) SOCl2, reflux; ii) CH2−CH−SnMe3,
PhCH2Pd(PPh3)2Cl, dimethoxyethane; iii) Me-CH=CH-Sn(n-Bu)3, Pd2(DBA)3,
toluene; iv) BF3 ·OEt2, benzene, reflux; v) H2O/i -PrOH.
When trans-methyl-substituted enone 104b is subjected to the same aza-Michael
addition conditions, the cyclisation yields 30% of trans-6-methyl-4-oxo-L-pipecolic acid
derivative 105b. According to their observations, no Michael products were formed when
dimethyl, methoxycarbonyl or phenyl substituted enones were reacted under similar
conditions. It seems plausible that the increased steric hindrance at these substituted
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enones combined with their reduced electrophilicity make them less active towards an
intramolecular nucleophilic addition, thereby not giving the desired cyclisation products
under the tested reaction conditions.
Due to the interesting biological properties of Diospongins,73 a tetrahydropyran-derived
class of natural products isolated from Dioscorea spongiosa, Chandrasekhar developed
an asymmetric route towards an unnatural, piperidin-based analogue of a diospongin,
namely aza-(-)-diospongin A 110 (Scheme 1.16).74 Amino alcohol 107 is prepared in
6 steps and used as the starting point for the synthesis. Employing Grubbs catalyst
111, enone product 109 is prepared by cross-metathesis of 107 with phenyl vinyl ketone
108. In the final step, a one-pot Boc-group deprotection and intramolecular aza-Michael


























Scheme 1.16: Reaction conditions: i) 20 mol% 111, CH2Cl2, rt, 1 h; ii) TFA, CH2Cl2,
0 ◦C, 5 h.
Exploring the synthetic versatility of the new sulfone building block 112, Barco devel-
oped a route towards 2-substituted 4-piperidones, which makes use of an intramolecular
tandem Michael reaction (Scheme 1.17).75 Building block 112 possesses a stabilised
ylide moiety on one side of the molecule and a sulfone functionality on the other and
can be conveniently prepared in three steps. The reaction of 112 with aldehyde 113
proceeds smoothly to yield enone 114.

































Scheme 1.17: Reaction conditions: i) heating in benzene or toluene for varying
reaction times (3-12 h); ii) THF, 25 ◦C, 15-20 h.
Barco demonstrated that upon reaction with benzylamine 115, racemic piperidone 118
can be accessed in yields of 50-76%. In this step the initial Michael adduct 116 is
formed, followed by basic elimination of p-toluenesulfinic acid in order to generate a
double bond which can act as a new Michael acceptor (117). Reaction of 114 with
chiral S -(-)-phenylethylamine as the nucleophilic partner under the same conditions
affords a separable mixture of diastereomers 119 and 120 in a 3:1 ratio and a combined
yield of 70% (Scheme 1.18). The major diastereomer 119 was subjected to two reductive



















Scheme 1.18: Reaction conditions: i) S -(-)-phenylethylamine, THF, 25 ◦C, 15-20 h.
Chapter 1. Introduction 24
An interesting example for an organocatalysed intramolecular aza-Michael reaction is
the addition of enone carbamates for the enantioselective synthesis of functionalized















Scheme 1.19: Reaction conditions: i) 20 mol% 124, TFA, THF, 25 ◦C, 8-120 h.
Employing chiral, Cinchona-derived catalyst 124 in combination with the Brønsted
acid TFA, a highly efficient and stereocontrolled conversion of enone carbamates 122 to
piperidines 123 has been developed (Scheme 1.19, Table 1.2). Alkyl and aryl-substitued
enone substrates 122 react to corresponding 2R-substituted piperidine products 123 in
yields of 75-95% and excellent optical purity (ee 96-98%). The reaction time for alkyl
substituted enone starting materials 122a and b is 8-10 h, whereas aryl substituted
enones 122c and d have prolonged reaction times of 24 and 120 h respectively, which can
be explained by steric hindrance and decreased electrophilicity of the Michael acceptor
moiety (Table 1.2). Using the highly electron-enriched para-methoxy-phenyl substituted
enone 122e as substrate, piperidine 123e is only obtained in traces after a reaction time
of 5 days.
Table 1.2: Organocatalysed asymmetric synthesis of piperidines 123.
Entry Substrate R Product t (h) Yield (%) Ee (%)a
1 122a Me 123a 8 95 98
2 122b Et 123b 10 94 96
3 122c Ph 123c 24 95 96
4 122d 4-Me-C6H4 123d 120 75 96
5 122e 4-MeO-C6H4 123e 120 trace -
a Determined by chiral HPLC.
In the presence of TFA, catalyst 124 and enone 122 form iminium intermediate 125,
which gives rise to two possible transition states, 125a and 125b (Figure 1.11). Tran-
sition state 125a is preferred due to decreased steric hindrance, therefore nucleophilic
attack of the Michael donor carbamate on the iminium moiety occurs almost exclusively
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Re face attack favoured Si face attack unfavoured
125a 125b
Figure 1.11: Transition states of iminium intermediate 125.
For the construction of similar 2-substituted piperidine building blocks, Carlson also
made use of a chiral amine catalyst for the promotion of an intramolecular aza-Michael
cyclisation (Scheme 1.20).77 In this case, the starting material is enal carbamate 126
and when Jørgensen’s trifluoromethyl-aryl derivative 13178 is added, the intramolecular
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Scheme 1.20: Reaction conditions: i) 20 mol% 131, MeOH/dichloroethane 1:1,
-25 ◦C, 2-3 d; ii) NaBH4, 0
◦C, 2 h; iii) 127a, MeMgBr, Et2O/THF, -78
◦C to rt, 4 h;
iv) Dess-Martin periodane (DMP), NaHCO3, CH2Cl2, 4 h; v) 10% Pd/C, H2, EtOAc,
2 h.
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Due to stability issues, aldehyde 127 is immediately converted to the corresponding
stable alcohol 128. With this protocol, 2R-substituted piperidine 128a is obtained in a
yield of 70% and an ee of 95%, whereas the analogue with a dimethyl-substitution 128b
is prepared in a yield of 63% and an ee of 95%. Aldehyde intermediate 127a can be
further used for the synthesis of the alkaloid pelletierine 130, which is achieved via a
Grignard addition to furnish diastereomeric alcohols 129, followed by an oxidation and
deprotection step.
During their effort to prepare tricyclic guadinium compound 134 as building block for
the total synthesis of the natural product cylindrospermin, McAlpine and Armstrong
utilised an intramolecular aza-Michael addition as the key reaction for the formation
of the important precursor 133 (Scheme 1.21).79 Chiral enone 132 was prepared in
11 steps from a commercially available derivative of aspartic acid and then refluxed in
benzene with catalytic tosylic acid to give the highly-substituted piperidine 133 as a
















Scheme 1.21: Reaction conditions: i) cat. tosylic acid, benzene, reflux.
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Ying developed a protocol for the stereoselective synthesis of 2,6-disubstituted piperidines
136 and 137 via an intramolecular aza-Michael addition to access both of (+)-myrtine
138 and (-)-epimyrtine 139 (Scheme 1.22).80 Alcohol 135 is oxidised and the crude
ketone subjected to an amine-catalysed Michael addition in a separate step. When
the conjugate Michael acceptor moiety is activated by the addition of 20 mol% of the
pyrrolidine derivative S -140, piperidine products 136 and 137 are obtained in high































Scheme 1.22: Reaction conditions: i) MnO2, CH2Cl2, 25
◦C, 3 h; ii) 20 mol% 140,
CH2Cl2, 0
◦C, 7-10 h.
Utilising S -140, in all cases cis piperidine 137 is obtained as the major product.
Reacting the precursor for the natural products 135a in the presence of R-140, gives
trans piperidine 136a as the major product, however, the observed diastereoselectivity
is considerably lower (Table 1.3, entry 1).
Table 1.3: Organocatalysed formation of piperidines 136 and 137.
Entry R Yield dr (136:137) Catalyst
1 Me a 90% 1:15 S -140
75% 2:1 R-140
2 CH2OBn b 91% 1:11 S -140
3 i -Pr c 78% 1:10 S -140
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For the synthesis of 2-substituted piperidines 142 and 143, Fustero explored the utility
of N -sulfinyl enone 141 as starting material for an intramolecular aza-Michael addition
(Scheme 1.23).60 The N -sulfinyl amine moiety of 141 can function as both nitrogen-
centred nucleophilic Michael donor and chiral auxiliary. The influence of different bases,
solvents and temperatures on stereoselectivity and yield were investigated and it was
found that 2R-piperidine 143 can be obtained as a single diastereoisomer in a yield
of 85% when potassium tert-butoxide is used in tetrahydrofuran at room temperature.
The high degree of stereoselectivity is explained by the pi-stacking interaction between

























Scheme 1.23: Reaction conditions: i) t-BuOK, THF, rt, 30 min.
Intermolecular Double Aza-Michael Additions
In a double aza-Michael reaction a primary amine adds twice to a double Michael
acceptor in succession. An example of such a double Michael acceptor is divinyl ketone
149 (Scheme 1.24), which is an important precursor used for the preparation of (-)-
lentiginosine 153 (Scheme 1.25).61
The synthetic approach for the synthesis of Michael acceptor 149 starts from dienediol
145, which is initially protected as a silyl ether, followed by a cross metathesis with
acrolein to give aldehyde 146. Upon protection of the second hydroxy group, resulting
in 147, the addition of vinyl Grignard reagent affords alcohol 148. This divinyl alcohol
is ultimately oxidised to give desired divinyl ketone 149.



























Scheme 1.24: Reaction conditions: i) TBSCl, imidazole, CH2Cl2, 0-45
◦C, 16 h; ii) 3
mol% Hoveyda-Grubbs catalyst 150, acrolein, CH2Cl2, rt, 48 h; iii) MOMCl, DIPEA,
CH2Cl2, 0-45
◦C, 16 h; iv) H2C−CHMgBr, THF, 0 ◦C, 2 h; v) DDQ, dioxane, rt, 48 h.
Double Michael acceptor 149 then undergoes a cyclisation process with benzylamine
to yield separable, diastereomeric 2-substituted 4-piperidone products 151 and 152
(Scheme 1.25). The piperidones were obtained in a diastereomeric ratio of 3:1, with
the major product being 151, in a combined yield of 54%. Different solvent systems,
reaction times and changing the reaction temperature does not significantly affect the
diastereomeric ratio. Adding 10 mol% TFA to the reaction mixture in CH2Cl2 increases
the yield to 75%, however the diastereomeric ratio drops to 2:1. Major piperidone
product 151 can be subjected to further synthetic modifications to gain access to the




















Scheme 1.25: Reaction conditions: i) benzylamine, MeCN, rt, 16 h.
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Rosiak81 has developed a route for the synthesis of 3-phenyl substituted 4-piperidones by
employing an intermolecular double aza-Michael cyclisation as the key step (Scheme 1.26).
The highly reactive and unstable divinyl ketone 156 is prepared in two steps. Starting
from a Shapiro reaction between 2,4,6-triisopropyl-phenyl-sulfonyl-hydrazone 154 and
acrolein, stable allylic alcohol 155 is obtained in a yield of 82%. Oxidation with an
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      Ph                                b (55%)
      R-PhCH(CH3)             c (62%,  dr 1:1)
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Scheme 1.26: Reaction conditions: i) n-BuLi, acrolein, THF, -78 ◦C-0 ◦C, 2 h; ii)
MnO2, CH2Cl2, 23
◦C, 20 min; iii) 157a, MeCN, 80◦C, 1.5 h; iv) 157b+c, MeCN, 80
◦C, 3 h, then 23 ◦C, 16 h; v) 158a, Pd/C, H2, cat. HCl, i -PrOH, 23
◦C, 16 h.
Optimised reaction conditions for the subsequent aza-Michael addition lead to 3-
substituted piperidone 158 in good yields (55-68%). When chiral amine 157c is used
for this cyclisation process, the ratio of diastereomeric piperidones 158c is 1:1, with no
chiral induction being observed. Unprotected piperidone 159a is further obtained by
hydrogenation of 158a over a palladium catalyst.
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1.4 Acetylcholinesterase Inhibitors for the Treatment of
Alzheimer’s Disease
Alzheimer’s Disease: A Short Overview
Alzheimer’s disease (AD) is the most common form of dementia and can be described
as a progressive, degenerative and incurable neurological brain disease that causes
deterioration of neurons and is ultimately fatal.82 Dementia has a global prevalence of
5-7% amongst the population aged ≥60 years and affected 35.6 million people worldwide
in 2010. This number is expected to double every 20 years, resulting in an estimated
65.7 million people suffering from dementia in 2030 and 115.4 million in 2050.83 AD
accounts for 60-80% of dementia cases and as it causes high health care costs, it also
has a large economic impact.84,85
Although current research provided an insight into the changes that occur in the
brain of an AD patient, the ultimate causes of the disease remain unknown. It is
the current understanding of AD that an interplay of different pathological factors
causes a number of brain changes which start taking place years before the clinical
onset of the disease.86,87 The most relevant developments in the brain include the
aggregation of of the β-amyloid (Aβ) protein, also called Aβ plaques, outside neurons.
Plaque formation interferes with the neurons’ synaptic communication processes and
contributes to cellular decline.88,89 Another pathological process is the self-assembly of
abnormal hyperphosphorylated tau proteins into so-called neurofibrillary tangles. As a
consequence the neurons’ transport system, being composed of microtubules stabilised
by normal tau protein, collapses and the transfer of nutrients along neurons is disrupted,
thereby further contributing to cell death.90,91 On a global level, the increasing neuronal
loss leads to extreme shrinkage of the brain, especially in the hippocampus and cortex
and to enlargement of the ventricles.92
People age ≥60 suffering from mild cognitive impairment (MCI) experience slight
memory difficulties, but are not clinically demented or affected in their daily activities.93
Almost half of those patients develop AD later on in their lives, therefore MCI is
sometimes referred to as “prodromal AD”.82,84 At a later stage, which is termed
“dementia due to AD”, daily living is severely affected and symptoms include memory
loss, problems with speaking and writing, disorientation, behaviour changes and
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difficulties with walking and swallowing. It is usually only in this phase that AD
is diagnosed clinically and pharmacological treatment is started.84 Since neuronal
loss starts long before the symptomatic onset of AD, current efforts are being made
to improve clinical tools, such as identifying biomarkers94 and developing imaging
techniques95 to facilitate earlier diagnosis and treatment.
So far, no disease-modifying treatment has been found and all currently prescribed drugs
merely address the symptomatic aspects of AD. At present, many therapeutic targets,
such as the Aβ-accumulation,96–98 the tau hyperphosphorylation,99 inflammation,100
oxidative stress101 and preventative measures102 are being investigated as potential new
starting points for finding a cure for AD.
Acetylcholinesterase Inhibitors and the Cholinergic Hypothesis
The cholinergic hypothesis is based on the observation that the brains of AD patients
exhibit decreased cholinergic activity in combination with a progressive loss in cognitive
function.103,104
Acetylcholine 160 (ACh) (Scheme 1.27) is produced in cholinergic neurons in the
brain and is an important neuromodulator, which has been found to be involved in
complex processes, such as memory, learning and circadian rhythmicity.105–107 A major
aggregation of cholinergic neurons is located in the basal forebrain, which also constitutes










Scheme 1.27: Enzymatic hydrolysis of acetylcholine to acetate and choline.
The concentration of ACh in the synaptic cleft of cholinergic neurons is regulated
by the enzyme acetylcholinesterase (AChE), which degrades the neurotransmitter into
acetate 161 and choline 162 (Scheme 1.27), thereby inactivating it and inhibiting further
neuronal transmission (Figure 1.12). Early discoveries found the anticholinergic tropane
alkaloid scopolamine to cause memory impairment in rhesus monkeys, which could
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Figure 1.12: Schematic depiction of a cholinergic synapse: Acetylcholinesterase
(AChE) degrades acetylcholine (ACh) into acetate (A) and choline (Ch) - a process
which is inhibited by acetylcholinesterase inhibitors (AChEI).
Following these observations it was anticipated that inhibition of AChE and the increased
availability of synaptic ACh could be beneficial for AD patients (Figure 1.12). The first
drug to be approved by the U.S. Food and Drug Administration for the treatment of mild
to moderate AD was tacrine 163 in 1993 (Figure 1.13). AChEIs such as tacrine, although
leading to improvements in cognitive function, could not stop the overall progression of
the disease for the long term.110 Due to the increased risk for hepatotoxic side effects
and the necessity for close patient monitoring111 tacrine is no longer prescribed.
The only four drugs that are currently approved for the treatment of various stages of AD
are the AChEIs rivastigmine 164, galantamine 165 and donepezil 12 and the N -methyl-
D-aspartate (NMDA) glutamate receptor antagonist memantine 166 (Figure 1.14).
Rivastigmine 164 is a derivative of the alkaloid physostigmine which inhibits both AChE
and butyrylcholinesterase and is used widely in all stages of AD.112 Furthermore it is
used in the treatment of Parkinson’s disease dementia.113,114 Galantamine 165 is an
alkaloid isolated from Galanthus nivalis and before being identified as a potential AChE
inhibitor, it has been used in traditional medicine in Eastern Europe for the treatment
of neurological problems.115,116 In addition to the AChE enzyme inhibiting properties,
galantamine also possesses an allosteric sensitising effect on nicotinic receptors for the
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binding of ACh in the synaptic cleft, thereby possibly further increasing the therapeutic
utility of this drug.117 Memantine 166 is the only approved drug for the treatment
of AD which does not act as an AChEI. It is classified as a centrally acting low to
medium affinity NMDA receptor receptor antagonist. The level of glutamate, another
important neurotransmitter in the brain, is pathologically increased in AD and leads to
an overstimulation of NMDA receptors, which subsequently causes excitotoxicity and
cell death. Memantine was found to block the NMDA receptor and thereby prevent
hyperpolarisation of the neurons,118 a mode of action which renders this drug useful in


















Figure 1.13: Drugs for the treatment of Alzheimer’s disease.
Donepezil
Donepezil was developed by the Japanese company Eisai120 and since its approval in
the U.S. in 1996 and shortly after worldwide, has been marketed as Aricept R© for the
treatment of mild to moderate AD.
Discovery of Donepezil
Esai’s initial research into the development of a novel class of acetylcholinesterase in-
hibitors started in 1983,121,122 when a blind screening process afforded N -benzylpiperazine
167 as a potential candidate (Figure 1.14). The in vitro AChE inhibitory activity of
167 was found to be 12.6 µM at IC50 and, albeit its moderate activity, it was used as a
template for the synthesis of approximately 700 analogues. An important step to improve
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the biological properties of 167 was the replacement of the piperazine moiety with a
piperidine ring. Compound 168 possessed a significantly increased AChE inhibition
activity of 340 nM at IC50. The replacement of the ether group with an amide moiety
and the removal of the nitro substituent gave piperidine compound 169, which had a
slightly decreased inhibitory activity of 560 nM at IC50. It was further shown that the
biological activity was maintained when the amide moiety was replaced with a ketone
function (170). An intermediate bearing an indanone substructure, such as 171, showed
a further increase in potency with an IC50 of 230 nM. Replacement of the ethylene
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Figure 1.14: Lead compounds towards the discovery of donepezil
Structure Activity Relationships
Analogue 172 was chosen as a lead compound for further synthetic modification in the
indanone series.120 Structure-activity relationship studies were undertaken and the in
vitro AChE inhibition of the synthesised derivatives evaluated according to a protocol
by Ellman.125 Lead structure 172 can be divided into four parts, the indanone moiety
A, a linker unit B, the piperidine moiety C and the benzyl moiety D (Figure 1.15).
Modifications on component A were shown to dramatically influence the inhibition
potencies of the analogues (Table 1.4). Expansion of the indanone ring (173) or the
removal of the carbonyl function as in indene derivative 174 led to deactivation, while
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O
CH2 N CH2
A B C D
172
Figure 1.15: Four subunits of the lead compound.
the introduction of a methoxy group on the indanone (175) greatly improved the activity.
Donepezil 12 bears two methoxy groups on the aromatic indanone part and was found
to be a potent inhibitor of AChE with an IC50 of 5.7 nM. When the chain length of
linker unit B was modified (Figure 1.15), the activity was also affected and it was found
that complete removal of the bridging unit was particularly disadvantageous in terms of
potency, leading to an analogue with an IC50 of 3300 nM.
120
Table 1.4: Inhibitory activity of compounds with modifications on subunit A.
A CH2 N CH2

















a Inhibition of AChE in vitro.
The position of the nitrogen on the ring proved to be be extremely important, as the
replacement of piperidine with piperazine, as in 176, and to an even greater extent, an
analogue with the piperidine ring reversed, as in 177, led to decreased inhibitory activity
(Table 1.5). Many derivatives bearing modifications on part D (Figure 1.15) have been
synthesised and it was found that complete removal of the benzyl group as well as the
introduction of a benzoyl or 2-naphthyl group drastically decreased the activity. It was
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concluded that both the basicity of the nitrogen as well as its distance to the indanone
carbonyl function are crucial for the inhibitory effects of such analogues.120,126
















a Inhibition of AChE in vitro.
Due to the presence of an asymmetric carbon on the indanone part of the molecule, all
of the evaluated analogues were racemic mixtures. Under physiological conditions, the
two enantiomers of indanone-compounds like donepezil 12 interconvert quickly because
of keto-enol tautomerism,127 which is the main reason why donepezil was developed and
commercialised as a racemic mixture.126
Pharmacology and Clinical Studies
Although donepezil has been classified as a mixed competitive-noncompetitive inhibitor
of AChE, the noncompetitive mode of action predominates.128,129 In initial in vitro
experiments,125 the inhibitory activity of donepezil towards AChE and butyryl-
cholinesterase (BuChE), a non-specific cholinesterase occurring especially in the liver,
was measured in comparison with tacrine and physostigmine.120 The concentration of
donepezil needed for inhibiting 50% of AChE (from rat brain homogenate) was found
to be 5.7 nM, whereas the IC50 for the inhibition of BuChE (from rat plasma) was
much higher (7138 nM), therefore demonstrating a strong selectivity towards AChE as
opposed to BuChE. Both physostigmine and tacrine express a much higher selectivity for
BuChE,130 which also associates these compounds with a higher occurrence of peripheral
side effects. In vivo experiments using rats further demonstrated that donepezil can
enhance the extracellular concentration of ACh in the cerebral cortex of rats at lower
doses than other AChE inhibitors, indicating that it possesses a selectivity towards the
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central cholinergic system.131 Compared to other common AChE inhibitors, the half-life
of donepezil is significantly longer (70-80 h)132 and patient compliance is improved by
only requiring one dose per day.133
To date many clinical trials for the use of donepezil in AD have been conducted and have
shown that donepezil is beneficial for AD patients in terms of slowing the progressive
cognitive impairment. A study which focussed on the effects of donepezil in patients
in the early stage of AD concluded that an improvement of daily cognitive functions
was achieved over the course of 24 weeks.134 Similar results were found in a study
with patients suffering from mild to moderate AD, as donepezil was well-tolerated and
improved global function and cognition.135 The long term efficacy and safety of donepezil
in patients with mild to moderately severe AD was assessed in a multi-centre open-label
study and it was found that donepezil was effective and well tolerated as a symptomatic
treatment over a period of up to 4.9 years.136
Acetylcholinesterase in Complex with Donepezil
The acetylcholinesterase enzyme is vital for correct signal transmission at neuronal
and neuromuscular synapses, degrading the neurotransmitter acetylcholine and thereby
controlling its concentration in the synaptic cleft.137 The enzyme is classified as a serine
hydrolase because its catalytic site, the “catalytic triad”, consists of a serine, histidine
and glutamate residue and hydrolyses acetylcholine to acetate and choline.138 The first
crystal structure of the enzyme was solved for the electric ray (Torpedo californica).
This made it possible to locate the catalytic triad at the bottom of a narrow gorge
which protrudes deep into the enzyme.139
The first crystal structure of a complex of donepezil with the Torpedo californica AChE
(TcAChE) was published by Kryger and allowed detailed insight into the orientation
and positioning of donepezil within the enzyme and its interactions with the amino
acid residues of the active-site.140 Even though donepezil was designed on the basis
of quantitative structure-activity relationship (QSAR) models,141,142 many of these
previous findings could be confirmed by analysis of the donepezil-TcAChE complex.
Only recently the structure of recombinant human AChE (rhAChE) in complex with
donepezil has been described and provides further understanding of donepezil’s binding
behaviour.143
Chapter 1. Introduction 39
Figure 1.16 depicts donepezil in complex with rhAChE and is described as being situated
along the narrow active-site gorge, spanning from the anionic site at the bottom of the
gorge to the upper peripheral anionic site.140 In this complex donepezil does not obstruct
or interfere directly with the catalytic triad, which is supported by the observation of a
binding-simulation where donepezil apparently inhibits both the acylated and the free
enzyme.144 Tyrosine Y337 has been described as a “swinging gate” which moves upon
donepezil binding, allowing entrance into the active-site gorge (Figure 1.16).140,143 In
rhAChE, pi-pi-stacking interactions are observed between the benzyl ring and tryptophan
W86 as well as between the indanone moiety and tryptophan W286. A water molecule
is held by forming hydrogen bonds to the nitrogen on the piperidine ring of donepezil
and to residues Y341 and Y337.143
Figure 1.16: Donepezil bound in the active site gorge of rhAChE.143 The carbons of
donepezil are coloured pink an the carbons of the residues are coloured yellow. Oxygen
and nitrogen atoms are coloured red and blue. Water molecules are light blue spheres
and hydrogen bonds are represented by pink dashes.
Both Kryger140 and Cheung143 conclude that additional substituents on the piperidine
ring of donepezil could be accommodated in the binding pocket and thereby lead to
an improvement of the drug’s pharmacological profile. Interestingly, such substituted
analogues of donepezil have not been described in the literature, despite the realisation
of extensive SAR studies and the early finding that the insertion of a piperidine into the
structure led to analogues possessing a much higher biological activity.120,123
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1.5 Aim of the Project
The piperidine ring is an important moiety in pharmaceutical research and is a
ubiquitous structural motif encountered in countless natural products.1,5 At present, the
1,4-disubstitution pattern on the piperidine ring prevails amongst pharmaceuticals due
to shorter synthetic routes from commercial precursors and the absence of stereochemical
complications. However, it has been shown that additional substituents on the
piperidine and can result in compounds with increased biological activity.31,32 The facile
preparation of chiral, versatile piperidine building blocks for the synthesis of biologically
active compounds is therefore of current interest.
A double aza-Michael addition of a primary amine to a divinyl ketone is an atom-efficient
approach to the synthesis of substituted 4-piperidones. The initial aim of this project
will be to evaluate the utility of unsubstituted ketone 178 as the electrophile in an


























Figure 1.17: Synthesis of N -substituted piperidone 179, racemic 2-substituted
piperidone 181 or diastereomeric piperidones 182 and 183.
Furthermore it is intended to achieve the synthesis of substituted divinyl ketones
180 and to cyclise them using the previously developed method to access racemic 2-
substituted 4-piperidones 181 (Figure 1.17). By employing a suitable chiral amine for
the aza-Michael cyclisation with substituted ketones 180, it is envisioned that it will be
possible to prepare separable, diastereomeric 2-substituted 4-piperidones 182 and 183
(Figure 1.17).
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The utility of the methodology will then be demonstrated by using the 2-substituted
4-piperidones 182 and 183 as building blocks for the synthesis of piperidine ring 2-
substituted analogues 185 of the acetylcholinesterase inhibiting drug donepezil 12 (Fig-
ure 1.18). The stereoselective synthesis of piperidine-substituted donepezil analogues has
not been reported, despite the fact that early structure-activity relationship studies126






























182 183 184 185
Figure 1.18: Donepezil 379 and stereoselectively piperidine 2-substituted analogue
185.
Donepezil analogues 185 are envisioned to be accessible via the transformation of
diastereomeric piperidones 182 and 183 into aldehydes 184, which will serve as key
precursors for the synthesis of the target compounds (Figure 1.18). The evaluation of
the biological activity of these analogues will provide information on how donepezil’s
inhibitory potency is affected by stereoselective substitution on the piperidine ring.
Chapter 2
Results and Discussion
2.1 Studies Into the Synthesis of Novel Piperidines
2.1.1 Synthesis of N -Substituted 4-Piperidones
For the synthesis of simple N -substituted 4-piperidones 187, divinyl ketone 178 was
chosen as the key building-block (Figure 2.1). As this dienone is unsubstituted and
therefore sterically accessible towards nucleophilc attack, it was envisioned that it would
be an ideal double Michael acceptor for an aza-Michael addition/cyclisation reaction.
Facile access to this reactive and unstable145 ketone was believed possible via the







Figure 2.1: Synthesis of N -substituted 4-piperidones 187 in two steps.
Having achieved the preparation of ketone 178, the next step would be the investigation
of a double aza-Michael addition involving various aromatic and aliphatic amines.
42
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Preparation of the Divinyl Ketone Building Block
Due to the unstable nature of divinyl ketone 178 it was necessary to achieve an efficient
and particularly mild oxidation of divinyl alcohol 186 (Figure 2.2). For this purpose,
2-iodoxybenzoic acid (IBX) was the oxidant of initial choice, as it is known to smoothly





Figure 2.2: Oxidation of divinylcarbinol 186.
IBX 189 was prepared from 2-iodobenzoic acid 188 following the procedure of
Santagostino147 in a yield of 85% (Scheme 2.1). The advantage of this method over other









Scheme 2.1: Reaction conditions: i) Oxone, H2O, 70
◦C, 3 h.
Initial attempts to oxidise divinylcarbinol 186 with IBX were carried out using the
procedure of Rao149 (Scheme 2.2). This method involves the oxidation of alcohols at




Scheme 2.2: Reaction conditions: i) IBX, β-cyclodextrin, H2O/acetone 7.5:1.0, rt, 48
h, 50◦C, 5 h; ii) IBX, DMSO, rt, 18 h.
When the reaction was performed according to this protocol, thin layer chromatography
(TLC) analysis revealed that no product formed after 48 hours of stirring at room
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temperature. After heating to 50 ◦C for 5 hours, 1H-NMR analysis of the crude residue
revealed that while no product was formed, considerable starting material remained,
accompanied by side-products that could not be identified. When the oxidation with
IBX was carried out under nitrogen using dimethyl sulfoxide (DMSO) as a solvent, no
formation of ketone 178 was observed.
Due to the lack of conversion of alcohol 186 to ketone 178 under the IBX-mediated
conditions, another oxidant, MnO2, was investigated for this conversion. MnO2 is a
mild and widely used oxidant especially for the selective transformation of benzylic and
allylic alcohols to the corresponding ketone or aldehyde.150–152 The oxidising power of
MnO2 is variable and depends on the origin of the reagent as well as on its structure, and
standardised protocols for the preparation of active MnO2 have been reported.
153,154
When Reed145 described the MnO2 oxidation of divinylcarbinol 186 to divinyl ketone
178 in 1962, he identified that the type of MnO2 oxidant employed for this conversion
was crucial for both the yield and the rate of the reaction (Figure 2.3). He compared
the commercially available reagent to MnO2 prepared according to the protocols of
Attenburrow153 and Harfenist154 and observed varying yields for ketone 178, not only






Figure 2.3: Oxidation of divinylcarbinol 186 with MnO2.
Reed observed that when reacting divinylcarbinol 186 in the presence of Attenburrow’s
MnO2 at room temperature for 24 h with the ratio of alcohol to oxidant being 1:15,
upon distillation of crude ketone 178, the maximum yield obtained was 50%. However,
he showed that when the divinyl ketone was isolated as its 2,4-dinitrophenylhydrazone,
a yield of 96% was obtained, indicating that a significant amount of product was lost
upon distillation.
For the purpose of oxidising divinylcarbinol 186, we decided to initially use commercially
available, technical grade activated MnO2 as received from the vendor (Alfa Aesar). The
alcohol was stirred at room temperature with a suspension of MnO2 (15 equivalents)
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in CH2Cl2 (Figure 2.3, Table 2.1, entry1). After the reaction mixture had been filtered
through a pad of Celite R©, washed with acetone and dichloromethane and carefully
reduced in vacuo, 1H-NMR analysis of the crude product showed that only 26% had
been converted to divinyl ketone 178, while the rest of the starting material remained
unreacted.
Table 2.1: Optimisation study on the oxidation of divinylcarbinol 186 employing
MnO2.
Entry MnO2 (equiv.) Type of MnO2
b Conditions Conversion to 178a(%)
1 15 untreated 22 h, rt 26
2 20 treated:untreated 1:1 22 h, rt 52
3 30 treated 20 h, 40 ◦C 68
4 30 treated, 4 A˚ MS 20 h, 40 ◦C 100
a Conversion was determined by 1H-NMR analysis of the crude spectra.
b Untreated MnO2: Reagent used as received from vendor (Alfa Aesar); Treated MnO2: Washed
with nitric acid (10%) and water, dried at 105 ◦C for two days.
As unreacted starting material remained when untreated, purchased MnO2 was
employed for the oxidation, we concluded that further activation was required to achieve
full conversion to the desired ketone. Harfenist154 reported an increased oxidising
activity of MnO2 when it was washed with nitric acid followed by drying. Following
this protocol, MnO2 was treated with diluted nitric acid (10%) and extensively washed
with water until the filtrate was neutral. The powder was then dried at 105 ◦C for two
days and the brittle, caked black solid was finely ground with mortar and pestle.
The oxidation of divinylcarbinol 186 was repeated with a mixture of untreated and
acid-washed MnO2 (1:1) which led to an improvement of the conversion rate to 52%
(Table 2.1, entry 2). The yield of the ketone was further increased to 68% by using
only acid-washed MnO2 at an elevated reaction temperature (Table 2.1, entry 3). Full
conversion by NMR to the desired divinyl ketone 178 was finally achieved when 4 A˚
molecular sieves (MS) were added to the reaction mixture (Table 2.1, entry 4). We
believe that the molecular sieves capture water, which is generated during the oxidative
process with MnO2. The removal of water prevents the inactivation of the surface
of MnO2 and maintains the rate of oxidation,
155 thereby leading to the observed
improvements in the conversion to ketone 178.



















Figure 2.4: Crude 1H-NMR spectra (7.1-4.5 ppm) of the experiments in Table 2.1.
Figure 2.4 depicts the crude 1H-NMR spectra for the oxidation of divinylcarbinol 186,
which were obtained by carrying out the reactions according to the protocols described
in Table 2.1. In entry 1-3, the conversion of alcohol 186 to ketone 178 was incomplete,
wherefore starting material was visible in the otherwise clean crude spectra (Figure 2.4).
In the spectrum that was obtained under the conditions of entry 4 in Table 2.1, ketone
178 was clean and no undesired side-products or remaining starting material were
observed. It was hence decided to use this crude ketone without further purification
for the next synthetic step. In order to prevent polymerisation of the ketone during
isolation, the filtrate was carefully concentrated at temperatures below 40 ◦C.
Having accessed the divinyl ketone building block, the next step towards the synthesis
of piperidones, a double aza-Michael cyclisation, could be targeted.
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Synthesis of 4-Piperidones via Double Aza-Michael Cyclisation
A double aza-Michael reaction consists of two conjugate additions which take place in the
same molecule. For our substrate, initially an intermolecular conjugate addition takes
place between the nucleophilic primary amine 190 and divinyl ketone 178 (Figure 2.5).
This results in the formation of intermediate enone 193, which is also a Michael acceptor.
Subsequent intramolecular conjugate addition occurs to yield the target six-membered,

































Figure 2.5: Mechanism of the double aza-Michael cyclisation giving N -substituted
4-piperidones.
Benzylamine was chosen as a test-substrate for the role of the nucleophilic primary
amine in this double Michael addition. The aromaticity of benzylamine would make
the product detectable by TLC and the prominent signal of the methylene group in
the 1H-NMR spectrum would enable the progress of the reaction to be conveniently
monitored.
Cyclisation in Two Steps
From related examples in the literature61,81 it has been shown that acetonitrile can
act as a suitable solvent for this type of aza-Michael cyclisations. Liu61 describes a
double aza-Michael reaction for the synthesis of piperidones 197 and 198 in acetonitrile
in a combined yield of 54% (Scheme 2.3), whereas Rosiak81 achieved the cyclisation
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of an α-substituted divinyl ketone with benzylamine in acetonitrile in a yield of 68%
(Scheme 2.4). The first attempt to synthesise a N -substituted 4-piperidone from





















Scheme 2.4: Reaction conditions: i) BnNH2, CH3CN, 80
◦C, 1.5 h.
Initially crude divinyl ketone 178 and benzylamine were refluxed in acetonitrile for 4
hours (Scheme 2.5). After workup, target piperidone 201 was obtained in poor yield
(11% over two steps). It was observed that due to its instability, dienone 178 had to be





11% over two steps178 201
Scheme 2.5: Reaction conditions: i) Crude 178, BnNH2, CH3CN, reflux, 4 h.
A subsequent investigation with a shorter reaction time of 1.5 hours gave a comparable
yield over two steps (12%). When the crude ketone was reacted with benzylamine
in acetonitrile at room temperature for 24 hours, only traces of product were found
Chapter 2. Studies Into the Synthesis of Novel Piperidines 49
in the crude 1H-NMR spectrum. To minimise loss and degradation of ketone 178,
the solvent from the previous step was not completely evaporated. The ketone in
residual dichloromethane was therefore added directly to a solution of acetonitrile and
benzylamine using the same conditions as previously (Scheme 2.5). Nevertheless, these
measurements did not improve the overall yield significantly (14% over two steps).
Cyclisation in a One-pot Approach
We envisioned that, due to the instability of divinyl ketone, an in-situ oxidation of
carbinol 186 followed by subsequent cyclisation in a one-pot approach could lead to a
higher yield of piperidone 201. A reaction of this type (Figure 2.6) would achieve both







Figure 2.6: One-pot preparation of N -benzyl-4-piperidone 201 in CH2Cl2 using
benzylamine as the primary amine.
In a stepwise one-pot process, divinylcarbinol 186 was first fully oxidised using the
previously optimised conditions, before benzylamine was added to the reaction mixture
(Table 2.2, entry 1). Stirring was continued for 24 hours and upon work-up and isolation
piperidone 201 was afforded in 34% yield over two steps. Although the yield for this
reaction was improved, the overall result was still unsatisfactory.
In further optimisation experiments, a simultaneous one-pot approach was investigated.
For these experiments benzylamine was added to the reaction mixture at the same time
as the MnO2. It was found that while only 1.4 equivalents of benzylamine were used, the
addition of the reagents in a simultaneous manner led to an improved isolated yield of
the desired piperidone product (entry 2). Further adjustments of the reaction conditions
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Table 2.2: Optimisation reactions for the synthesis of N -benzyl-4-piperidone 201.
Entry BnNH2 BnNH2 addition MnO2 Conditions Yield
aof 201 (%)
1 2.1 equiv stepwise 30 equiv 20 h, 24 hb 34
2 1.4 equiv simultaneous 30 equiv 18 h, 50 ◦C 45
3 1.5 equiv simultaneous 25 equiv 18 h, 50 ◦C 55
4 1.5 equiv simultaneous 25 equiv 18 h, 50 ◦C, 51
20 mol% TFA
a Isolated yields.
b Oxidation of 186 to 178 at 45 ◦C for 20 h, followed by the addition of benzylamine and
subsequent cyclisation at 50 ◦C for 24 h
gave an improved isolated yield of 55% (entry 3). When this experiment was repeated
using a shorter reaction time of 6 hours, the yield was found to be significantly lowered
(30% as determined by the analysis of the crude 1H-NMR spectrum).
Liu61 reported reduced side-product formation and an increased yield for the product
of a similar double aza-Michael addition in the presence of 10 mol% trifluoroacetic acid.
However, under our one-pot oxidation-cyclisation conditions, neither the addition of 10
mol%, nor the addition of 20 mol% trifluoroacetic acid further increased the yield of
piperidone 201 (Figure 2.6, entry 4).
Having improved the yield over two steps of piperidone 201 from 12% in acetonitrile to
55% in dichloromethane, we decided to apply this protocol to the synthesis of further
piperidone derivatives to explore the scope of the methodology.
Chapter 2. Studies Into the Synthesis of Novel Piperidines 51
Synthesis of Piperidone Analogues
Table 2.3 summarises the piperidone derivatives synthesised according to the previously
established protocol. The in-situ oxidation-cyclisation reaction of dienone 178 with
benzylamine derivatives (entry 1-4) led to the formation of piperidones 201, 204, 206
and 208 and yields for these substrates ranged from 45 to 55% over two steps. Amine
205, bearing a methoxy group in para position of the benzyl ring (entry 3) resulted in a
slightly lower yield of piperidone 206 of 45%. We believe that due to the polar methoxy
substituent, amine 205 is adsorbed to the surface of the surface of MnO2 to a higher
extent than the other benzylamines and is thus less available for the cyclisation reaction
with divinyl ketone 178.
Using α-phenylethylamine 209 as substrate for the double aza-Michael reaction gave
piperidone 210 in a yield of 49% (entry 5), therefore indicating that the additional
methyl group on the benzyl moiety does not have a sterically detrimental effect on the
cyclisation reaction. Amine 211 (Table 2.3, entry 6) gave a low yield of piperidone 212
(28%) which could be explained by the steric bulk of the amine that possibly hinders
the intramolecular addition step in the cyclisation process. Employing phenylethylamine
213 as substrate (entry 7), piperidone 214 was obtained in a higher yield of 58%. When
aliphatic amines were used as substrates for the double aza-Michael reaction (entry 8
and 9), yields for the isolated products 216 and 218 were 60 and 61% over two steps.
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Table 2.3: In-situ oxidation-cyclisation giving various N -substituted 4-piperidones.














































a Isolated yield over two steps.
Chapter 2. Studies Into the Synthesis of Novel Piperidines 53
The main byproducts of the one-pot oxidation/cyclisation reaction with benzylamine
were isolated and identified as benzyl alkylimine 220 and benzaldehyde 221 based on
the analysis of their 1H-NMR spectrum (Figure 2.7). From the crude 1H-NMR spectra
of the optimisation experiments (Table 2.2, entry 2-4) it was found that approximately
60% of the benzylamine used was converted to benzyl alkylimine 220 and benzaldehyde
221. The ratio of the aldehyde to the imine was determined from the crude 1H-NMR












186 219 201 220 221
Figure 2.7: Identified byproducts 220 and 221.
We believe that, in the presence of MnO2, benzylamine 219 undergoes an oxidation to
unstable imine 222, which is further hydrolysed to aldehyde 221 (Figure 2.8).156 The
aldehyde then reacts with a molecule of benzylamine 219 to give alkylimine 220. This
side-reaction, which is due to the reactivity of benzylamine derivatives towards MnO2,
consequently leads to a lowered availability of the amine substrate for the participation
in the double aza-Michael cyclisation with ketone 178.










219 222 221 220
Figure 2.8: Proposed pathway for the formation of byproducts 221 and 220.
Side products as shown in Figure 2.7 were not observed when using aliphatic amine
substrates, which explains the higher yields that were obtained for the corresponding
N -alkyl piperidones in comparison to the N -benzylic piperidones.
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2.1.2 Preparation of Substituted Divinyl Ketones
As the previously developed one-pot oxidation/cyclisation protocol proved successful for
the synthesis of a range of N -substituted 4-piperidones, it was envisioned that when using
a substituted divinyl alcohol 223, the same method could be applied to the preparation






















RNH2 = chiral amine*
223 224 225
223 224 226 227
Figure 2.9: Schematic route towards the synthesis of racemic piperidone 225 or
diastereomeric piperidones 226 and 227.
Synthesis of mono-substituted divinyl alcohols
For the synthesis of substituted divinyl alcohols 233-237, the corresponding vinyl
aldehydes 228-232 were subjected to a Grignard reaction utilising commercially
available vinylmagnesium bromide (Scheme 2.6). The dienols were obtained in high
























Scheme 2.6: Reaction conditions: i) CH2−CHMgBr, THF, 0 ◦C (dropwise), then rt,
1 h.
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Table 2.4: Grignard reaction giving mono-substituted divinyl alcohols.































a Standard reaction conditions: Aldehyde, CH2−CHMgBr, THF, 0 ◦C
(dropwise), then rt, 1 h.
b Crude yield. Isolated yield in parentheses.
The synthesised divinyl alcohols (Table 2.4) can be stored in the fridge (4 ◦C) for several
weeks without observed degradation as judged by 1H-NMR analysis and are therefore
practical precursors for the synthesis of substituted piperidones.
Substituted Divinyl Alcohols in the One-pot Double Aza-Michael Reaction
With the mono-substituted dienols in hand, their utility as substrates for the one-pot
oxidation/aza-Michael reaction could be investigated. Subjecting alcohols 233 and 235
to the same reaction conditions as previously described, using benzylamine as the amine
component, gave racemic 2-substituted piperidones 241 and 242 in low yields over two
steps (17% and 21% respectively, Scheme 2.7).





























Scheme 2.7: Reaction conditions: i) BnNH2, MnO2, 4 A˚ MS, CH2Cl2, 50
◦C, 18 h;
ii) MnO2, 4 A˚ MS, CH2Cl2, 45
◦C, 3 h, microwave irradiation; iii) BnNH2, 45
◦C, 1 h,
microwave irradiation.
We believe that in comparison to unsubstituted divinyl ketone 178, substituted dienones,
such as 238, 240 and 239, possess a lowered reactivity towards the subsequent double
Michael reaction with benzylamine. A substituent β to the carbonyl function decreases
the electrophilicity of the Michael acceptor and leads to steric hindrance during the
cyclisation process with benzylamine. The piperidone formation takes place at a slower
rate and consequently more time is allowed for the previously described MnO2 mediated
side reaction to occur, which is further contributing to a decreased yield by resulting in
a reduced availability of benzylamine over time.
Investigating the effects of microwave irradiation on this type of reaction, propyl alcohol
234 was oxidised to its ketone 240 in the presence of only 10 equivalents of MnO2 within
a reaction time of three hours. Addition of benzylamine to the reaction mixture and
microwave irradiation for another hour gave piperidone 243 in a yield of 22%. This
shows that a stepwise reaction sequence under the influence of microwave irradiation
did not significantly promote the formation of the piperidone product.
As these preliminary results were not satisfactory, we decided to first oxidise the
substituted divinyl alcohols to their corresponding ketones before using them in the aza-
Michael addition. In this way it would be easier to evaluate the utility of a substituted
dienone as a double Michael acceptor.
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Oxidation of Mono-substituted Dienols
A MnO2 mediated oxidation of crude divinyl alcohol 233 gave corresponding ketone
238 in a crude yield of 71% (Scheme 2.8). Monitoring the reaction by TLC showed
that the conversion took place faster (3 h) than previously observed for unsubstituted
divinylcarbinol 186 (20 h). However, when employing MnO2 as the oxidant, phenyl-
substituted alcohol 235 was not converted to its corresponding ketone. Despite complete
consumption of the starting material, no formation of ketone 239 was observed even after
a prolonged reaction time. Analysis of the crude 1H-NMR spectrum showed a complex
mixture of products.
OH O
(R=Me)  71% (crude)      i










Scheme 2.8: Reaction conditions: i) MnO2, 4 A˚ MS, CH2Cl2, 50
◦C, 3 h; ii) MnO2,
4 A˚ MS, CH2Cl2, 50
◦C, 18 h.
The phenyl-substituted ketone 239 must have formed during the one-pot reaction with
benzylamine (Scheme 2.7), since the final piperidone product was not only observed
but also isolated. Therefore we can deduce that dienol 235 is oxidised to ketone 239
and then, in the absence of a primary amine and promoted by MnO2, undergoes an
immediate polymerisation/degradation process.
As dienone 239 was not stable under the previous reaction conditions employing MnO2
and as no product could be isolated, another reagent suitable for oxidising allylic and
benzylic alcohols, 2,3-dichloro-5,6-dicyano-p-quinone (DDQ),157,158 was investigated.
DDQ is a powerful oxidant at room temperature and upon conversion of the alcohol
substrate it conveniently precipitates from a suitable solvent as its hydroquinone.155
Scheme 2.9 shows the results of DDQ-mediated oxidation with the methyl, propyl and
phenyl substituted allylic alcohols 233, 234 and 235.
Chapter 2. Studies Into the Synthesis of Novel Piperidines 58
All substrates were smoothly converted to their corresponding ketones and due to the
DDQ hydroquinone’s low solubility in dioxane, we were able to filter this off at the end
of the reaction (Scheme 2.9). Analysis of the crude products by 1H-NMR showed clean
spectra, however, an intense red colour of the dienone residues remained. This suggests
that the crude products still contained traces of the reagent, which might be detrimental
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Pr      CH2Cl2 (ii)         97                  18
Ph     dioxane  (i)         98                  74
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Scheme 2.9: Reaction conditions: i) DDQ, dioxane, rt, 18 h; ii) DDQ, 4 A˚ MS,
CH2Cl2, rt, 18 h.
To investigate the effect of solvents on this oxidation, propyl dienol 234 was reacted
in dichloromethane instead of dioxane (Scheme 2.9). DDQ hydroquinone has a lower
solubility in dichloromethane compared to dioxane157 and has the additional advantage
of being highly volatile, thereby facilitating complete removal of the solvent under milder
conditions. Nevertheless, the red colour remained regardless of the choice of solvent.
In the case of phenyl dienone 239, column chromatography could be applied and
pure product was obtained in a yield of 74%. In contrast, crude crotyl dienone 238
is highly unstable and degraded completely upon attempts of purification by column
chromatography. Pure propyl divinyl ketone 240 was obtained in a significantly
diminished yield of 18% when subjected to column chromatography on silica. In addition
to not tolerating column chromatography conditions, it was necessary to use dienones
238 and 240 shortly after their isolation, in order to avoid further loss of material. A
similar observation concerning the instability of 238 is reported by Han and Krische159
and comments about the capricious nature of similar divinyl ketones have been made in
the literature.81,160,161
Table 2.5 depicts a summary of all synthesised divinyl ketones. When aliphatically
substituted ketones 238 and 240 were synthesised from their corresponding alcohols by
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Table 2.5: Summary of prepared divinyl ketones employing MnO2 or DDQ as the
oxidant.


























a Crude starting materials.
b Reaction conditions for entry 1 and 2: Alcohol, MnO2, 4 A˚ MS, CH2Cl2, 50◦C 3 h; Reaction conditions for entry 3-5: Alcohol, DDQ, dioxane, rt, 18 h.
c Isolated yield unless otherwise stated.
d Crude yield.
oxidation with DDQ, a purification by column chromatography was necessary because
traces of the reagent were present in the crude residues. However, ketones 238 and 240
are instable on silica, wherefore we chose to synthesise them from their corresponding
alcohols by oxidation with MnO2, thereby ensuring complete removal of the reagent by
simple filtration. The crudes of ketones 238 and 240 were of sufficient purity to be used
in the next synthetic step without further purification. As dienone products 239, 244
and 245 were stable on silica, the DDQ-facilitated oxidation was chosen for aromatically
substituted dienols and pure products were obtained in moderate to good isolated yields
over two steps.
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2.1.3 Synthesis of 2-Substituted 4-Piperidones
Since the synthesis of 2-substituted 4-piperidones using a one-pot oxidation/cyclisation
approach starting from mono-substituted divinyl alcohols did not give satisfactory
results, a stepwise oxidation and double aza-Michael cyclisation was investigated.
As the stability of phenyl dienone 239 allows purification on silica, this ketone substrate
was selected for the exploration of suitable reaction conditions for the conversion to
piperidone 242 from cyclisation with benzylamine (Figure 2.10). It was believed that
the excess of MnO2 in the one-pot method was limiting the availability of benzylamine
in the aza-Michael reaction due to its previously described conversion to an imine and an
aldehyde byproduct. Therefore an experiment was carried out under the same one-pot
reaction conditions, but in the absence of the MnO2 oxidant (Table 2.6, entry 1). The
reaction time ranged from 3-24 h, but only traces of piperidone 242 were observed in the
crude 1H-NMR spectrum. Phenyl dienone 239 was completely consumed and besides






Figure 2.10: Reaction conditions and yields for the synthesis of 242 detailed in
Table 2.6.
Microwave irradiation has the potential to shorten reaction times and has been
successfully employed in aza-Michael reactions,162–164 therefore microwave heating was
investigated in promoting the cyclisation of ketone 239 in dichloromethane (entry 2).
However, under these conditions only traces of product were formed, despite complete
consumption of the starting ketone.
Both dichloromethane59,74,80 and acetonitrile61,81 are commonly used solvents for aza-
Michael reactions, hence acetonitrile was also investigated in an attempt to synthesise
242 (entry 3). The reaction was followed by TLC over the course of 4 days, but analysis
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Table 2.6: Tested reaction conditions for the synthesis of 242 (see Figure 2.10).
Entry Solvent Conditions Reagents/Catalysts Yield (%)
1 CH2Cl2 50
◦C, 3-24 h - tracesa ,c
2 CH2Cl2 75
◦C, 2 h microwave irradiation tracesa ,c
3 CH3CN rt, 4 d - no product
4 CH2Cl2 rt, 48 h - 11
b
5 CH2Cl2 rt, 18 h TFA (0.1 equiv) 9
b
6 CH3CN/H2O
d 16-95 ◦C, 1.5 h NaHCO3 (3.75 equiv) 79
b
a Traces of product found in crude 1H-NMR spectrum. Isolation of the product was not
possible.
b Isolated yield.
c 4 A˚ MS added to the reaction mixture.
d Ratio of CH3CN/H2O: 3:1. Addition of the ketone at 16
◦C over 40 min followed by reflux at
95 ◦C for 1.5 h.
of the crude 1H-NMR spectrum showed no piperidone formation and a only complex
mixture of products that was not further investigated.
When 239 was reacted with benzylamine in dichloromethane at room temperature
without added molecular sieves (entry 4), 11% of piperidone product 242 could be
isolated. We believe that the trace water, which is present in the absence of molecular
sieves, leads to an improved yield by acting as a proton shuttle and thereby facilitates the
cyclisation process of ketone 239. Adding a catalytic amount of trifluoroacetic acid to
increase the electrophilicity of 239 (entry 5) did not significantly influence the obtained
yield under these conditions.
The patent literature described a procedure for the synthesis of 2-methyl substituted N -
benzyl 4-piperidone 241, using crotyl dienone 238 for the cyclisation with benzylamine
(Scheme 2.10).165–167 In the procedure outlined by Guzzo,167 benzylamine was added to
a mixture of acetonitrile and 1.8 M aqueous sodium bicarbonate. At a temperature of 16
◦C, crude divinyl ketone 238 was slowly added over a period of 40 min and the mixture
refluxed for one hour. The yield of isolated piperidone product 241, as reported by
Guzzo, was 54% (Scheme 2.10). When reacting phenyl dienone 239 with benzylamine
under these reaction conditions, the yield of the 2-phenyl substituted piperidone 242
was 79% (Table 2.6, entry 6), which is a considerable improvement over what had been
achieved in previous attempts.






Scheme 2.10: Reaction conditions: benzylamine, NaHCO3, CH3CN/H2O 3:1, 16
◦C
40 min., then reflux 1 h.167
Since the earlier experiment in acetonitrile (Table 2.6, entry 3) had not led to any
product formation, it was surprising to see such a significant improvement when using
acetonitrile/water as a mixed solvent system. In the literature a report was identified
about the rate accelerating effect of water on the aza-Michael reaction.168 The addition
of a broad range of cyclic and acyclic aliphatic primary amines and benzylamine to
Michael acceptors in pure water at room temperature is described by Ranu.168 It was
shown that benzylamine reacts much faster with Michael acceptor 246 and results in a
higher yield of product 251 in water than in organic solvents, such as tetrahydrofuran
and dichloromethane (Figure 2.11, Table 2.7).
Table 2.7: Effect of different solvents on the yield and reaction time of product 251.
Entry Solvent Time (h) Yield of 251 (%)
1 THF 15 30
2 CH2Cl2 15 50
3 H2O 0.8 85
The rationale for the promotion of the reaction is that water increases not only the
electrophilicity of the Michael acceptor through the formation of a hydrogen bond with
the carbonyl moiety, but also the nucleophilicity of the primary amine by forming another
hydrogen bond between the water molecule’s oxygen atom and the amine hydrogen atom
(Figure 2.11).168
Recently, Tang reported the reaction of aniline derivatives with ethyl acrylate at 50 ◦C
in aqueous sodium carbonate (Figure 2.12).169 While in pure water at room temperature
the yield of addition product 254 was less than 10% when using aniline as the substrate,
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Figure 2.11: Rationale for the rate accelerating effect of water in the aza-Michael
reaction.
it could be improved to 90% in the presence of sodium carbonate and at an elevated
temperature of 50 ◦C. Water is again forming a hydrogen bond to the carbonyl oxygen to
enhance the Michael acceptor’s electrophilic character. In addition, carbonate is present
in the activated complex 253, acting as a proton shuttle by supporting the proton


























Figure 2.12: Rationale for the rate accelerating effect of aqueous sodium carbonate
in the aza-Michael reaction.169
We believe that under the reaction conditions used in entry 6 (Table 2.6), the water and
sodium bicarbonate act together and facilitate the double aza-Michael addition to form
the piperidone product. As seen previously, neat acetonitrile is unsuitable as a solvent
for this reaction. However, because of its ability to solubilise both starting materials
and products and its miscibility with aqueous sodium bicarbonate, the combination
with water becomes an active solvent system, where the solvent is participating in the
reaction.
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Synthesis of Further Analogues
Utilising the protocol employing acetonitrile and aqueous sodium bicarbonate, a diverse
range of aliphatically and aromatically substituted piperidones have been prepared
(Table 2.8). As expected, the yields for the methyl and propyl substituted piperidones
241 and 243 (entry 1 and 2) were lower due to the unstable nature of the crude starting
ketones 238 and 240. When purified, aromatically substituted dienones 239, 244 and
245 were used for the cyclisation with benzylamine (entry 3-5), the desired piperidones
242, 255 and 256 were obtained in high yield (79-84%).
The obtained products possess only a single stereocentre in position two of the piperidine
ring and are therefore inseparable enantiomeric mixtures that cannot be distinguished
by NMR analysis. Although these piperidones are interesting building blocks for further
synthetic modifications, they are only of limited use when incorporated into more
complex biologically active molecules, as they will not give easily interpretable results
in stereosensitive SAR studies. In order to gain clear insight into the structural activity
related to piperidine compounds it would be necessary to evaluate compounds that
have resolved stereochemistry on the ring moiety, thereby facilitating an unambiguous
determination of the influence of a piperidine ring substituent on a compound’s biological
activity.
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Table 2.8: Synthesis of 2-substituted N -benzylic 4-piperidones.

































a Standard reaction conditions: Ketone, benzylamine, NaHCO3, CH3CN/H2O
3:1, 16 ◦C, 40 min, 95 ◦C, 1.5 h.
b Isolated yield.
c Crude ketone from MnO2 oxidation used as starting material.
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The Synthesis of Diastereomeric 2-Substituted N -α-Phenylethyl-4-piperidones
In order to obtain diastereomeric, potentially separable 2-substituted 4-piperidones,
chiral S -α-phenylethylamine 257 was chosen as a suitable primary amine for the aza-
Michael cyclisation (Figure 2.13). S -α-phenylethylamine is both a nucleophile and
a potential chiral auxiliary,170–172 besides being commercially available and cheap.
Furthermore it possesses similar chemical properties as the previously employed
benzylamine and can be easily removed by hydrogenolysis over a palladium catalyst.
H2N
257
Figure 2.13: S -α-Phenylethylamine.
Table 2.9 records the combined yields and product ratios of the diastereomeric
piperidones that were synthesised according to the previously developed method using
aqueous sodium bicarbonate. Since dienones 238 and 240 were used as crude for this
cyclisation reaction, the combined yields for the aliphatically substituted crotyl and
propyl piperidones were lower (27-37%, entry 1 and 2). The isolation of 258 and 259
as well as 260 and 261 was straight forward due to good separation of the respective
distereomers under silica column chromatography conditions. Aromatically substituted
piperidones (entry 3-5) were obtained in good (61-68%), albeit lower combined yields as
when compared to the cyclisation with benzylamine (Table 2.8). Due to their comparable
Rf values, the separation of the aryl substituted diastereomeric pairs proved more
difficult. In order to obtain the diastereomer bearing the lower Rf value in a pure
form, it was necessary to repeat the column chromatography. In this way complete
removal of traces of the diastereomer with the higher Rf value could be achieved.
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Table 2.9: Synthesis of diastereomeric 2-substituted N -α-phenylethyl-4-piperidones.























a Standard reaction conditions: Ketone, S -α-phenylethylamine, NaHCO3, CH3CN/H2O 3:1, 16
◦C, 40 min, 95 ◦C, 1.5 h.
b Isolated combined yield.
c Ratio of isolated products.
d Crude ketone used for reaction.
Assignment of the Correct Stereochemistry
The 2-methyl substituted diastereomeric piperidones 258 and 259 are known com-
pounds173,174 with their stereochemistry having been confirmed by X-ray analysis.175
In order to assign the stereochemistry of the other diastereomeric pairs of piperidones
correctly, their spectroscopic data was analysed.
It can be seen in Table 2.10, entry 1, that the experimentally obtained signal for the
methyl group on the α-phenylethyl substituent in the 13C-NMR is shifted upfield by
approximately 5.5 ppm in S,S -methyl diastereomer 258 when compared to the same
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b CHb C=O 2-CH3
c
1 Me S,S -258 16.47 57.76 210.54 16.33
R,S -259 21.93 58.84 210.54 14.78
2 Pr Major 19.30 58.19 210.89 14.34
Minor 22.50 58.71 210.79 14.11
3 Ph Major 9.52 54.97 209.15
Minor 19.56 56.63 208.83
4 4-Cl-Ph Major 9.83 55.16 208.61
Minor 19.52 56.87 208.22
5 4-MeO-Ph Major 9.57 54.85 209.34
Minor 19.65 56.45 209.50
a Referring to the substituent in position two on the piperidine ring.
b Referring to the α-phenylethyl substituent in position one on the ring.
c Referring to the methyl group-substituent in position two on the ring.
signal in R,S -259. Besides that, a small upfield shift of 1.1 ppm for the α-phenylethyl-
CH signal and a small downfield shift in the methyl group in position two on the
piperidine ring is observed in 258. The carbonyl signals of 258 and 259 are identical.
The chemical shifts of the propyl-substituted analogues were investigated (Table 2.10,
entry 2) and the signals for the major and the minor diastereomer were in accordance
with the pattern that had been observed for compound S,S -258 in respect to R,S -259.
In addition, the carbonyl peak belonging to the major and firstly eluting product was
also the one that was shifted slightly downfield in the spectrum.
For the 2-phenyl diastereomeric piperidones (Table 2.10, entry 3), the major product
possessed the higher Rf value and presented the same
13C-NMR signal pattern as S,S -
258. In this case, the major product’s α-phenylethyl methyl signal is shifted 10.0
ppm upfield in comparison to the same carbon signal in its minor diastereomer. The
same pattern of difference in chemical shifts in the 13C-NMR spectra between the two
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diastereomers was observed in the 4-chloro- and the 4-methoxy-phenyl 2-substituted
piperidone compounds (Table 2.10, entry 4 and 5).
Leshcheva176 conducted a similar analysis of the 13C-NMR spectra of methyl piperidones
258 and 259 and used the difference in chemical shifts to elucidate the configuration
of the substituents on the piperidine ring. The molecular models developed were
established based on the assumption that the nitrogen inversion equilibrium is com-
pletely shifted towards the equatorial position of the N -alkyl substituent. Figure 2.14
shows the most favoured rotamers with respect to the N -α-phenylethyl moiety for both

























































Figure 2.14: Most favourable rotamers of the equatorial conformers of 2S -258 and
2R-259 in their conformational equilibria.176
According to this analysis, the large upfield shift in the methyl group on the α-
phenylethyl substituent of one diastereomer is caused by a hyperconjugation effect which
is due to the methyl group’s axial orientation in relation to the nitrogen lone pair of
electrons. Only in this conformation can the nitrogen lone pair be donated into to the σ*
orbital of the adjacent C-C bond and cause the observed upfield shift of the CH3 group.
As shown in Figure 2.14, such an axial position of the methyl group is only found in
the 2S diastereomer, therefore the correct configuration of the two diastereomers can be
readily assigned.176
According to this rationale, the major propyl-substituted diastereomer with the higher
Rf value was assigned as S,S -260 and subsequently the minor one with the lower Rf
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value as R,S -261 (Table 2.11, entry 2).




















































a Ratio of isolated products.
The phenyl-substituted diastereomer 262, bearing the same configuration as the the
methyl and propyl substituted S,S -258 and S,S -260, is hence labelled with R-chirality
in position two on the ring (Figure 2.15).
In conclusion, the major phenyl-diastereomer was assigned as R,S -262 and subsequently
the minor product as S,S -263 (Table 2.11, entry 3). According to this rationale, the
other aryl-piperidones were assigned in analogy as R,S -264, S,S -265, R,S -266 and S,S -
267 concerning their configuration in position two on the piperidine ring (Table 2.11,
entry 4 and 5).













Figure 2.15: Major piperidones S,S -258, S,S -260 and R,S -262.
Investigation of the diastereomeric piperidone products by Nuclear Overhauser effect
spectroscopy (NOESY) was not possible in most cases, due to overlapping signals that
prevented an unambiguous analysis. However, in one of the synthesised piperidones,
2S -phenyl substituted 263, the analysis of the NOESY spectrum was conclusive
(Figure 2.16). The signal of Hax-1 in the
1H-NMR spectrum was observed at 3.67 ppm as
a dd with coupling constants of J 9.4 and 4.5 Hz, but unfortunately the couplings of the
Hax-2, Heq-2 and Hax-5 could not be determined due to overlapping signals. Nevertheless
the observed coupling constants for Hax-1 indicate an axial position for this proton, a
suggestion which is further supported by the observed NOE correlation to Hax-5. Hax-5
has a chemical shift of 2.20-2.24 ppm and is therefore much further upfield than its



















Figure 2.16: Observed NOESY interactions for S,S -diastereomer 263.
Chapter 2. Studies Into the Synthesis of Novel Piperidines 72
Diastereoselectivity of the Reaction
As derived from the ratios of the isolated piperidones, a certain degree of diastereoselec-
tivity was observed in this double aza-Michael cyclisation depending on the substituent
in position two on the ring (Table 2.11).
The isolated yields of 2-methyl piperidones 258 and 259 suggest a roughly equal
product distribution. The crude 1H-NMR spectrum was too complex to allow an
accurate analysis of the product distribution, therefore it could not be unambiguously
determined whether chiral induction had taken place during the formation of 258 and
259. For the propyl substituted analogues 260 and 261, the ratio of diastereomers
could be derived from the crude 1H-NMR and was found to be 1.37:1.00, respectively.
This is in accordance with the isolated product ratio of 1.45:1.00 and suggests a small
diastereoselective effect due to the increased chain length of the substituent on the ring.
In the case of phenyl-substituted 262 and 263, a higher degree of chiral induction was
observed. A ratio of 2.55:1.00 was deducted from the crude 1H-NMR spectrum and a




S,S Colour    2-Substituent
red           Ph
green       4-MeO-Ph
blue         4-Cl-Ph
Figure 2.17: Expanded, overlaid, crude 13C-NMR spectra of 2-aryl 1-α-phenylethyl-
4-piperidones.
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Determination of the diastereoselectivity of the reaction of 4-methoxy- and 4-chloro-
phenyl substituted piperidone products was not possible from the crude 1H-NMR
spectra, but their isolated product ratios suggest a similar extent of chiral induction
as what had been observed with the phenyl substituted piperidones (Table 2.11, entry
3-5). The comparable product distribution for the aromatically substituted piperidones
was further visualised by overlaying the crude 13C-NMR spectra. In Figure 2.17 the
superimposed spectra are expanded to the ketone region and show that the carbonyl
signals of the major R,S -diastereomers 262, 266 and 264 are shifted downfield when
compared to their corresponding minor S,S -diastereomers 263, 267 and 265.
The stereochemical outcome of the double aza-Michael cyclisation is determined during
the second addition process, where the amine nucleophile intramolecularly attacks
the sterically more hindered double bond bearing a substituent. We believe that
in accordance with the conformational analysis by Leshcheva176 (Figure 2.14), the
hyperconjugation effect that leads to the significant difference in chemical shift of
the methyl groups in the two diastereomers, is also responsible for the observed
diastereoselectivity in this reaction (Figure 2.18). The favoured transition state is the
one that leads to a cyclisation product in which the two orbitals can interact. As this is











Figure 2.18: Rationale for the observed diastereoselectivity.
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2.2 A Facile Method For The Oxidation of Benzylic
Primary Amines
Manganese Dioxide in Organic Chemistry
Manganese has three oxidation states (+II, +III, +IV), giving rise to a diverse range
of stable mineral oxides that are used extensively in pigments, in batteries and
as catalysts.177 There are various types of manganese dioxides, including α-MnO2
(cryptomelane), β-MnO2 (pyrolusite), γ-MnO2 (nsutite) and δ-MnO2 (birnessite), but









Figure 2.19: A MnO6 octahedron.
Depending on the type of MnO2, these octahedra can be arranged in either a




= MnO2 octrahedron 
Figure 2.20: Structure representation of MnO2 frameworks: A) cryptomelane B)
pyrolusite C) birnessite.
Manganese dioxide is used extensively in organic synthesis and is a versatile and selective
oxidising agent.155 The observation that MnO2 can act as an oxidant if suspended in
Chapter 2. A Facile Method For The Oxidation of Benzylic Primary Amines 75
organic solvents was first made by Ball180 in 1948. He showed that MnO2 was able to
efficiently oxidise vitamin A 269 and thereby convert it to retinene 270 (Scheme 2.11).
Attenburrow153 also explored the properties of this oxidant during his work on vitamin A
and furthermore described the preparation of activated MnO2 from manganese sulphate
and potassium permanganate under basic reaction conditions.
OH O
i
vitamin A retinene269 270
Scheme 2.11: Reaction conditions: i) MnO2, petroleum ether, rt, 6-10 d.
MnO2 has become a widely used oxidant for the selective transformation of benzylic
and allylic alcohols into their corresponding aldehydes and ketones.150–152,181 This is
particularly useful for the oxidation of allylic alcohols in the presence of aliphatic alcohols
and other oxidant-sensitive functional groups (Scheme 2.12).182 The secondary benzylic
















Scheme 2.12: Reaction conditions: i) MnO2, acetone, rt.
MnO2 can also be employed in tandem oxidation processes. The important natural
product building block 275 can be prepared by either a stepwise approach or a
MnO2-mediated tandem oxidation process (Scheme 2.13). Various oxidants have
been investigated for their use to access the highly unstable aldehyde 274, but upon
treatment with (carboxyethoxymethylene)triphenylphosphorane, the product of the
Wittig olefination 275 is obtained only in poor overall yield (10-30%).183 When the
reaction was modified to a one-pot method employing MnO2 as the oxidant, the handling
of the labile intermediate 274 can be avoided and dienoate 275 isolated in a yield of
78% over two steps.184
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iii i,ii: 10-30% over two steps
iii: 78%
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Scheme 2.13: Reaction conditions: i) various oxidants ii) Ph3P=CHCO2Et iii)
MnO2, Ph3P=CHCO2Et, CH2Cl2, rt, 24 h.
In reactions employing MnO2, the choice of solvents plays a crucial role in the success
of the oxidation. Polar solvents and alcohols can adsorb to the surface of MnO2 and
compete with the substrate’s hydroxyl group, thus leading to a decreased activity of the
oxidant.155 Furthermore it is important to use dry solvents, because additional water,
other than the water that is bound to the surface of the metal oxide, can deactivate
MnO2.
155
A Manganese Dioxide Mediated Oxidation of Benzylic Primary Amines
During the synthesis of N -benzyl-4-piperidone 201, aromatic byproducts were formed
(Figure 2.21). The side-products were identified as alkylimine 220 and aldehyde 221.
As the reactivity of benzylamine towards MnO2 was lowering the yield of the piperidone











186 219 201 220 221
Figure 2.21: Aromatic byproducts 220 and 221 in the one-pot oxidation/aza-Michael
reaction.
Under the same conditions as in the synthesis of piperidone 201 (Figure 2.21),
benzylamine 219 alone was reacted with MnO2 (Scheme 2.14). In the absence of
divinylcarbinol 186, benzamide 276 was obtained in a yield of 98%.







Scheme 2.14: Reaction conditions: i) MnO2, 4 A˚ MS, CH2Cl2, 40
◦C, 24 h.
The direct oxidative transformation of primary amines to their corresponding amides is
difficult to achieve and has not been extensively explored in the literature. Yoshifuji185
previously reported a procedure which employs in-situ generated RuO4 as oxidant, but
requires prior tert-butoxycarbonyl (Boc) protection of the amino group (Scheme 2.15).
R NHBoc R NHBoc
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Scheme 2.15: Reaction conditions: i) RuO2 · xH2O, NaIO4 aqu., EtOAc, rt, 0.25-15
h; ii) TFA/CH2Cl2 1:1, rt, 1 h.
Nishinaga’s procedure186 involves the condensation of arylmethylamines 280 with 2,6-
di-tert-butyl-p-benzoquinone 281 followed by base catalysed oxygenation to yield the
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Scheme 2.16: Reaction conditions: i) reflux in EtOH; ii) t-BuOK, t-BuOH, O2, 25◦C, 2-6 h.
More recently, two systems have been reported for a dehydrogenation-hydration sequence
which achieves the conversion of primary amines to their corresponding amide in a one
pot reaction (Scheme 2.17, Scheme 2.18).156,187 Kim’s procedure187 allows the conversion
of primary amines into their corresponding amides in good to excellent yield (77-98%),
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employing an alumina supported ruthenium hydroxide catalyst, Ru(OH)x/Al2O3, in
water (Scheme 2.17).
R NH2 R NH2
O
R= alkyl or aryl (77-98%)
i
284 285
Scheme 2.17: Reaction conditions: i) Ru(OH)x/Al2O3 (Ru: 5 mol%), H2O, 130-
160◦C, 5 atm air, 10-24 h, sealed teflon vessel.
Wang156 recently reported the amide formation from benzylamine derivatives in
excellent yields, utilizing manganese oxide based octahedral molecular sieves (OMS-
2) and aqueous ammonia (Scheme 2.18). The OMS-2 catalyst used in this method is a
cryptomelane-type MnO2 consisting of a tunnel framework (Figure 2.20) and is prepared
from manganese sulphate and potassium permanganate.188
R NH2 R NH2
O
R= alkyl or (hetero)aryl (65-98%)
i
286 287
Scheme 2.18: Reaction conditions: i) OMS-2, NH3 aqu., 1,4-dioxane, 130-160
◦C, 6
atm air, 3 h, sealed teflon vessel.
The drawbacks of both Kim’s and Wang’s procedure are the forcing conditions which
involve reaction temperatures of 130-160◦C, the application of 5-6 atmospheres of air
and the necessity of an explosion-proof Teflon apparatus. These reactions can not be
carried out in a standard laboratory and are therefore impractical to use. In comparison
to these methods, our oxidation (Scheme 2.14) possesses several advantages. Firstly, we
are able to use commercially available, cheap, pyrolusite-type189,190 manganese dioxide
(Alfa Aesar), which only requires activation by treatment with 10% nitric acid and
drying at 105 ◦C for 48 h. Furthermore, there is no need for the addition of aqueous
ammonia or other reagents. As conversion to the amide proceeds smoothly under mild
conditions, at a reaction temperature of 40 ◦C and at atmospheric pressure, the reaction
can be carried out in standard glassware.
Figure 2.22 shows the mechanism for the OMS-2 mediated transformation of primary
amines to primary amides as proposed by Wang.156 An OMS-2 catalysed oxidative
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dehydrogenation first transforms the primary amine into unstable aldimine 287 and
successively into nitrile 288. Subsequently, the nitrile is hydrated and leads to the
formation of primary amide 289. If the unstable imine hydrolyses to aldehyde 290, it
can subsequently react with starting material and give alkylimine 291.
Under Wang’s experimental conditions, the addition of aqueous ammonia was crucial for
a successful hydration of the nitrile to the amide. In the absence of ammonia, alkylimine
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Figure 2.22: Reaction pathway for the transformation to the primary amide proposed
by Wang.156
For our initial investigations into this reaction pathway, 4-chlorobenzylamine 292 was
selected as the starting amine. It gives an easily distinguishable pair of doublets in the
aromatic region of the 1H-NMR-spectrum and therefore facilitates the assignment and
identification of the resulting products. When 4-chlorobenzylamine 292 was evaluated
under the same conditions (Scheme 2.19), the corresponding amide 293 formed in
quantitative yield. The product was obtained by filtration and washing with hot (60






Scheme 2.19: Reaction conditions: i) MnO2, 4 A˚ MS, CH2Cl2, 40
◦C, 24 h.
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As the reaction does not need to be carried out in a sealed vessel, the reaction mixture
could be sampled at any time point during the reaction to monitor the progress of
the amide formation by 1H-NMR analysis. After a reaction time of one hour, all the
major intermediate products proposed by Wang156 could be identified in the 1H-NMR
spectrum (Figure 2.23). Aldehyde 296 was only visible in traces whereas the other




























Figure 2.23: Intermediate products in the oxidation of 4-chlorobenzylamine to 4-
chlorobenzamide after a reaction time of one hour.
To follow the conversion of these intermediates to the amide, samples were taken at
further time points (Figure 2.24). After one hour, a small amount of amide 293 had
formed and it increased gradually as the signals for alkylimine 295 decreased (the
methylene protons of the alkylimine appear at 4.76 ppm, Figure 2.23). Nitrile 294 could
only be detected in the first spectrum after one hour, suggesting that its hydration to
the amide happens rapidly. After a reaction time of 24 h, a complete conversion to
amide 293 had taken place and no signals of the intermediate products were observed.








Figure 2.24: NMR-investigation experiment for the transformation of amine 292 to
amide 293.
To further probe the mechanism of the MnO2 mediated amide formation, a range of
reaction conditions was investigated (Figure 2.25, Table 2.12). Under the standard
reaction conditions, 4-chlorobenzylamine 292 was quantitatively converted to its
corresponding amide 293 (Table 2.12, entry 1). It is noteworthy that not only MnO2
from Alfa Aesar, but also the acid-treated MnO2 from Sigma Aldrich achieved a
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Figure 2.25: Oxidation of 4-chloro-benzylamine 292 using MnO2.
In order to investigate the role of the molecular sieves, the reaction was carried out
in their absence (Table 2.12, entry 2). The yield of the amide obtained under these
conditions was low (44%), with considerable nitrile 294 (16%) and alkylimine 295 (36%)
formation. We believe that the molecular sieves play a crucial role in the reaction
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by preventing the inactivation of the manganese dioxide’s surface due to its ability to
capture excess water from the reaction mixture. Without the molecular sieves, the MnO2
mediated oxidative conversion of the unstable aldimine to nitrile 294 is less efficient,
which is demonstrated by the formation of alkylimine 295. Obtaining nitrile 294 as
product further means that without the added molecular sieves, the hydration to the
amide product is incomplete.
Employing untreated MnO2, which was used as received from the vendor, resulted in a
drop yield of the desired amide 293 to 63% (Table 2.12, entry 3). This demonstrates
that pre-treatment of the oxidant is vital for the performance of MnO2 as an oxidant in
this reaction. Decreasing the amount of MnO2 in the reaction to 12.5 equivalents also
resulted in a significantly reduced amide formation, with nitrile 294 and alkylimine 295
having formed as well (entry 4). Hereby it is shown that when less MnO2 is present,
the hydration of nitrile 294 can not proceed to completion. Furthermore, under these
conditions the unstable aldimine is not fully converted to nitrile 294 and is hydrolysed
to aldehyde 296, ultimately leading to the formation of alkylimine 295.
Table 2.12: Summarising table for the effects of various reaction conditions on the
MnO2-mediated transformation of 292 to 293.
Yield (%)a
Entry Conditionsb 293 294 295 296
1 Standard conditions 99 ≤1 ≤1 ≤1
2 No molecular sieves 44 16 36 3
3 Untreated MnO2 63 ≤1 37 ≤1
4 12.5 equiv. MnO2 56 17 24 3
5 Under N2 atmosphere 71 ≤1 29 ≤1
6 Recycled MnO2 73 ≤1 27 ≤1
7 Aqu. NH3, untreated MnO2 66 ≤1 33 ≤1
8 NH3 in THF, untreated MnO2 70 24 5 ≤1
9 NH3 in THF, no molecular sieves 77 23 ≤1 ≤1
a Yields were determined by 1H-NMR analysis.
b Standard reaction conditions: amine 292 (0.5 mmol), acid-washed MnO2 (25
equiv), 4 A˚ molecular sieves, CH2Cl2 (3.5 mL), 40
◦C, 24 h
Carrying out the reaction under an inert nitrogen atmosphere (Table 2.12, entry 5),
resulted in amide 293 being formed in a yield of 71%, indicating that it is not oxygen
coming from the air, but rather oxygen bound to the surface of MnO2 which achieves the
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oxidation.151 Although employing recycled MnO2 in this reaction resulted in a reduced
yield of amide 293 (entry 6), the distribution of products was simpler compared to
when a smaller amount of MnO2 was used (entry 4). Only a trace of nitrile 294, but
a considerable amount of alkylimine 295 was formed. This means that although the
recycled MnO2 achieves a complete hydration of nitrile 294 to the amide, a lack in
oxygen on the surface of MnO2 prevents a complete conversion of the the unstable
aldimine to nitrile 294. The aldimine is therefore hydrolysed to aldehyde 296 and
consequently converted to alkylimine 295.
The addition of aqueous ammonia in combination with untreated MnO2 did not
significantly improve the yield of the amide (entry 7), compared to when untreated
MnO2 was used (entry 3). This is in contrast to the results obtained by Wang, who
reported that without the addition of aqueous ammonia, alkylimine 295 was obtained as
the major product.156 Under our reaction conditions, the addition of aqueous ammonia
results in a biphasic solvent system, due to the immiscibility of dichloromethane with
water. The ammonia molecules are therefore highly solvated in the aqueous phase which
means that the ammonia is not able to transfer to the organic phase and participate in
the reaction.
To avoid these shortcomings, the experiment was repeated using a 0.5 M solution
of ammonia in tetrahydrofuran (entry 8). The yield for amide 293 was only
modestly increased (70%), in addition to a change in the product distribution. While
alkylimine 295 was the major intermediate product observed in the presence of aqueous
ammonia (entry 7), nitrile 294 was favourably formed when using 0.5 M ammonia in
tetrahydrofuran (entry 8). The ammonia in the reaction mixture is competing with
amine 292 to react with aldehyde 296. If an excess of ammonia is present, the aldehyde
is more likely to react to nitrile 294 via the unstable aldimine than to alkylimine
295, which also explains the considerable amount of nitrile which was observed in this
experiment (entry 8). When aqueous ammonia is used in the reaction (entry 7), no such
excess of ammonia is available, therefore aldehyde 296 rather reacts with amine 292,
leading to the observed formation of alkylimine 295.
A similar product distribution was also obtained when the experiment was repeated
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with 0.5 M ammonia in tetrahydrofuran using activated MnO2 without added molecular
sieves (entry 9). As there was also a considerable amount of nitrile 294 formed in this
experiment, we believe that the excess of ammonia in this reaction interacts with the
MnO2 in a way that reduces its ability to hydrate the nitrile.
Conversion of the Reaction Intermediates to the Amide
In order to further investigate the MnO2 mediated oxidation process, the intermediates
alkylimine 295 and 220 were synthesised in quantitative yield by condensation of their
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221 202 220
Scheme 2.20: Reaction conditions: i) 4 A˚ MS, CH2Cl2, 40
◦C, 1.5 h.
Alkylimine 295 was reacted with MnO2 under the standard reaction conditions and
amide 293 was obtained in a yield of 95% (Scheme 2.21), thereby demonstrating that
alkyminine 295 can be hydrolysed back to amine 292 and aldehyde 296, rendering it
possible for the amine to undergo the MnO2 facilitated oxidation to the amide. Unlike
Wang’s observations, where additional ammonia was required to convert the alkylimine






95% 97%295 293 296
Scheme 2.21: Reaction conditions: i) MnO2, 4 A˚ MS, CH2Cl2, 40
◦C, 24 h.
In a further experiment (Scheme 2.22), nitrile 294 was reacted under the same conditions
and afforded amide 293 in quantitative yield within only two hours. This result supports
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the data that was obtained from the NMR-investigation experiment earlier (Figure 2.24)
and shows that nitrile 294 is rapidly converted to the final amide. Wang reported a
yield of 70% for the amide when reacting the nitrile in the presence of aqueous ammonia
under their standard reaction conditions. However, adding pure water to this reaction







Scheme 2.22: Reaction conditions: i) MnO2, 4 A˚ MS, CH2Cl2, 40
◦C, 2 h.
An interesting observation in this context is that even though the conversion from the
nitrile to the amide happens via hydration, the addition of water-scavenging molecular
sieves used in our standard reaction conditions seems to be important for complete
conversion to amide 293 (Table 2.12, entry 2). We believe that the water necessary for
the hydration of the nitrile is not provided by the solvent, but by MnO2. The molecular
sieves capture water from the solvent environment and therefore prevent deactivation
of the MnO2. On the contrary, water bound to the surface of MnO2 is not affected by
added molecular sieves and can thus still take part in the hydration process.155
Reacting aldehyde 296 with activated MnO2 and ammonia (0.5 M in THF, 1.5 equiv)
gave amide 293 in quantitative yield both in the presence and absence of molecular
sieves (Scheme 2.23) thereby showing that an external source of ammonia can be used








Scheme 2.23: Reaction conditions: i) MnO2, NH3, CH2Cl2/THF (1.7:1), 40
◦C, 24
h.
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The Dual Role of Manganese Dioxide
From the previous experiments we concluded that MnO2 not only acts as a catalyst in
the oxidation processes, but also serves as a source of water during the reaction. As
the molecular sieves remove water from the reaction mixture, it is the water bound
to the surface of the MnO2
151 which facilitates the hydrolysis of alkylimine 295 to
the aldehyde 296 and consequently the hydration of the nitrile 294 to the final amide
product. Furthermore, if only oxygen from the air was used to achieve the oxidative
dehydration of amine 292 to nitrile 294 via the unstable aldimine, no amide formation
would be observed in a reaction under an inert nitrogen atmosphere (Table 2.12, entry
5).This indicates that the oxygen consumed during the reaction is originating from the
surface of activated MnO2. If there is insufficient oxygen available, for example when
reused MnO2 is employed (Table 2.12, entry 6), the remaining aldehyde intermediate is
locked away as the easily formed alkylimine.
The Role of the Molecular Sieves
The 4 A˚ molecular sieves used in this reaction are microporous alumino-silicate zeolites
bearing Brønsted acidic sites.191 In addition to water, other molecules with a diameter
smaller than 4 A˚ can be adsorbed within the pores of this material. Ammonia is known
to be adsorbed on the surface of these zeolites as the ammonium ion NH+4 .
192,193
When ammonia is released upon the formation of aldehyde 296 from the unstable
aldimine, ultimately leading to the formation of alkylimine 295, it must be available
for the reaction back as well, otherwise quantitative formation of amide 293 would not
be observed. We believe that the molecular sieves play a crucial role in this process
and prevent the loss of ammonia from the reaction mixture by acting as a storage
and making the ammonia available for the reaction with the aldehyde back to nitrile
294. Hence, through a dual mode of action, the molecular sieves render the ammonia
available throughout the reaction process and furthermore retain excess water to prevent
the inactivation of the MnO2 surface.
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When an excess of ammonia was added to the reaction with aldehyde 296, the amide
product was obtained in quantitative yield both in the presence and absence of molecular
sieves (Scheme 2.23). We believe that in this case the molecular sieves are not vital for
a complete conversion to the amide, since with the increased availability of ammonia in
the reaction mixture, there is no need for its storage throughout the reaction process.
Synthesis of Further Analogues
A diverse range of amides has been synthesised according to our protocol (Table 2.13).
The products were obtained after filtration of the reaction mixture with hot methanol
followed by evaporation of the solvent. In some cases it was not necessary to further
purify the crude residue since pure product was obtained. If small amounts of by-
products were present, it was sufficient to wash the crude residue with a few millilitres
of hexane. The amide products are practically insoluble in hexane, which allows a
selective dissolution of the nitrile, alkylimine and aldehyde by-products. In only a few
cases was column-chromatography required.
For most amide products the yields are good to excellent. When benzylic amines
with a methoxy substituent were used in this reaction (entry 5-7), lower yields of
the corresponding amides were obtained compared to when substrates with a chloro
substituent on the benzyl moiety were employed (entry 9-11). The lowest yield was
obtained when the methoxy substituent was placed in the ortho position on the aromatic
ring (entry 7). In this case, 2-methoxybenzonitrile was also isolated in a 28% yield. We
believe that the hydration of this particular nitrile substrate takes place more slowly
due to steric hindrance and therefore causes the comparatively lower yield of amide 308
after 24 hours. When the aliphatic amine octylamine was subjected to these reaction
conditions, no amide product was formed.
When the reaction was carried out on a larger scale, using 19 mmol of benzylamine
202, the yield of the amide product was not significantly affected. Benzamide 276 was
obtained in a yield of 96% as compared to a yield of 98% on a 1 mmol scale, thereby
further demonstrating the synthetic utility of this protocol.
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Table 2.13: Summarising table for the transformation of primary benzylic amines to
primary amides.












































































a Standard reaction conditions: amine substrate, acid-washed MnO2, 4 A˚
molecular sieves, CH2Cl2, 40
◦C, 24 h
b Isolated yield.
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2.3 Studies Towards the Synthesis of Donepezil Analogues
Having prepared aliphatically and aromatically 2-substituted, diastereomeric 1-α-
phenylethyl-4-piperidones 315, we set about incorporating these building blocks into the
AChE inhibitor donepezil 12 to obtain analogues 316 with modified biological activity
(Figure 2.26). Initially, experiments would utilise both diastereomers of the methyl
as well as the phenyl substituted piperidone 315 and the AChE inhibition potency of
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Figure 2.26: Incorporation of chiral piperidones 315 into donepezil 12 for the
synthesis of analogues 316.
1-Benzyl-4-formyl-piperidine 319 is an important building block in the synthesis of
donepezil. This aldehyde is unstable, therefore its easy and clean preparation is
particularly relevant for the overall cost-efficient synthesis of donepezil. Sugimoto194
described the synthesis of this vital reagent from commercially available 1-benzyl-4-
piperidone 317 (Scheme 2.24). The piperidone is subjected to a Wittig reaction to give
methoxymethylene intermediate 318, followed by hydrolysis under acidic conditions to
desired aldehyde 319.













Scheme 2.24: Reaction conditions: i) ((Ph3)PCH2OCH3)Cl, n-BuLi, Et2O, rt→0◦C→rt, 3 h; ii) MeOH/1 M HCl 1:1, reflux, 3 h.
An alternative route to aldehyde 319 was described by Niphade195 (Scheme 2.25).
Commercially available carboxylic ester 320 is firstly benzylated to give 321, followed
by a reduction with the organoaluminium compound Vitride R© to alcohol 322. A final
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Scheme 2.25: Reaction conditions: i) BnCl, TEA, toluene, 75 ◦C, 7 h; ii) Vitride R©,
toluene, 15 ◦C, 3 h; iii) (CO2)Cl2/DMSO, TEA, CH2Cl2, -60
◦C→-70 ◦C, 5 h.
Sheng and Hu196 reported a route consisting of only two steps and a high overall yield of
82% (Scheme 2.26). Again, 1-benzyl-4-piperidone 317 is used as starting material and
transformed to epoxide 323 via a Corey-Chaykovsky reaction, followed by a Meinwald













Scheme 2.26: Reaction conditions: i) TBAB, (CH3)3S
+OI–, NaOH, toluene/water
3.3:1, 80 ◦C, 4 h; ii) MgBr2 ·OEt2, toluene, 40 ◦C, 20 min.
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It was envisioned that when following either Sugimoto’s194 or Sheng’s196 route (Scheme 2.24,
Scheme 2.26), not only N -benzyl-4-piperidinone 317, but also 2-substituted piperidones
315 could be converted into their corresponding aldehydes to serve as building blocks
for the synthesis of donepezil analogues 316 (Figure 2.26).
The synthesis of donepezil was first reported by Sugimoto120,194 (Scheme 2.27). Aldol
condensation of 5,6-dimethoxy-1-indanone 324 and aldehyde 319 gives enone 325
(62%), hydrogenation of which over a palladium catalyst yields racemic donepezil as





















Scheme 2.27: Reaction conditions: i) n-BuLi/THF/hexamethylphosphoric triamide
(HMPA), -78 ◦C to rt, 2 h; ii) 10% HCl-EtOAc; iii) 10% Pd-C, H2, THF, rt, 6 h; iv)
10% HCl-EtOAc.
2.3.1 Access to Aldehyde Building Blocks via Epoxidation and
Rearrangement of 4-Piperidones
The initial efforts towards the synthesis of chiral 2-substituted 1-benzyl-4-formyl-
piperidine building blocks were undertaken following Sheng’s196 route, as it consists
of only two steps in high overall yield (Scheme 2.26).
Epoxidation of 4-Piperidones
The first step in the synthesis is a Corey-Chaykovsky epoxidation,197 where a methylide
nucleophile 329 is generated by the deprotonation of trimethylsulfoxonium iodide 327
by a base (Figure 2.27).

















Figure 2.27: Formation of methylide nucleophile 329.
In Sheng’s procedure, which uses a mixture of toluene and aqueous NaOH, a phase
transfer catalyst facilitates the deprotonation step. Dropwise addition of the aqueous
NaOH is necessary to achieve a better dispersion of the aqueous droplets, thereby
ensuring a gradual TBAB aided transfer of the base to the organic phase.
When piperidone 317 was subjected to these conditions, analysis of the crude 1H-NMR
spectrum showed that after 4 h, 90% of product 323 had formed while 10% of the
starting material remained (Scheme 2.28). Not only to further improve the conversion
rate, but also because the dropwise addition of aqueous NaOH was found impractical,











Scheme 2.28: Reaction conditions: i) TBAB, (CH3)3S
+OI–, NaOH, toluene/water
3.3:1, 80 ◦C, 4 h; ii) (CH3)3S
+OI– and t-BuOK premixed (1:1), DMSO, 55 ◦C, 50 min.
Ciaccio198 reported the epoxidation of various ketones and aldehydes in high yields using
a modified version of the standard Corey-Chaykovsky reaction procedure which employs
potassium t-butoxide as the base. t-Butoxide is a solid and can be conveniently pre-
mixed with the trimethylsulfoxonium iodide salt and then stored for prolonged periods
of time without loss of activity.198 When 317 was reacted with this mixture at 55
◦C in DMSO, a complete conversion to epoxide 323 was observed within 50 minutes
(Scheme 2.28). Since this protocol required a lower reaction temperature, a shorter
reaction time and was overall more practical, we decided to apply this method to the
preparation of 2-substituted epoxide analogues. The 2-methyl and 2-phenyl substituted
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enantiomeric piperidones 241 and 242 were epoxidised and obtained as inseparable
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Scheme 2.29: Reaction conditions: i) (CH3)3S
+OI– and t-BuOK premixed (1:1),
DMSO, 55 ◦C, 50 min.
When diastereomer 2R-259 was subjected to these epoxidation conditions, the formation
of a minor and a major epoxide product was observed (Scheme 2.30). From the analysis
of the crude 1H-NMR spectrum the diastereomeric mixture was a 1:3 ratio of 332:333.
The two epoxides 332 and 333 could be separated by column chromatography and were







Scheme 2.30: Reaction conditions: i) (CH3)3S
+OI– and t-BuOK premixed (1:1),
DMSO, 55 ◦C, 60 min.
The rationale for the assignment of the correct stereochemistry of epoxide products 332
and 333 is depicted in Figure 2.28. An attack at the carbonyl group of piperidone
334 is possible from both faces, but due to 1,3-diaxial interactions, axial addition of
a large nucleophile such as the methylide is less favoured. An equatorial attack is less
hindered and results in the formation of epoxide 2R,4S -338 as the major product. The
chirality of the stereocenter in position 4 on the piperidine ring of epoxides 332 and 333
(Scheme 2.30) was assigned in analogy to this model.













































Figure 2.28: Rationale for the preferred equatorial attack of methylide 329.
Having achieved the epoxidation of simple 1-benzyl-4-piperidone as well as chiral 2-
methyl and 2-phenyl substituted piperidones, the next step in the synthesis, a Meinwald
rearrangement, was investigated.
Meinwald Rearrangement of Epoxides to Aldehydes
A Meinwald rearrangement is a Lewis acid catalysed reaction in which an epoxide is
converted to an aldehyde or ketone.199 The proposed mechanism of this rearrangement
process involves Lewis acid activation of 339, the epoxide ring opening of 340 and
the formation of intermediate 341, which bears a tertiary carbocation in position 4 on
the piperidine ring (Figure 2.29). A subsequent 1,2-hydride shift, followed by aqueous
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Figure 2.29: Mechanism for the Meinwald rearrangement of epoxide 339 to aldehyde
343.
Sheng196 reacted epoxide 323 in the presence of the Lewis acid magnesium bromide
etherate and upon distillation of the crude reaction mixture, obtained the rearranged
N -benzyl-4-formyl-piperidine 319 in a yield of 83% (Scheme 2.31). Repeating Sheng’s
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rearrangement protocol of epoxide 323, analysis of the crude 1H-NMR spectrum showed
that approximately 40% of the epoxide had been converted to the aldehyde, while there
was still unreacted starting material present (18%), in addition to two unidentified
byproducts (18% and 25%) (Scheme 2.31). While the separation of the epoxide starting
material by column chromatography was possible, aldehyde 319 was only obtained in a









Scheme 2.31: Reaction conditions: i) MgBr2 ·OEt2, toluene, 40 ◦C, 20 min; ii)
MgBr2 ·OEt2, toluene, 40 ◦C, 4 A˚ MS, N2, 30 min.
When the reaction was carried out under an atmosphere of nitrogen in the presence of
molecular sieves, epoxide 323 was found to be completely consumed as determined by
TLC. Analysis of the crude 1H-NMR spectrum showed that an improved 59% of aldehyde
319 were present, accompanied by the same two unknown byproducts that were observed
under the previous reaction conditions. Upon reduced pressure distillation of the crude
material, due to the decomposition of the unstable aldehyde 319, only 19% of pure
product could be isolated.
When this procedure was applied to 2-methyl and phenyl substituted epoxides 330 and
331, the formation of the corresponding aldehydes did not occur (Scheme 2.32). The
crude 1H-NMR spectra showed only traces of the characteristic aldehyde proton and
considerable starting material remained alongside an unidentified byproduct. When
330 was subjected to the rearrangement conditions for an extended reaction time of 4
h, all epoxide starting material was consumed, but only traces of aldehyde 344 were
found in the crude spectrum. The same reaction at room temperature gave a similar
result, with unreacted starting material present in the crude mixture. Although the
byproduct observed in these experiments was not isolated, we believe that epoxide 330
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Scheme 2.32: Attempted synthesis of aldehydes 344 and 345.
To identify whether the formation of the unidentified byproduct also occured in the
presence of a different Lewis acid catalyst, boron trifluoride etherate was investigated for
its utility in this rearrangement reaction. Although the use of boron trifluoride etherate
has been reported in similar epoxide-opening reactions,202,203 it was not effective for the
rearrangement of epoxide 330 in dichloromethane both at 0 ◦C and at room temperature.
Analysis of the 1H-NMR spectra of the crude residues showed a complex mixture of
products, while the byproduct which had been observed earlier, when using magnesium
bromide etherate, was not detected under these conditions.
Despite the successful synthesis of 1-benzyl-4-formyl-piperidine 319 according to Sheng’s
protocol, the same methodology was found unsuitable for the rearrangement of 2-
substituted epoxides under various tested conditions. It was therefore decided that
another route should be investigated in order to achieve the synthesis of the desired
aldehyde intermediates for the further synthesis of donepezil analogues.
2.3.2 Access to Aldehyde Building Blocks from 4-Piperidones via
Wittig Reaction and Enol Ether Hydrolysis
Sugimoto194 describes an alternative route towards the synthesis of 1-benzyl-4-formyl-
piperidine 319 from 1-benzyl-4-piperidone 317 via a Wittig reaction and acidic
deprotection (Scheme 2.33). The reported yields for these transformations are low to
moderate (33% and 54%) and purification by column chromatography of aldehyde 319
is necessary to obtain pure product.











Scheme 2.33: Reaction conditions: i) ((Ph3)PCH2OCH3)Cl, n-BuLi, diethyl ether,
rt→0 ◦C→rt, 3 h; ii) MeOH/1 M HCl 1:1, reflux, 3 h.
Meyer204 subjected cyclohexanone derivative 346 to a Wittig-Horner reaction using
the phosphine oxide methoxymethyldiphenylphosphine to give intermediate 347; treat-
ment with trifluoroacetic acid in water and tetrahydrofuran yielded aldehyde 348
(Scheme 2.34). Although the yield for the first synthetic step is high (72%), the
method uses the comparatively more expensive methoxymethyldiphenylphosphine as






Scheme 2.34: Reaction conditions: i) (Ph)2P(O)CH2OCH3, LDA, HMPA, THF, 0◦C→rt→reflux, 2 h; ii) TFA, THF/water 50:1, reflux, 15 h.
In another example a similar Wittig conversion of piperidone 349 to intermediate 350
is achieved in 57% yield and after acidic deprotection under mild conditions, aldehyde













Scheme 2.35: Reaction conditions: i) ((Ph3)PCH2OCH3)Cl, LDA, THF, rt→-25◦C→rt, overnight; ii) 1.6 M HCl, H2O/THF 1:1, 40 ◦C, 1 h.
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Wittig Reaction of 4-Piperidones to 4-Methoxymethylene-piperidines
To prepare methoxymethylene piperidine 318, piperidone 317 was subjected to a
Wittig reaction using methoxymethylene triphenylphosphonium chloride and lithium
diisopropylamide (Scheme 2.36). Analysis of the crude 1H-NMR spectrum showed that
the Wittig product had formed, but only in low yield (41%), while the rest of the mixture
contained unreacted piperidone. In this experiment the characteristic color change,
indicating a successful ylide formation, was not observed and we believe that this was










Scheme 2.36: Reaction conditions: i) ((Ph3)PCH2OCH3)Cl, LDA, THF, -78
◦C→0
◦C, 1 h; ii) ((Ph3)PCH2OCH3)Cl, LDA, 4 A˚ MS, THF, -78
◦C→rt→-20 ◦C→rt, 16 h.
In an example from the literature205 (Scheme 2.35) the reaction was allowed to warm
to room temperature after the addition of lithium diisopropylamide to the Wittig salt
had been completed. Repeating the experiment, upon warming the ylide salt from -78
◦C to room temperature, we observed the development of the characteristic red color
(Scheme 2.36). A slight excess of the phosphonium salt and the base was used (1.5 equiv)
to provide a sufficient amount of yilde, moreover molecular sieves were added to ensure
anhydrous conditions. During the subsequent addition of piperidone substrate 317, the
mixture was cooled to -20 ◦C and then warmed to room temperature. The addition
of the piperidone resulted in a gradual discolouration of the mixture and stirring for a
prolonged period of time (16 h) afforded the desired Wittig product 318 in an isolated
yield of 92%.
This protocol was also used for the synthesis of chiral methoxymethylene products,
bearing a methyl or phenyl substituent on the piperidine ring (Table 2.14). The cis and
trans products were obtained in good to excellent combined yields (75-97%) and it was
possible to partially separate the stereoisomers by column chromatography in all cases.
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Table 2.14: Combined yields and product ratios for the synthesised methoxymethylene
piperidines.





































a Standard reaction conditions: 4-piperidone, ((Ph3)PCH2OCH3)Cl, LDA, 4 A˚ MS, THF, -78◦C→rt→-20 ◦C→rt, 16 h.
b Isolated combined yield.
c Entry 1-3: Ratio of products was determined by analysis of the crude 1H-NMR spectra. Entry 4:
Ratio was determined by isolation of the products.
The obtained product ratios were determined by analysis of the crude 1H-NMR spectra,
with a slight preference towards the formation of cis-isomers being observed for the
methyl substituted products (entry 1 and 2), while the phenyl substituted products
formed without preference (entry 3 and 4). The partial separation of the two isomers of
all substrates allowed the unambiguous determination of their correct stereochemistry
thanks to distinct NOE correlations found in all isolated products (Figure 2.30).













Figure 2.30: Observed NOESY interactions in chiral methoxymethylene Z /E isomers.
Deprotection of 4-Methoxymethylene-piperidines to Aldehydes
As Sugimoto’s originally reported conditions194 for the acidic hydrolysis of methoxymethy-
lene intermediate 318 to 1-benzyl-4-formyl-pipereridine 319 resulted in a moderate yield
of 54%, due to the necessity for purification of the product by column chromatography,









Scheme 2.37: Reaction conditions: i) THF/1.6 M HCl 1:1, 45 ◦C, 2 h.
A mild hydrolysis to aldehyde 319 was achieved by treating enol ether 318 with a
1:1 mixture of tetrahydrofuran and 1.6 M aqueous HCl at 45 ◦C. Aldehyde 319 was
obtained in a crude yield of 95% with the starting material completely converted and
the product being pure by NMR analysis. It was observed that storage of the aldehyde
at low temperatures (-20 ◦C) was necessary in order to prevent degradation over time.
When the cis/trans mixtures of chiral enol ethers were subjected to the hydrolysis
conditions, mixtures of the corresponding diastereomeric aldehydes were obtained in
excellent yields (97-100%) and purity (Table 2.15).
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Table 2.15: Combined yields and product ratios for the synthesised aldehydes.













































a Standard reaction conditions: cis/trans methoxymethylene mixtures, THF/1.6 M HCl 1:1, 45
◦C, 2-3 h.
b Crude combined yield.
c Ratio of products was determined by analysis of the crude 1H-NMR spectra.
It was possible to determine the diastereomeric ratio by analysis of the crude 1H-NMR
spectra and to assign the chirality of the 4-formyl moiety in all products from the
observed NOESY correlations. Figure 2.31 shows the detected NOESY interactions
for 2R-methyl substituted aldehydes 364 and 365. In aldehyde 364 correlations were
observed between Hax-2 and and the proton in position 4. This suggests an axial position
for H-4 and hence R-chirality for the stereocenter. In diastereomer 365, no such NOESY
correlation between Hax-2 and the proton in position 4 was found, instead an interaction
between the protons of the methyl group in position 2 and Heq-4, confirming S -chirality
for this piperidine.























Figure 2.31: Observed NOESY correlations in diastereomeric aldehydes 364 and 365.
Furthermore, single cis and trans methoxymethylene stereoisomers were subjected to the
hydrolysis conditions to investigate whether this would result in the exclusive formation
of a syn or anti product (Scheme 2.38). If a single aldehyde diastereomer had formed in
this reaction, its use in the subsequent aldol condensation step would have led to only

























Scheme 2.38: Reaction conditions: i) THF/1.6 M HCl 1:1, 45 ◦C, 2 h.
2.3.3 Synthesis of Donepezil Analogues
Having achieved the preparation of diastereomeric mixtures of 2-methyl and 2-phenyl
4-formyl-piperidines, these building blocks could be used as substrates for the next step
in the synthetic route towards donepezil analogues.
Aldol Condensation of 4-Formyl-piperidines and 5,6-Dimethoxy-1-indanone
For the synthesis of donepezil precursor 370, aldehyde 319 and 5,6-dimethoxy-1-
indanone 324 were subjected to an aldol condensation reaction (Scheme 2.39). The
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protocol used for this conversion was similar to the one described by Imai206 and
avoided the low temperatures (-78 ◦C) and toxic solvents (HMPA) reported by
Sugimoto.120,194 The base catalysed nucleophilic enolate addition of 324 to the carbonyl
function of aldehyde 319 was achieved by reacting the substrates in the presence of
sodium methoxide in methanol. Upon dehydratation of the aldol product at reflux,
donepezil-precursor 370 was obtained in good yield (84%) after isolation by column
chromatography. An increased yield (91%) could be achieved by precipitating the












Scheme 2.39: Reaction conditions: i) 319, 324, NaOMe, MeOH, 80 ◦C, 75 min.
When a mixture of the 2S -methyl substituted aldehydes 362 and 363 was subjected
to the aldol condensation with indanone derivative 324, two diastereomeric products
were obtained in a combined yield of 87% (Table 2.16, entry 1). The different Rf
values of the two products allowed the partial separation of indanones 371 and 372
by column chromatography. Similarly, 2R-methyl substituted aldehydes 364 and 365
were subjected to the aldol condensation and the diastereomeric products were again
partially separated (Table 2.16, entry 2). In this case the yield was lower due to
loss of material upon isolation by column chromatography, caused by closely running
minor impurities. The diastereomeric ratios for both methyl-substituted diastereomeric
product pairs (entry 1 and 2) were determined by analysis of the signals for the olefinic
protons in the crude 1H-NMR spectra.
Chapter 2. Studies Towards the Synthesis of Donepezil Analogues 104
Table 2.16: Combined yields and product ratios for the aldol condensation products.





















































a R= -S -α-phenylethyl. Standard reaction conditions: aldehyde mixture, 324, NaOMe, MeOH, 80
◦C, 1.5-2 h.
b Combined isolated yield.
c Ratio of products was determined by analysis of the crude 1H-NMR spectra. ND= not
determined.
Figure 2.32 shows the observed NOESY correlations in the diastereomeric products 371
and 372. In the product with the higher Rf value, a correlation is observed between the
proton on C-4 and Hax-2, therefore indicating an equatorial position for the indanone-
substituent in position 4 on the ring. Conversely, no such correlation is observed in the
product with the lower Rf value and an interaction between the protons of the methyl
group in position 2 and the proton on C4 confirmed the axial position of the indanone-
moiety in this diastereomer. Hence, the chirality for the aldol products was assigned as
4S and 4R for 371 and 372, respectively.




























Figure 2.32: Observed NOESY correlations in diastereomeric aldol products 371 and
372.
For both 2-phenyl substituted aldehyde mixtures, 4R-366+4S -367 and 4R-368+4S -
369 (entry 3 and 4), the corresponding aldol products were obtained as inseparable
mixtures. It was neither possible to determine a diastereomeric ratio from the NMR
spectra of the crude nor of the isolated product mixtures. The signals in the 13C-NMR
were identical for both diastereomers and also in the 1H-NMR spectra most signals were
identical and overlapping, complicating a determination of the product ratio.
Having successfully prepared the diastereomeric aldol condensation products with
methyl and phenyl substituents in position 2 on the piperidine ring in good to high
yields (59-87%), the next step was a hydrogenation of the double bond to give the
target donepezil analogues.
Reduction to Donepezil Analogues
Hydrogenation of alkene 370 using palladium on activated carbon was investigated
according to a protocol by Sugimoto120 (Scheme 2.40). After shaking 370 in the
presence of 1 atm of hydrogen gas at room temperature in tetrahydrofuran for 6 hours,
racemic donepezil 379 was obtained in a yield of 84% after purification by column
chromatography.
When the diastereomeric 2S or 2R-methyl substituted aldol condensation products
371-374 were individually subjected to these hydrogenation conditions, the methyl-
substituted donepezil analogues were obtained as inseparable, diastereomeric mixtures
(Table 2.17, entry 1-4). The low isolated yields for the product mixtures in entry 2











Scheme 2.40: Reaction conditions: i) 10% Pd/C, 1 atm H2, THF, rt, 6 h.
and 3 are explained by a complicated purification by column chromatography, caused
by closely eluting and streaking minor byproducts.
Table 2.17: Combined yields for the synthesised donepezil analogues bearing a methyl
substituent on the piperidine ring.





























a R= -S -α-phenylethyl. Standard reaction conditions: 10% Pd/C, 1 atm H2, THF, rt,
7-9 h.
b Combined isolated yield.
The synthesised donepezil analogues with 2R or 2S phenyl substituents in position
2 of the piperidine ring are shown in Table 2.18. As the starting materials in
these hydrogenation reactions were diastereomeric mixtures due to the unresolved
stereocentres in position 4 on the piperidine ring, the reduced products were obtained
as mixtures of 4 diastereomers in yields of 77-84%.
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Table 2.18: Combined yields for the synthesised donepezil analogues bearing a phenyl
substituent on the piperidine ring.



























a R= -S -α-phenylethyl. Standard reaction conditions: 10% Pd/C, 1 atm H2, THF,
rt, 8-10 h.
b Combined isolated yield.
It has been reported that the R and S enantiomers of donepezil interconvert in an
aqueous solution at 37 ◦C with a racemisation half-life of 78 h due to ketoenol-
tautomerism.127 A similar racemisation behaviour of the stereocentre on the indanone
moiety is also anticipated for the synthesised donepezil analogues. Therefore, in order
to avoid the time of separating the diastereomeric pairs by chiral preparative high-
performance liquid chromatography (HPLC), it was decided to take these analogues
forward as mixtures when evaluating their AChE inhibitory activity.
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Synthesis of the N -S-α-Phenylethyl Donepezil Analogue
To evaluate the influence that substituents in position 2 on the piperidine ring of the N -
α-phenylethyl diastereomers have on the AChE inhibitory activities in comparison with
donepezil, it was necessary to synthesise reference analogues 401+402, which possess
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Scheme 2.41: Reaction conditions: i) methyl iodide, acetone, 25 ◦C, 2 h; ii) 399,
S -α-phenylethylamine, K2CO3, ethanol/water 1:1, 95
◦C, 30 min.
N -S -α-Phenylethyl-4-piperidone 400 was conveniently prepared from commercially
available N -methyl-4-piperidone 398 (Scheme 2.41). In the first step methylation with
methyl iodide in acetone afforded N,N -dimethyl-4-oxopiperidinium iodide 399 in a yield
of 99%.207 Iodide salt 399 was then reacted with S -α-phenylethylamine in a substitution
reaction under basic conditions208,209 to give desired piperidone 400 in a yield of 69%.
Mistryukov’s209 proposed mechanism for this exchange reaction is shown in Figure 2.33
and consists of an initial base catalysed conversion of iodide salt 399 to enolate 403.
Primary amine 405 can then add to the β carbon of 404 in a an aza-Michael type manner
to give the intermediate addition product. Upon protonation of the tertiary amine, the
secondary amine in 405 attacks intramolecularly to displace the dimethylamine and
gives N -substituted piperidone 406.



























Figure 2.33: Mechanism for the β-elimination/intramolecular cyclisation to yield N -
substituted piperidone 407.209,210
Scheme 2.42 shows the synthetic route from piperidone 400 to the final donepezil
analogues. Following the previously discussed protocols, Wittig product 408 was
obtained in a yield of 93% and subsequently hydrolysed to aldehyde 409 in a crude
yield of 92%. Aldol condensation with 5,6-dimethoxy-1-indanone gave alkene 410 in
a yield of 67%, which was then subjected to a hydrogenation to give an inseparable




















Scheme 2.42: Reaction conditions: i) ((Ph3)PCH2OCH3)Cl, LDA, 4 A˚ MS, THF, -78◦C→rt→-20 ◦C→rt, 16 h; ii) THF/1.6 M HCl 1:1, 45 ◦C, 2.5 h; iii) 409, 5,6-dimethoxy-
1-indanone, NaOMe, MeOH, 80 ◦C, 75 min; iv) 10% Pd/C, 1 atm H2, THF, rt, 8 h.
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2.4 Acetylcholinesterase Inhibition Assay
To evaluate the inhibitory activity of the synthesised donepezil analogues, an ultraviolet-
visible (UV-Vis) spectrophotometric assay was selected from the range of available
methods.211 The Ellman method125 is the most widely used protocol to determine both
AChE activity and its inhibition and was therefore considered suitable for our purposes.
The principle of this assay involves the enzymatic hydrolysis of the substrate acetylth-
iocholine (ATCI) 411 into acetate 412 and thiocholine 413, followed by a colorimetric
reaction (Figure 2.34). In this colorimetric step, the Ellman reagent dithiobisnitroben-
zoate (DTNB) 414 reacts with hydrolysis product thiocholine 413 to form disulfide 415
and yellow 5-thio-2-nitrobenzoic acid (TNB) 416. The intensity of the yellow colour is





























Figure 2.34: The principle of the colorimetric AChE inhibition assay based on
Ellman’s reagent.
Changes of the original Ellman method have led to modified protocols using microplates,
thereby facilitating a simple and reproducible determination of IC50 values of AChE
inhibitors. According to Ja¨rvinen,212 IC50 values for the same inhibitor can vary largely
across the literature, because of a lack of consistency in the applied protocol. The IC50
value for donepezil towards AChE of the electric eel (eeAChE) has been reported as 0.01
µM,213 0.04 µM,214 as well as 0.12 µM.215,216. Details concerning the sequence of reagent
addition, the concentrations of reagents and the buffer systems are frequently omitted,
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despite the fact that these factors are known to affect the obtained half-inhibitory
concentrations.212
The commercially available human AChE is expensive and therefore the significantly
cheaper AChE from the electric eel is routinely used in inhibition bioassays.211 Although
donepezil inhibits hAChE at slightly lower concentrations than eeAChE,215,217 the
electric eel enzyme is a useful and inexpensive alternative to obtain initial inhibitory
results.
For the analysis of the donepezil analogues, the assay was carried out following a
protocol described by Mohamed.218 In Mohamed’s procedure, dilutions of the test
compounds were prepared in buffer (pH=8) containing 1% DMSO, with the positive
control donepezil giving an IC50 value of 0.032 µM against hAChE. When Mohamed’s
protocol was applied, a half-inhibitory concentration of donepezil for eeAChE of 0.094
µM was obtained, a value which is comparable with those found in the literature
(Figure 2.35, A).214,215
Figure 2.35: The effect of different solvents on the IC50 value of donepezil.
As the donepezil derivatives bearing a phenyl ring on the piperidine ring (389-392 and
394-397) were not soluble in buffer containing 1% DMSO, it was necessary to find
a more suitable solvent for the test compounds. When the donepezil control dilution
series was made up in pure DMSO, the final DMSO concentration in the assay changed
from less than 1% to 4%. This increase in the total DMSO concentration resulted in a
10-fold higher IC50 of 0.974 µM, caused by a much smaller change of absorption over
time (Figure 2.35, B). As DMSO severely interfered with the assay, it was deemed to be
unsuitable as solvent. Methanol had been previously reported as a suitable solvent
for test compounds in the Ellman-based assay219 and when applied to the current
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protocol, an IC50 of 0.068 µM was obtained for donepezil (Figure 2.35, C). Hence,
as the inhibitory activity and the change of absorption over time were not significantly
influenced, methanol was chosen for all subsequent analyses.
Another factor known to influence the observed potency of an inhibitor is the order
of enzyme and ATCI substrate addition.212 In our protocol, the inhibitors were
preincubated with eeAChE for 7 minutes and subsequently the hydrolysis reaction
initiated by the addition of ATCI. Following this order of reagent addition, spontaneous
hydrolysis of the substrate before the start of the enzyme reaction is avoided.125,212
Furthermore, the time elapsed between the beginning of the ATCI addition and the start
of the spectrophotometric measurement was kept at 2 minutes, again to ensure consistent
results. Two measurements at 412 nm were made 5 minutes apart and the IC50 values
were calculated using GraphPad Prism software applying a nonlinear regression analysis
(sigmoidal dose-response fit with a variable slope).
The Inhibitory Activities of Piperidine-Ring Substituted
Donepezil Analogues
The half inhibitory concentrations of all compounds possessing a substituent in position
2 on the piperidine ring were evaluated in comparison to the diasteriomeric pair of
compounds lacking a substituent on the the piperidine ring, bearing only a N -S -α-
phenylethyl moiety (401+402), and the N -benzyl substituted donepezil reference 379
(Table 2.19).
The mixture of piperidine-ring unsubstituted derivatives 401 and 402 has an IC50 of
1.83 µM (entry 2) and is approximately 27 times less active than the donepezil 379
(entry 1), signifying that the additional methyl group has a detrimental effect on the
drug’s inhibitory activity.
Interestingly, 2S -methyl-4S compounds 380 and 381 possess a lower half-inhibitory
concentration of 1.01 µM (entry 3), indicating that the additional methyl group on the
piperidine partially compensates for some of the initial drop in activity caused by the
N -S -α-phenylethyl moiety in 401 and 402 (entry 2).
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Table 2.19: eeAChE IC50 values for the synthesised donepezil analogues.




























































a R= -S -α-phenylethyl.
b Chirality of the stereocentres on the piperidine ring.
c IC50 values are the mean of two separate experiments ± standard deviation (SD). Each
experiment was carried out in triplicates.
d This IC50 value is the mean of three separate experiments.
e Not active in the tested concentration range.
The 2S -methyl-4R-mixture of 382 and 383 (entry 4) is 9 times less active than the
2S -methyl-4S -mixture (entry 3), suggesting that the stereocentre in position 4 on the
piperidine ring is of importance for the overall inhibitory activity.
Chapter 2. Acetylcholinesterase Inhibition Assay 114
Both mixtures bearing the 2-methyl group in R-chirality demonstrated decreased
activities (entry 5 and 6) in comparison to the compounds with the 2-substituent in
S -chirality (entry 3 and 4). The reduced inhibitory potency of these derivatives signifies
that donepezil is sensitive to stereoselective substitution in position 2 on the piperidine
ring, possibly caused by significant changes in the overall conformation within the
enzyme’s binding pocket and therefore also in the binding affinities.
Both mixtures possessing a phenyl ring in position 2 on the ring (entry 7 and 8) showed
no activity in the tested concentration range (0.001-100 µM). We believe that the
bulky phenyl ring prevents these compounds from entering the narrow, “swinging-gate”-
controlled140,143 entry site to the binding gorge of the enzyme.
When comparing the IC50 values of the syn-substituted compounds (entry 3, entry 6) to
the anti -substituted analogues (entry 4, entry 5), in both cases the syn-compounds
are significantly more active. 2S,4S -syn-Substituted compounds 380 and 381 are
approximately 24 times more active than the 2R,4S -anti -substituted analogues 384
and 385 (Figure 2.36), demonstrating that the stereochemistry of the substituent in
position 4 relative to the stereochemistry of the substituent in position 2 significantly
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Figure 2.36: Activities of syn and anti -substituted donepezil analogues.
It can be summarised that, despite the S -α-phenylethyl moiety’s detrimental effect on
the inhibition potency, an additional methyl substituent in position 2 on the piperidine
ring leads to compounds with modified activity. We observed that among the 2-methyl
substituted analogues, those with 2S -chirality are more active than the ones with 2R-
chirality, furthermore we deduced that a 2,4-syn-substitution pattern gives lower IC50
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values than a 2,4-anti -substitution pattern. These are interesting initial results which
encourage further investigations into the search for donepezil analogues with an improved
pharmacological profile.
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2.5 Overall Summary and Conclusions
In the initial study, a double aza-Michael addition of primary amines to divinyl ketone
178 was investigated. A manganese dioxide facilitated one-pot oxidation-cyclisation
protocol was developed, generating the unstable ketone in situ and allowed a diverse
range of aromatically and aliphatically N -substituted 4-piperidones to be synthesised
in moderate to good yields over two steps (28-61%). The reactivity of benzylamine
substrates towards activated manganese dioxide was identified as a side-reaction in this
one-pot method.
Aliphatically and aromatically substituted divinyl alcohols were prepared from their
corresponding aldehydes and their utility as substrates in the previously developed one-
pot oxidation-cyclisation protocol was investigated. Since 2-substituted N -benzylic 4-
piperidones could not be efficiently prepared using this method, a stepwise approach
was investigated. Employing substituted divinyl ketones in an aza-Michael cyclisation
protocol using aqueous sodium bicarbonate in acetonitrile resulted in high yields of
the 2-aryl substituted N -benzylic 4-piperidone products (79-84%) and moderate yields
for the 2-alkyl substituted piperidones (36-42%). Furthermore, to obtain separable
piperidone products with resolved stereochemistry in position 2 on the piperidine ring,
S -α-phenylethylamine was used as amine substrate in the cyclisation reaction. The
stereochemistry of the diastereomeric piperidone products was assigned on the basis
of their distinct differences in chemical shifts as observed in their 13C-NMR spectra.
In this aza-Michael cyclisation, a small degree of diastereoselectivity was observed,
which was found to be more significant amongst the aryl-substituted piperidone products
investigated. In conclusion, chirally resolved 2-substituted 4-piperidones were prepared
from commercially available starting materials in three steps, thereby giving easy access
to valuable building blocks for the assembly of new, biologically relevant piperidine
scaffolds.
Investigating the manganese dioxide mediated side reaction in the one-pot oxidation-
cyclisation protocol, it was discovered that in the absence of a divinyl ketone Michael
acceptor, the oxidation of primary benzylic amines proceeded smoothly to the corre-
sponding amides under mild conditions. The intermediates of the reaction pathway
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were identified and their interconversion to the amide product followed by 1H-NMR
experiments. Varying the reaction conditions allowed the crucial role of both the
manganese dioxide and molecular sieves to be elucidated. All intermediates were
converted to the amide under the standard reaction conditions and a range of benzylic
amides was prepared in good to excellent yield (69-99%).
The 2-methyl and 2-phenyl N -α-phenylethyl 4-piperidones were used as building
blocks for the synthesis of donepezil analogues. In order to access the important
4-formyl piperidine compounds, the piperidones were subjected to a Wittig reaction
and the methoxymethylene products were obtained in high combined yields (75-97%).
Subsequent hydrolysis under acidic conditions gave the desired, inseparable aldehydes
in excellent yields (97-100%). There was no need for further purification of the unstable
aldehyde building blocks, thereby making this route superior with respect to overall
yield and purity in comparison to procedures published earlier.194–196 Condensation of
the aldehydes with an indanone derivative furnished partially separable diastereomeric
intermediates, which were subjected to hydrogenation over a palladium catalyst to give
the final donepezil analogues as inseparable mixtures of diastereomers. Despite the
importance of the piperidine ring for the biological activity of donepezil,126 the synthesis
of analogues of this drug bearing sterically resolved substituents in position 2 on the ring
has not yet been reported in the literature.
The AChE inhibitory activity of the synthesised donepezil analogues was evaluated in
comparison to donepezil. An UV-Vis spectrophotometric based assay was conducted and
the IC50 values for the diastereomeric mixtures determined. It was found that while the
phenyl substituted donepezil analogues were inactive, the methyl substituted analogues
possessed moderate inhibitory activity. The S -methyl substituted analogues were
significantly more active than the analogues bearing a methyl group with R-chirality,
therefore demonstrating that the stereochemistry of substituents on the piperidine ring
plays an important role in the binding behaviour of such compounds within the enzyme’s
binding pocket.
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2.6 Future Work
Having prepared diastereomeric 2-substituted 4-piperidones building blocks for the
synthesis of donepezil analogues, scope for further research lies in the optimisation of the
double aza-Michael cyclisation reaction. The stereoselectivity as well as the yield of this
reaction might be improved by the addition of chiral amine catalysts, for example proline-
derivative 41777,78,80 or cinchona alkaloid derived catalyst 41876 (Figure 2.37). These
catalysts enhance the electrophilicity of the dienone by the formation of an iminium
intermediate, thereby facilitating the nucleophilic attack of the primary amine on the
β-carbon of the Michael acceptor. Furthermore, a more diverse range of chiral amine
substrates could be investigated to evaluate their utility as nucleophiles in the reaction














Figure 2.37: Chiral amine catalysts.
The methyl and phenyl substituted donepezil analogues prepared bear a S -α-phenylethyl
moiety on the piperidine nitrogen. The initial evaluation of the biological activity of these
analogues revealed that the additional methyl group on the N -benzyl substituent has
a detrimental effect on the inhibition potency. Thus, the synthesis of further donepezil
analogues, bearing a simple N -benzyl substituent, could fully elucidate the biological
effects of chiral substituents in position 2 of the drug’s piperidine ring. Removal of the
nitrogen substituent by hydrogenation of the diastereomeric 2-substituted 4-piperidones
419 over a palladium catalyst,174 followed by the reaction with benzylbromide220 gives
enantiopure N -benzylic 2-substituted piperidones 421 which could be used as precursors
for the preparation of additional donepezil analogues 422 (Figure 2.38).





















419 420 421 422
Figure 2.38: Synthesis of donepezil analogues bearing a N -benzyl substituent.
Moreover, α-substituted divinyl ketones 42381,221,222 could be investigated for their
use in a double aza-Michael cyclisation to obtain 3-substituted 4-piperidones 424
(Figure 2.39). Although the stereochemistry of the substituent in position 3 will
be determined by keto-enol tautomerism and not by chiral induction from the chiral
Michael donor amine substrate, piperidone products 424 will be obtained as separable
diastereomers. In further synthetic steps, piperidones 424 can be employed for the
preparation of donepezil analogues 426, bearing the substituent in position 3 on the
piperidine ring. These analogues will possess modified biological activity and can





















423 424 425 426
Figure 2.39: Synthesis of donepezil analogues bearing a substituent in position 3 on
the piperidine ring.
Scope for further research also remains in the biological evaluation of the synthesised
donepezil analogues. As the determination of the biological activity was carried out
using the AChE enzyme from the electric eel, the analogues’ potency to inhibit the
human enzyme could be varied due to structural differences in the binding pockets of the
two enzyme species. Furthermore, in order to explain the results obtained, a molecuar
dynamics study can be carried out to investigate the analogues’ ability to enter the
binding pocket. Such a study would shed light on the question whether the entrance
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to the binding pocket of 2-phenyl substituted analogues via the narrow “swinging”-
gate140 is prevented due to the increased bulkiness of the additional phenyl ring. A
docking study of the analogues in their energy minimised conformations would further
lead to an understanding of whether the additional piperidine ring substituents protrude




3.1 General Experimental Procedures
Infrared spectra were obtained on a Perkin Elmer 100 FTIR spectrometer operating
in attenuated total reflection (ATR) mode. Only significant absorptions (νmax) are
reported and all absorptions are recorded in wavenumbers (cm-1). Melting points were
measured with an Electrothermal apparatus and are uncorrected.
Proton magnetic resonance spectra (1H-NMR) were recorded at 400 MHz using a Bruker
spectrometer. Chemical shifts (δ) are quoted in parts per million (ppm) and are
referenced to the residual protonated solvent peak. The order of citation in parentheses is
(i) number of equivalent nuclei (by integration), (ii) multiplicity (s, singlet; d, doublet;
t, triplet; q, quartet and m, multiplet), (iii) coupling constant (J ) quoted in Hertz
(Hz) to one decimal place, (iv) assignment. Signals on a monosubstituted and a 1,4-
disubstituted aromatic ring are described using the terms ipso, ortho, meta and para.
Carbon magnetic resonance spectra (13C-NMR) were recorded at 100.6 MHz using a
Bruker spectrometer. Chemical shifts (δ) are quoted in parts per million (ppm) and are
referenced to the appropriate solvent peak. The assignment is quoted in parentheses.
Where necessary, assignments were made with the aid of DEPT, COSY, HSQC, HMBC
or NOESY correlation experiments.
Low resolution mass spectra (m/z ) were recorded using an LCQ DECA XP instrument
by electron spray ionization (ESI). Only molecular ions and major fragments of the
molecular ions are reported. Accurate masses were determined using a quadrupole time-
of-flight mass (QTOF) spectrometer at King’s College London or a Thermofisher LTQ
Orbitrap XL instrument at the EPSRC National Mass Spectrometry Facility in Swansea
using nanospray ESI (NSI) and atmospheric pressure chemical ionization (APCI).
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Flash Chromatography was carried out using silica gel (Aldrich, 230-400 mesh) as the
stationary phase. Thin Layer Chromatography was carried out on aluminium plates pre-
coated with silica (Merck silica gel 60 F254 on aluminium) which was visualized by the
quenching of ultraviolet fluorescence (λmax=254 nm) and/or by staining with potassium
permanganate solution followed by heat. All reactions were carried out at atmospheric
pressure with stirring unless otherwise stated. All reagents were used as received unless
otherwise stated. The fractions of light petroleum ether boiling between 40 and 60 ◦C are
referred to as “hexanes”. Optical rotations ([α]TD= α/l.c) were measured by a Bellingham
and Stanley ADP 220 polarimeter at 589 nm (sodium-D line). Concentration (c) is in
g 100 mL-1.
The HPLC analysis was performed on a Hewlett-Packard 1050 system equipped with an
autosampler, a reversed-phase HPLC column (Agilent Zorbax 300 A˚, C-18, 2.1 mm x
100 mm, particle size 3.5 µm) and a diode-array detector (DAD) set to monitor 281 nm.
The flow rate was 0.2 mL/min and the column was eluted using three different linear
gradients:
i) 0-90% MeCN in 0.1% (v/v) trifluoroacetic acid aqueous solution in 20 min (tR1);
ii) 0-90% MeCN in 0.1% (v/v) trifluoroacetic acid aqueous solution in 30 min (tR2);
iii) 0-50% MeCN in 0.1% (v/v) trifluoroacetic acid aqueous solution in 50 min (tR3);
3.2 Experimental Procedures
Preparation of activated manganese dioxide
MnO2 was purchased from Alfa Aesar (Cat. No. 014340.22, Manganese(IV) oxide,
activated, tech., Mn 58% min, 100 g) and further activated by treatment with dilute
nitric acid:
MnO2 (50 g) was placed on a large Bu¨chner funnel and 10% nitric acid (80 mL) was
added slowly. After the addition was completed, the MnO2 cake was washed with water
(2-3 L) until the filtrate was neutral. The MnO2 was subsequently dried at 105
◦C for
two days.




Divinylcarbinol (165 µl, 1.70 mmol, 1.0 equiv) was added to a suspension of 4 A˚ molecular
sieves (1.00 g) in CH2Cl2 (10 mL). MnO2, which had been previously activated by
washing with diluted nitric acid (4.44 g, 51.0 mmol, 30.0 equiv), was added portionwise.
The temperature was kept at 40 ◦C and after 20 h the mixture was filtered through a
pad of Celite, followed by washing with acetone (150 mL). The solvent was evaporated
in vacuo and crude ketone 178 (131 mg, 88%) was obtained as a pale yellow oil. It
could be used in the next step without further purification; Rf 0.40 (3:1 hexane:ethyl
acetate); νmax (film) 3162, 3062, 1651 (C=O), 1618, 1575, 1448, 1296, 1178, 1141, 1120,
1024, 917; δH (400 MHz, CDCl3) 6.58 (2H, dd, J 17.5 Hz, 10.6 Hz, 2 x -CH=CH2),
6.26 (2H, dd, J 17.5 Hz, 1.2 Hz, 2 x -CH=CH2 trans), 5.82 (2H, dd, J 10.7 Hz, 1.2 Hz,
2 x -CH=CH2 cis); δC (100.6 MHz, CDCl3) 189.1 (C=O), 133.3 (CH), 128.3 (CH2). In














2-Iodobenzoic acid (24.800 g, 100.00 mmol, 1.0 equiv) was added to a solution of Oxone
(potassium peroxymonosulfate) (79.920 g, 130.00 mmol, 1.3 equiv.) in deionized water
(295 mL, 0.44 M) and stirred at 70 ◦C for 4 h. The mixture was then cooled to 5 ◦C and
kept stirring at this temperature for 1.5 h. The mixture was filtered and the solid was
washed with deionized water and acetone. 2-Iodoxybenzoic acid 189 (23.870 g, 85%)
was obtained as white crystals; mp 231-233 ◦C; δH (400 MHz, DMSO-d6) 8.14 (1H, d, J
8.0 Hz, Ar-H-3), 8.06-7.97 (2H, m, Ar-H-5, Ar-H-6), 7.84 (1H, app t, J 7.3 Hz, Ar-H-4);
δC (100.6 MHz, DMSO-d6) 167.61 (C=O), 146.61 (Arquart.), 133.47 (Ar), 133.03 (Ar),
131.48 (Arquart.), 130.16 (Ar), 125.05 (Ar).
In agreement with published data.147





To a suspension of 4 A˚ molecular sieves (1.00 g) in CH2Cl2 (11 mL) was added
divinylcarbinol (165 µl, 1.70 mmol, 1.0 equiv), followed by portionwise addition of MnO2
(3.69 g, 42.50 mmol, 25.0 equiv). Benzylamine (278 mg, 2.55 mmol, 1.5 equiv) was
added and the mixture was stirred at 50 ◦C for 18 h. MnO2 was filtered through a pad of
Celite and washed with acetone (250 mL). Concentration of the combined filtrates under
reduced pressure and purification by column chromatography (ethyl acetate:hexane 1:1
with 1% TEA) gave product 201 (164 mg, 51% over two steps) as a pale yellow oil; Rf
0.20 (1:1 ethyl acetate:hexane); νmax (film) 2960, 2910, 2807, 2764, 1718 (C=O), 1599,
1495, 1454, 1349, 1195, 1126, 1072, 1012, 739, 699; δH (400 MHz, CDCl3) 7.29-7.19 (5H,
m, Ph), 3.55 (2H, s, N-CH2-Ph), 2.68 (4H, t, J 5.9 Hz, 2 x β-CH2), 2.39 (4H, t, J 6.0
Hz, 2 x α-CH2); δC (100.6 MHz, CDCl3) 208.3 (C=O), 137.1 (ipso Ph), 127.9 (ortho
Ph), 127.4 (meta Ph), 126.3 (para Ph), 61.0 (N-CH2-Ph), 51.9 (β-CH2), 40.3 (α-CH2).






To a suspension of 4 A˚ molecular sieves (1.00 g) in CH2Cl2 (11 mL) was added
divinylcarbinol (165 µl, 1.70 mmol, 1.0 equiv), followed by portionwise addition of MnO2
(3.69 g, 42.50 mmol, 25.0 equiv). 4-Chloro-benzylamine (361 mg, 2.55 mmol, 1.5 equiv.)
was added and the mixture was stirred at 50 ◦C for 18 h. MnO2 was filtered through a
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pad of Celite and washed with acetone and CH2Cl2. Concentration of the combined
filtrates under reduced pressure and purification by column chromatography (ethyl
acetate:hexane 1:1 with 1% TEA) gave product 204 (210 mg, 53% over two steps)
as a pale yellow oil; Rf 0.29 (1:1 ethyl acetate:hexane + 1% TEA); νmax (film) 2960,
2910, 1718 (C=O), 1596, 1491, 1348, 1196, 1128, 1087, 1015, 845, 799; δH (400 MHz,
CDCl3) 7.24 (4H, s, 4 x Ar-H), 3.51 (2H, s, N-CH2-Ar), 2.66 (4H, t, J 6.2 Hz, 2 x
β-CH2), 2.38 (4H, t, J 6.0 Hz, 2 x α-CH2); δC (100.6 MHz, CDCl3) 208.1 (C=O), 135.7
(ipso Ar), 132.0 (para Ar), 129.1 (ortho Ar), 127.5 (meta Ar), 60.2 (N-CH2-Ar), 51.9
(β-CH2), 40.3 (α-CH2); m/z (ESI+) 256 [M+H+CH3OH]






To a suspension of 4 A˚ molecular sieves in (1.00 g) CH2Cl2 (11 mL) was added
divinylcarbinol (165 µl, 1.70 mmol, 1.0 equiv), followed by portionwise addition of MnO2
(3.69 g, 42.50 mmol, 25.0 equiv). Phenylethylamine (310 mg, 2.55 mmol, 1.5 equiv) was
added and the mixture was stirred at 50 ◦C for 18 h. MnO2 was filtered through a pad of
Celite and washed with CH2Cl2. Concentration of the combined filtrates under reduced
pressure and purification by column chromatography (ethyl acetate:hexane 1:1 with 1%
TEA) gave product 214 (186 mg, 58% over two steps) as a yellow solid; mp 59-61 ◦C;
Rf 0.24 (1:5.5 hexane:ethyl acetate); νmax (solid) 3062, 3023, 2972, 2984, 2809, 2772,
1716 (C=O), 1602, 1495, 1457, 1230, 1123, 1009, 752, 707, 699; δH (400 MHz, CDCl3)
7.14-7.25 (5H, m, Ph), 2.75-2.8 (6H, m, 2 x β-CH2, N-CH2-CH2-Ph), 2.64-2.68 (2H,
m, N-CH2-CH2-Ph), 2.42 (4H, t, J 6.1 Hz, 2 x α-CH2); δC (100.6 MHz, CDCl3) 208.1
(C=O), 139.0 (ipso Ph), 127.7 (meta Ph), 127.5 (ortho Ph), 125.2 (para Ph), 58.3 (N-
CH2-CH2-Ph), 52.1 (β-CH2), 40.3 (α-CH2), 33.1 (N-CH2-CH2-Ph). In agreement with
published data.226





To a suspension of 4 A˚ molecular sieves (1.00 g) in CH2Cl2 (8 mL) was added
divinylcarbinol (165 µl, 1.70 mmol, 1.0 equiv), followed by portionwise addition of MnO2
(3.69 g, 42.50 mmol, 25.0 equiv). 2-(Aminomethyl)naphthalene (374 mg, 2.38 mmol, 1.4
equiv) was added and the mixture stirred at 50 ◦C for 18 h. MnO2 was filtered through
a pad of Celite and washed with acetone. Concentration of the combined filtrates under
reduced pressure and purification by column chromatography (ethyl acetate:hexane 1:1
with 1% TEA) gave product 212 (113 mg, 28% over two steps) as a pale yellow solid;
mp 89-91 ◦C; Rf 0.39 (1.5:1 hexane:ethyl acetate); νmax (solid) 3046, 2960, 2907, 2809,
1716 (C=O), 1597, 1509, 1472, 1365, 1344, 1233, 1197, 1122, 1018, 796; δH (400 MHz,
CDCl3) 8.27 (1H, d, J 8.2 Hz, Ar-H), 7.79 (1H, dd, J 7.5 Hz, 2.4 Hz, Ar-H), 7.73 (1H,
dd, J 7.2 Hz, 2.4 Hz, Ar-H), 7.41-7.48 (2H, m, 2 x Ar-H), 7.32-7.37 (2H, m, 2 x Ar-H),
3.94 (2H, s, N-CH2-Ar), 2.74 (4H, t, J 6.0 Hz, 2 x β-CH2), 2.37 (4H, t, J 6.1 Hz, α-CH2);
δC (100.6 MHz, CDCl3) 208.5 (C=O), 132.9 (2 x Arquart.), 131.4 (Arquart.), 127.5 (Ar),
127.3 (Ar), 126.3 (Ar), 124.9 (Ar), 124.7 (Ar), 124.1 (Ar), 123.6 (Ar), 59.2 (N-CH2-Ar),
52.1 (β-CH2), 40.3 (α-CH2); m/z (ESI+) 258 [M+H+H2O]
+, 240 [M+H]+, 141; Exact
Mass Calcd for C16H17NO [M+H]






To a suspension of 4 A˚ molecular sieves in (1.00 g) CH2Cl2 (11 mL) was added
divinylcarbinol (165 µl, 1.70 mmol, 1.0 equiv), followed by portionwise addition of MnO2
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(3.69 g, 42.50 mmol, 25.0 equiv). 4-Methoxy-benzylamine (350 mg, 2.55 mmol, 1.5 equiv)
was added and the mixture was stirred at 50 ◦C for 18 h. MnO2 was filtered through a
pad of Celite and washed with CH2Cl2. Concentration of the combined filtrates under
reduced pressure and purification by column chromatography (ethyl acetate:hexane 1:1
with 1% TEA) gave product 206 (169 mg, 45% over two steps) as a yellow oil; Rf 0.27
(1.5:1 ethyl acetate:hexane); νmax (film) 2958, 2910, 2804, 2763, 1717 (C=O), 1612, 1585,
1512, 1463, 1349, 1302, 1246, 1178, 1122, 1084, 1034, 835, 802; δH (400 MHz, CDCl3)
7.19 (2H, d, J 8.7 Hz, ortho Ar-H), 6.81 (2H, d, J 8.7 Hz, meta Ar-H), 3.74 (3H, s,
-OCH3), 3.49 (2H, s, N-CH2-Ar), 2.66 (4H, t, J 6.1 Hz, 2 x β-CH2), 2.38 (4H, t, J 6.2
Hz, 2 x α-CH2); δC (100.6 MHz, CDCl3) 209.43 (C=O), 158.92 (para Ar), 130.15 (ortho
Ar), 130.09 (ipso Ar), 113.74 (meta Ar), 61.36 (N-CH2-Ar, 52.79 (-OCH3), 55.29 (β-
CH2), 41.30 (α-CH2); m/z (ESI+) 252 [M+H+CH3OH]













To a suspension of 4 A˚ molecular sieves (1.00 g) in CH2Cl2 (11 mL) was added
divinylcarbinol (165 µl, 1.70 mmol, 1.0 equiv), followed by portionwise addition of MnO2
(3.69 g, 42.50 mmol, 25.0 equiv). 1-Methyl-hexylamine (0.299 g, 2.55 mmol, 1.5 equiv)
was added and the mixture was stirred at 50 ◦C for 18 h. MnO2 was filtered through a
pad of Celite and washed with acetone. Concentration of the combined filtrates under
reduced pressure and purification by column chromatography (20% ethyl acetate in
hexane) gave product 216 (201 mg, 60% over two steps) as a pale yellow oil; Rf 0.22
(20% ethyl acetate in hexane); νmax (film) 2959, 2929, 2858, 2806, 1720 (C=O), 1589,
1463, 1381, 1346, 1220, 1163, 1076; δH (400 MHz, CDCl3) 2.92-2.64 (5H, m, H-2, 2
x β-CH2), 2.52-2.31 (4H, m, 2 x α-CH2), 1.59-1.21 (8H, m, 4 x CH2), 0.98 (3H, d, J
6.6 Hz, CH3-1), 0.90 (3H, t, J 7.0 Hz, CH3-7); δC (100.6 MHz, CDCl3) 210.12 (C=O),
58.90 (C2), 48.12 (β-CH2), 42.13 (α-CH2), 33.91 (C3), 31.99 (C5), 26.68 (C4), 22.68
(C6), 14.36 (C1), 14.1 (C7); m/z (ESI+) 230 [M+H+CH3OH]
+, 198 [M+H]+; Exact
Mass Calcd for C12H23NO [M+H]
+requires m/z 198.1852 Found 198.1853 (NSI+)



















To a suspension of 4 A˚ molecular sieves (1.00 g) in CH2Cl2 (11 mL) was added
divinylcarbinol (165 µl, 1.70 mmol, 1.0 equiv), followed by portionwise addition of MnO2
(3.69 g, 42.50 mmol, 25.0 equiv). Tetradecylamine (550 mg, 2.55 mmol, 1.5 equiv) was
added and the mixture was stirred at 50 ◦C for 18 h. MnO2 was filtered through a pad
of Celite and washed with acetone and ethyl acetate. Concentration of the combined
filtrates under reduced pressure and purification by column chromatography (20% ethyl
acetate in hexane) gave product 218 (306 mg, 61% over two steps) as a waxy, pale
yellow solid; mp 35-37 ◦C; Rf 0.21 (20% ethyl acetate in hexane); νmax (solid) 2956,
2914, 2847, 2805, 2768, 1728 (C=O), 1475, 1463, 1376, 1350, 1218, 1212, 1129, 1084,
1009, 806, 761, 730, 719; δH (400 MHz, CDCl3) 2.67 (4H, t, J 6.1 Hz, 2 x β-CH2),
2.56-2.22 (6H, m, CH2-1, 2 x α-CH2), 1.51-1.06 (24H, m, 12 x CH2), 0.81 (3H, t, J
6.8 Hz, CH3-14); δC (100.6 MHz, CDCl3) 207.79 (C=O), 55.95 (C1), 51.49 (β-CH2),
39.57 (α-CH2), 30.23 (C12), 28.00 (CH2), 27.99 (CH2), 27.97 (CH2), 27.96 (CH2), 27.93
(CH2), 27.90 (CH2), 27.86 (CH2), 27.67 (CH2), 25.84 (CH2), 25.80 (CH2), 21.00 (C13),
12.44 (C14); m/z (ESI+) 328 [M+H+CH3OH]
+; 296 [M+H]+; Exact Mass Calcd for
C19H38NO [M+H]






To a suspension of 4 A˚ molecular sieves (1.00 g) in CH2Cl2 (11 mL) was added
divinylcarbinol (165 µl, 1.70 mmol, 1.0 equiv), followed by portionwise addition of MnO2
(3.69 g, 42.50 mmol, 25.0 equiv). 4-Trifluoromethyl-benzylamine (447 mg, 2.55 mmol,
1.5 equiv) was added and the mixture was stirred at 50 ◦C for 18 h. MnO2 was filtered
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through a pad of Celite and washed with CH2Cl2. Concentration of the combined
filtrates under reduced pressure and purification by column chromatography (20% ethyl
acetate in hexane with 1 % TEA) gave product 208 (232 mg, 53% over two steps) as a
pale yellow oil; Rf 0.25 (1:1 ethyl acetate:hexane); νmax (film) 2961, 2915, 2807, 2767,
1720 (C=O), 1620, 1418, 1350, 1326, 1240, 1196, 1163, 1124, 1087, 1066, 1019, 850; δH
(400 MHz, CDCl3) 7.53 (2H, d, J 8.1 Hz, meta Ar-H), 7.43 (2H, d, J 8.0 Hz, ortho
Ar-H), 3.60 (2H, s, N-CH2-Ar), 2.69 (4H, t, J 6.1 Hz, 2 x β-CH2), 2.40 (4H, t, J 6.2 Hz,
2 x α-CH2); δC (100.6 MHz, CDCl3) 207.82 (C=O), 128.62 (q,
2JCF 32 Hz, para Ar)
127.95 (ortho Ar), 124.35 (q, 3JCF 3.8 Hz, meta Ar), 123.15 (q,
1JCF 272 Hz, -CF3),
60.42 (N-CH2-Ar), 51.98 (β-CH2), 40.23 (α-CH2); m/z (ESI+) 290 [M+H+CH3OH]
+,
258 [M+H]+; Exact Mass Calcd for C13H15F3NO [M+H]






To a suspension of 4 A˚ molecular sieves (1.00 g) in CH2Cl2 (10 mL) was added
divinylcarbinol (165 µl, 1.70 mmol, 1.0 equiv), followed by portionwise addition of MnO2
(3.69 g, 42.50 mmol, 25.0 equiv.). 1-Phenyl-ethylamine (309 mg, 2.55 mmol, 1.5 equiv)
was added and the mixture was stirred at 50 ◦C for 18 h. MnO2 was filtered through a
pad of Celite and washed with acetone and methanol. Concentration of the combined
filtrates under reduced pressure and purification by column chromatography (20% ethyl
acetate in hexane) gave product 210 (169 mg, 49% over two steps) as a pale yellow
oil; Rf 0.29 (1:1 ethyl acetate:hexane); νmax (film) 3028, 2971, 2908, 2806, 2756, 1718
(C=O), 1493, 1454, 1412, 1386, 1342, 1316, 1284, 1220, 1131, 1080, 1011, 767, 703; δH
(400 MHz, CDCl3) 7.24-7.37 (5H, m, 5 x Ar-H), 3.62 (1H, q, J 6.7 Hz, N-CH<), 2.69-2.80
(4H, m, 2 x β-CH2), 2.42 (4H, t, J 6.2 Hz, 2 x α-CH2), 1.42 (3H, d, J 6.7 Hz, -CH3); δC
(100.6 MHz, CDCl3) 209.86 (C=O), 143.57 (ipso Ar), 128.49 (meta Ar), 127.50 (ortho
Ar), 127.29 (para Ar), 63.55 (N-CH<), 50.15 (β-CH2), 41.69 (α-CH2), 19.51 (CH3); m/z
(ESI+) 236 [M+H+CH3OH]
+, 204 [M+H]+; In agreement with published data.228
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N -Benzylidene benzylamine 220
N
220
To a suspension of 4 A˚ molecular sieves (3 g) in dichloromethane (15 mL) was added
benzaldehyde (212 mg, 2.0 mmol, 1.0 equiv) and benzylamine (214 mg, 2.0 mmol, 1.0
equiv). The reaction was left to stir at 40 ◦C for 1.5 h. The molecular sieves were filtered
off and washed with some acetone. Concentration under reduced pressure gave product
220 (386 mg, 99%) as a colourless oil; Rf 0.65 (1:1 ethyl acetate:hexane); νmax (film)
3085, 3062, 3028, 2872, 2840, 1702, 1644 (imine), 1601, 1580, 1496, 1452, 1379, 1343,
1311, 1292, 1027, 753, 694; δH (400 MHz, CDCl3) 8.41 (1H, s, Ph-CH=N-), 7.81-7.78
(2H, s, 2 x Ar-H), 7.43-7.26 (8H, m, 8 x Ar-H), 4.84 (2H, s, N-CH2-Ph); δC (100.6 MHz,
CDCl3) 162.15 (Ph-CH=N-), 139.42 (ipso Ph-CH=N-), 136.28 (ipso Ph-CH2N), 130.91,










Crotonaldehyde (747 mg, 10.70 mmol, 1.3 equiv) in THF (6 mL) was added dropwise to
an ice-cooled solution of vinylmagnesium bromide in THF (8.00 mmol, 1.0 M in THF,
1.0 equiv) under an atmosphere of nitrogen. After stirring at room temperature for 1 h,
the reaction mixture was poured into a mixture of saturated NH4Cl (10 mL) and ice (10
g) and stirred vigorously for 5 min. The aqueous solution was extracted with ether (3
x 15 mL) and the combined organic phases were dried over MgSO4. Concentration
of the solvent under reduced pressure and purification by column chromatography
(ethylacetate:hexane 1:3) gave alcohol 233 (639 mg, 82%) as a pale yellow oil; Rf 0.17
(5:1 hexane:diethyl ether); νmax (film) 3370, 3296, 2918, 1671, 1634, 1336, 1378, 1074,
990, 967, 924; δH (400 MHz, CDCl3) 5.83 (1H, ddd, J 17 Hz, 10.4 Hz, 5.9 Hz, H-2), 5.66
(1H, dqd, J 15.3 Hz, 6.5 Hz, 0.8 Hz, H-5), 5.46 (1H, ddq, J 15.3 Hz, 6.7 Hz, 1.5 Hz,
H-4), 5.18 (1H, dt, J 17.2 Hz, 1.4 Hz, H-1trans), 5.06 (1H, dt, J 10.4 Hz 1.2 Hz, H-1cis),
4.51 (1H, t, J 6.0 Hz, H-3), 1.82-1.74 (3H, m, H-6); δC (100.6 MHz, CDCl3) 138.78
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Crude allylic alcohol 233 (167 mg, 1.70 mmol, 1.0 equiv) was added to 4 A˚ molecular
sieves suspended in CH2Cl2 (13 mL). MnO2(3.69 g, 42.50 mmol, 25.0 equiv) was added
in portions and the mixture was stirred at 50 ◦C for 3 h. The mixture was filtered
through a pad of Celite, followed by washing with CH2Cl2 (150 mL). Concentration of
the solvent under reduced pressure gave crude ketone 238 (115 mg, 71%) as a yellow
oil; Rf 0.34 (5:1 hexane:ethyl acetate); νmax (film) 2969, 2931, 1713, 1444, 1377, 1256,
1164, 1129, 1086, 970, 735; δH (400 MHz, CDCl3) 6.96 (1H, dq, J 15.5 Hz, 6.8 Hz, H-5),
6.59 (1H, dd, J 17.4 Hz, 10.6 Hz, H-2), 6.39 (1H, dq, J 15.6 Hz, 1.6 Hz, H-4), 6.28 (1H,
dd, J 17.4 Hz, 1.3 Hz, H-1trans), 5.81 (1H, dd, J 10.6 Hz, 1.3 Hz, H-1cis), 1.94 (3H, dd,
J 6.8 Hz, 1.6 Hz, H-6); δC (100.6 MHz, CDCl3) 189.83 (C3), 144.31 (C5), 134.98 (C2),












trans-2-Hexenal (1.37 g, 14.00 mmol, 1.0 equiv) in THF (12 mL) was added dropwise to
an ice-cooled solution of vinylmagnesium bromide in THF (16.00 mmol, 0.7 M in THF,
1.1 equiv) under an atmosphere of nitrogen. After allowing the flask to warm to room
temperature and stirring for 1 h, the reaction mixture was poured into a mixture of
saturated NH4Cl (20 mL) and ice (24 g) and stirred for 10 min. The aqueous solution
was extracted with ether (3 x 30 mL) and the combined organic phases were washed
with water and brine. The organic phase was dried over MgSO4, filtered and the solvent
was evaporated under reduced pressure. Crude alcohol 234 (1.74 g, 99%) was obtained
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as a yellow oil; Rf 0.40 (3:1 hexane:ethyl acetate); νmax (film) 3392, 3081, 2960, 2930,
2873, 1692, 1639, 1458, 1380, 1262, 1019, 989, 970, 920 δH (400 MHz, CDCl3) 5.91 (1H,
ddd, J 16.9 Hz, 10.4 Hz, 5.8 Hz, H-2), 5.64-5.74 (1H, m, H-5), 5.50 (1H, dd, J 15.4 Hz,
6.7 Hz, H-4), 5.26 (1H, d, J 17.3 Hz, H-1trans), 5.12 (1H, d, J 10.5 Hz, H-1cis), 4.59
(1H, t, J 5.5 Hz, H-3), 2.03 (2H, app q, J 7.1 Hz, H-6), 1.36-1.45 (2H, m, H-7), 0.90
(3H, t, J 7.4 Hz, H-8); δC (100.6 MHz, CDCl3) 140.01 (C2), 132.95 (C5), 131.21 (C4),













2,3-Dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) (343 mg, 1.51 mmol, 1.1 equiv) was
added to crude allylic alcohol 234 (173 mg, 1.37 mmol, 1.0 equiv.) and 4 A˚ molecular
sieves in CH2Cl2 (4 mL). The mixture was stirred at rt for 18 h, filtered and washed with
CH2Cl2 (30 mL). Concentration of the solvent under reduced pressure and purification
by column chromatography (hexane:diethyl ether 5:1) gave ketone 240 (30 mg, 18%) as
a colourless oil.
Method B:
Crude allylic alcohol 234 (711 mg, 5.64 mmol, 1.0 equiv) was added to 4 A˚ molecular
sieves suspended in CH2Cl2 (30 mL). MnO2(12.26 g, 141.00 mmol, 25.0 equiv) was
added in portions and the mixture was stirred at 50 ◦C for 3 h. The mixture was filtered
through a pad of Celite, followed by washing with CH2Cl2 (400 mL). Concentration of
the solvent under reduced pressure gave crude ketone 240 (433 mg, 62%) as a yellow
oil; Rf 0.65 (3:2 hexane:ethyl acetate); νmax (film) 2962, 2932, 2874, 1667, 1633, 1612,
1403, 1219, 1100, 1043; δH (400 MHz, CDCl3) 6.94 (1H, dt, J 15.6 Hz, 6.9 Hz, H-5),
6.61 (1H, dd, J 17.4 Hz, 10.6 Hz, H-2), 6.36 (1H, dt, J 15.7 Hz, 1.5 Hz, H-4), 6.28 (1H,
dd, J 17.4 Hz, 1.3 Hz, H-1trans), 5.81 (1H, dd, J 10.6 Hz, 1.3 Hz, H-1cis), 2.20-2.26 (2H,
m, H-6), 1.47-1.57 (2H, m, H-7), 0.94 (3H, t, J 7.4 Hz, H-8); δC (100.6 MHz, CDCl3)
189.99 (C3), 149.06 (C5), 135.04 (C2), 128.45 & 128.44 (C4 & C1), 34.84 (C6), 21.50
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(C7), 13.85 (C8); m/z (ESI+) 157 [M+H+CH3OH]
+, 125 [M+H]+; Exact Mass Calcd
for C8H12O [M+H]








Cinnamaldehyde (925 mg, 10.70 mmol, 1.3 equiv) in THF (6 mL) was added dropwise
to an ice-cooled solution of vinylmagnesium bromide in THF (8.00 mmol, 1.0 M in THF,
1.0 equiv) under an atmosphere of nitrogen. After stirring at room temperature for 1 h,
the reaction mixture was poured into a mixture of saturated NH4Cl (10 mL) and ice (10
g) and stirred for 5 min. The aqueous solution was extracted with ether (3 x 15 mL) and
the combined organic phases were dried over MgSO4. Concentration of the solvent under
reduced pressure and purification by column chromatography (ethylacetate:hexane 1:8)
gave alcohol 235 (1.09 g, 86%) as a pale yellow oil; Rf 0.41 (3:2 hexane:ethyl acetate);
νmax (film) 3351, 3027, 1656, 1599, 1494, 1449, 987, 966, 750, 692; δH (400 MHz, CDCl3)
7.37-7.11 (5H, m, Ph), 6.55 (1H, d, J 16.0 Hz, H-5), 6.17 (1H, dd, J 15.9 Hz, 6.4 Hz,
H-4), 5.91 (1H, ddd, J 17.2 Hz, 10.4 Hz, 5.9 Hz, H-2), 5.28 (1H, dt, J 17.2 Hz, 1.2
Hz, H-1trans), 5.13 (1H, dt, J 10.4 Hz, 1.1 Hz, H-1cis), 4.75 (1H, t, J 6.0 Hz, H-3);
δC (100.6 MHz, CDCl3) 138.19 (C2), 135.51 (ipso Ph), 129.83 (C4), 129.26 (para Ph),








2,3-Dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) (674 mg, 2.97 mmol, 1.1 equiv) was
added to crude allylic alcohol 235 (436 mg, 2.70 mmol, 1.0 equiv) in 1,4-dioxane (8.5
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mL). The mixture was stirred at rt for 18 h, filtered and washed with CH2Cl2 (20
mL). Concentration under reduced pressure and purification by column chromatography
(ethylacetate:hexane 1:8) afforded ketone 239 (317 mg, 74%) as a yellow oil; Rf 0.54 (3:2
hexane:ethyl acetate); νmax (film) 3048, 1655, 1623, 1592, 1497, 1451, 1404, 1348, 1205,
1104, 984, 875, 691; δH (400 MHz, CDCl3) 7.68 (1H, d, J 16.0 Hz, H-5), 7.58-7.60 (2H,
m, 2 x Ar-H), 7.40-7.42 (3H, m, 3 x Ar-H), 7.02 (1H, d, J 16.0 Hz, H-4), 6.72 (1H, dd, J
17.4 Hz, 10.6 Hz, H-2), 6.39 (1H, dd, J 17.4 Hz 1.2 Hz, H-1trans), 5.90 (1H, dd, J 10.4
Hz, 1.1 Hz, H-1cis); δC (100.6 MHz, CDCl3) 189.72 (C3), 144.14 (C5), 135.59, 134.77,









E -4-Chlorocinnamaldehyde (1.000 g, 6.00 mmol, 1.0 equiv) in THF (8 mL) was added
dropwise to an ice-cooled solution of vinylmagnesium bromide in THF (7.20 mmol, 0.7
M in THF, 1.1 equiv) under an atmosphere of nitrogen. After allowing the flask to
warm to room temperature and stirring for 1 h, the reaction mixture was poured into a
mixture of saturated NH4Cl (10 mL) and ice (12 g) and stirred for 10 min. The aqueous
solution was extracted with ether (3 x 15 mL) and the combined organic phases were
washed with water and brine. The organic phase was dried over MgSO4, filtered and the
solvent was evaporated under reduced pressure. Crude alcohol 236 (1.160 g, 100%) was
obtained as a yellow oil; Rf 0.14 (1:2.7 diethyl ether:hexane); νmax (film) 3369, 1592,
1491, 1405, 1090, 1013, 967, 926, 807; δH (400 MHz, CDCl3) 7.26-7.31 (m, 4 H, ortho
Ar-H and meta Ar-H), 6.56 (dd, 1 H, J 16.0 Hz, 1.1 Hz, H-5), 6.20 (dd, 1 H, J 15.9 Hz,
6.3 Hz, H-4), 5.96 (ddd, 1 H, J 17.1 Hz, 10.3 Hz, 5.9 Hz, H-2), 5.33 (dt, 1 H, J 17.1
Hz, 1.3 Hz, H-1trans), 5.20 (dt, 1H, J 10.3 Hz, 1.3 Hz, H-1cis), 4.80 (td, 1 H, J 6.2 Hz,
1.3 Hz, H-3); δC (100.6 MHz, CDCl3) 139.16 (C2), 135.18 (ipso Ar), 133.50 (para Ar),
131.07 (C5), 129.59 (C4), 128.86 (ortho Ar), 127.86 (meta Ar), 115.76 (C1), 73.79 (C3);
Mass ion not found (ESI+/-) Exact Mass Calcd for C11H11ClO [M-OH]
+ requires m/z
177.0461 Found 177.0466 (APCI+).








2,3-Dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) (1.45 g, 6.38 mmol, 1.1 equiv) was
added to crude allylic alcohol 236 (1.128 g, 5.80 mmol, 1.0 equiv) in dioxane (19 mL).
The mixture was stirred at rt for 18 h, filtered and washed with CH2Cl2. Concentration
of the solvent under reduced pressure and purification by column chromatography
(hexane:diethyl ether 3:1) gave ketone 244 (627 mg, 56%) as a yellow solid; mp 178-182
◦C; Rf 0.20 (1:2.7 diethyl ether:hexane); νmax (solid) 1656, 1603, 1591, 1566, 1491, 1408,
1382, 1313, 1294, 1260, 1240, 1194, 11779, 1090, 1014, 970, 827; δH (400 MHz, CDCl3)
7.61 (1H, d, J 16.0 Hz, H-5), 7.50 (2H, d, J 8.3 Hz, ortho Ar-H), 7.36 (2H, d, J 7.4
Hz, meta Ar-H), 6.97 (1H, d, J 16.0 Hz, H-4), 6.69 (1H, dd, 17.4 Hz, 10.6 Hz, H-2),
6.38 (1H, dd, J 17.4 Hz, 1.1 Hz, H-1trans), 5.89 (1H, dd, J 10.6 Hz, 1.1 Hz, H-1cis); δC
(100.6 MHz, CDCl3) 189.35 (C=O), 142.55 (C5), 136.60 (para Ar), 135.56 (C2), 133.23
(ipso Ar), 129.63 (ortho Ar), 129.36 (meta Ar), 128.97 (C1), 124.50 (C4); Mass ion not
found (ESI+/-) Exact Mass Calcd for C11H9ClO [M+H]










E -4-Methoxycinnamaldehyde (5.000 g, 30.82 mmol, 1.0 equiv) in THF (26 mL) was
added dropwise to an ice-cooled solution of vinylmagnesium bromide in THF (35.13
mmol, 0.7 M in THF, 1.1 equiv) under an atmosphere of nitrogen. After allowing the
flask to warm to room temperature and stirring for 1 h, the reaction mixture was poured
into a mixture of saturated NH4Cl (45 mL) and ice (54 g) and stirred for 5 min. The
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aqueous solution was extracted with ether (3 x 60 mL) and the combined organic phases
were washed with water and brine. The organic phase was dried over MgSO4, filtered
and the solvent was evaporated under reduced pressure. Crude alcohol 237 (5.740 g,
98%) was obtained as a thick, yellow oil; Rf 0.46 (2:3 ethyl acetate:hexane); νmax (film)
3392, 2961, 2837, 1660, 1606, 1512, 1464, 1422, 1300, 1251, 1175, 1109, 1032, 969, 925,
805; δH (400 MHz, CDCl3) 7.26-7.33 (m, 2 H, ortho Ar-H), 6.84-6-86 (2H, m, meta
Ar-H), 6.55 (1H, d, J 16.0 Hz, H-5), 6.10 (1H, dd, J 15.9 Hz, 6.6 Hz, H-4), 5.98 (1H,
ddd, J 17.3 Hz, 10.5 Hz, 5.9 Hz, H-2), 5.33 (1H, dt, J 17.3 Hz, 1.5 Hz, H-1trans), 5.18
(1H, dt, J 10.3 Hz, 1.3 Hz, H-1cis), 3.80 (3H, s, -OCH3); δC (100.6 MHz, CDCl3) 159.47
(para Ar), 139.56 (C2), 130.59 (C5), 129.42 (ipso Ar), 128.26 (C4), 127.87 (ortho Ar),









2,3-Dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) (1.85 g, 8.13 mmol, 1.1 equiv) was
added to crude allylic alcohol 237 (1.404 g, 7.39 mmol, 1.0 equiv) and in dioxane (27 mL).
The mixture was stirred at rt for 18 h, filtered and washed with CH2Cl2. Concentration
of the solvent under reduced pressure and purification by column chromatography
(hexane:diethyl ether 3:1) gave ketone 245 (741 mg, 53%) as a yellow solid; mp 64-
67 ◦C; Rf 0.51 (2:3 ethyl acetate:hexane); νmax (solid) 2936, 2838, 1654, 1601, 1572,
1512, 1463, 1442, 1424, 1404, 1306, 1254, 1222, 1200, 1174, 1103, 1030, 988, 830; δH
(400 MHz, CDCl3) 7.65 (1H, d, J 15.9 Hz, H-5), 7.52-7.55 (2H, m, ortho Ar-H), 6.86-
6.95 (3H, m, meta Ar-H and H-4), 6.70 (1H, dd, J 17.4 Hz, 10.6 Hz, H-2), 6.36 (1H,
dd, J 17.4 Hz, 1.3 Hz, H-1trans), 5.84 (1H, dd, J 10.6 Hz, 1.3 Hz, H-1cis), 3.84 (3H, s,
-OCH3); δC (100.6 MHz, CDCl3) 189.61 (C=O), 161.83 (para Ar), 143.93 (C5), 135.65
(C2), 130.28 (ortho Ar), 128.23 (C1), 127.44 (ipso Ar), 122.12 (C4), 114.55 (meta Ar),
55.52 (-OCH3). In agreement with published data.
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To a suspension of 4 A˚ molecular sieves in CH2Cl2 (10.5 mL) was added divinyl alcohol
233 (216 mg, 2.20 mmol, 1.0 equiv), followed by portionwise addition of MnO2 (4.78
g, 55.00 mmol, 25.0 equiv). Benzylamine (330 mg, 3.08 mmol, 1.4 equiv) was added
and the mixture was stirred at 50 ◦C for 18 h. MnO2 was filtered through a pad of
Celite and washed with a mixture of CH2Cl2 and methanol (1:1). Concentration of the
combined filtrates under reduced pressure and purification by column chromatography
(ethyl acetate:hexane 1:4) gave product 241 (76 mg, 17% over three steps) as a pale
yellow oil;
Method B:
Benzylamine (2.90 g, 27.06 mmol, 1.3 equiv) was dissolved in acetonitrile (30 mL) and a
solution of aqueous NaHCO3 (6.56 g in 17 mL H2O) was added. The resulting suspension
was cooled to 16 ◦C and crude ketone 238 (2.00 g, 20.83 mmol, 1.0 equiv) in acetonitrile
(20 mL) was slowly added over a period of 35 minutes. Upon addition of the ketone, the
reaction was stirred at reflux for 1.5 h. Evaporation of acetonitrile in vacuo was followed
by the addition of ethyl acetate (60 mL). The solution was stirred for 20 min, the layers
were separated and the aqueous layer was again extracted with ethyl acetate (2 x 60
mL). The organic layers were combined and washed with water (60 mL) and brine (60
mL). The organic layer was dried with anhydrous Na2SO4, filtered and the solvent was
evaporated in vacuo. Purification by column-chromatography (ethyl acetate:hexane 1:2
with 1% TEA) afforded product 241 (1.66 g, 39%) as a pale yellow oil; Rf 0.33 (1:1
ethyl acetate:hexane); νmax (film) 2966, 2802, 1720, 1601, 1495, 1453, 1377, 1349, 1332,
1250, 1177, 1137, 1064, 1028, 762, 733; δH (400 MHz, CDCl3) 7.25-7.38 (5H, m, 5 x
Ar-H), 3.97 (1H, d, J 13.4 Hz, 1 x N-CH2-Ph) 3.45 (1H, d, J 13.5 Hz, 1 x N-CH2-Ph),
2.97-3.02 (2H, m, H-1 and 1 x H-5), 2.53-2.56 (2H, m, 1 x H-5 and 1 x H-4), 2.37-2.40
(2H, m, H-2), 2.26-2.31 (1H, m, 1 x H-4), 1.18 (3H, d, J 6.4 Hz, -CH3); δC (100.6 MHz,
CDCl3) 209.89 (C=O), 139.13 (ipso Ar), 128.80 (Ar), 128.49 (Ar), 127.26 (para Ar),
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57.18 (N-CH2-Ph) 56.30 (C1), 48.89 and 48.75 (C4 and C5), 41.03 (C2), 17.61 (-CH3).












Benzylamine (196 mg, 1.83 mmol, 1.3 equiv) was dissolved in acetonitrile (5 mL) and a
solution of aqueous NaHCO3 (454 mg in 3 mL H2O) was added. The resulting suspension
was cooled to 16 ◦C and crude ketone 240 (179 mg, 1.44 mmol, 1.0 equiv) in acetonitrile
(5 mL) was slowly added over a period of 40 minutes. Upon addition of the ketone, the
reaction was stirred at reflux for 1.5 h. Evaporation of acetonitrile in vacuo was followed
by the addition of ethyl acetate (12 mL). The solution was stirred for 20 min, the layers
were separated and the organic layer was washed with water (12 mL) and brine (12
mL). The organic layer was dried over anhydrous Na2SO4 and filtered. Evaporation
of the solvent and purification by column-chromatography (ethyl acetate:hexane 1:2.95)
afforded product 243 (120 mg, 36%) as a pale yellow oil; Rf 0.15 (5:1 hexane:ethyl
acetate); νmax (film) 3028, 2958, 2930, 2872, 2807, 1718, 1495, 1454, 1419, 1350, 1264,
1201, 1174, 1139, 1071, 1027, 942, 733; δH (400 MHz, CDCl3) 7.25-7.39 (5H, m, 5 x
Ar-H), 3.90 (1H, d, J 13.5 Hz, 1 x N-CH2-Ph), 3.66 (1H, d, J 13.5 Hz, 1 x N-CH2-Ph),
2.97-3.07 (2H, m, H-1 and 1 x H-5), 2.69-2.75 (1H, m, 1 x H-5), 2.57 (1H, ddd, J 14.0
Hz, 4.7 Hz, 1.3 Hz, 1 x H-2), 2.38-2.45 (1H, m, 1 x H-4), 2.29-2.35 (2H, m, 1 x H-2 and 1
x H-4), 1.54-1.64 (1H, m, 1 x H-6), 1.28-1.45 (3H, m, 1 x H-6 and 2 x H-7), 0.90 (3H, t, J
7.2 Hz, H-8); δC (100.6 MHz, CDCl3) 210.28 (C=O), 139.39 (ipso Ar), 128.70 (ortho Ar),
128.53 (meta Ar), 127.30 (para Ar), 60.63 (C1), 56.11 (N-CH2-Ph), 48.09 (C5), 44.83
(C2), 39.62 (C4), 33.53 (C6), 19.04 (C7), 14.27 (C8); m/z (ESI+) 264 [M+H+CH3OH]
+,
232 [M+H]+; Exact Mass Calcd for C16H26NO [M+H+CH3OH]
+requires m/z 264.1958
Found 264.1960 (NSI+)











Benzylamine (139 mg, 1.30 mmol, 1.3 equiv) was added to a mixture of acetonitrile (3
mL) and aqueous NaHCO3 (315 mg in 2 mL H2O). The resulting suspension was cooled
to 15 ◦C and ketone 239 (158 mg, 1.00 mmol, 1.0 equiv) in acetonitrile (3 mL) was
slowly added over a period of 25 minutes. Upon addition of the ketone, the reaction
was stirred at reflux for 1.5 h. Evaporation of acetonitrile in vacuo was followed by
the addition of ethyl acetate (8 mL). The solution was stirred for 15 min, the layers
were separated and the aqueous layer was again extracted with ethyl acetate (2 x 10
mL). The organic layers were combined and washed with water (10 mL) and brine (10
mL). The organic phase was dried with anhydrous Na2SO4, filtered and the solvent
was evaporated under reduced pressure. Purification by column-chromatography (ethyl
acetate:hexane 1:7) afforded product 242 (210 mg, 79%) as a pale yellow oil; Rf 0.19
(ethyl acetate:hexane 1:8); νmax (film) 3025, 2797, 1726, 1495, 1454, 1257, 1236, 1160,
1101, 1073, 1023, 907, 823; δH (400 MHz, CDCl3) 7.24-7.48 (10H, m, 10 x Ar-H) 3.84
(1H, d, J 13.4 Hz, 1 x N-CH2-Ph), 3.59 (1H, dd, J 11.0 Hz, 3.7 Hz, H-1), 3.20-3.25 (1H,
m, 1 H, 1 x H-5), 2.94 (1H, d, J 13.6 Hz, 1 x N-CH2-Ph), 2.62-2.74 (2H, m, 1 x H-2 and
1 x H-4), 2.54 (1H, app dq, J 14.6 Hz, 2.5 Hz, 1 x H-2), 2.32-2.39 (2 H, m, 1 x H-4 and
1 x H-5); δC (100.6 MHz, CDCl3) 208.68 (C=O), 142.67 (ipso ArII), 139.10 (ipso ArI),
129.13, 128.66, 128.45, 127.95, 127.46 (para ArII), 127.20 (para ArI), 68.50 (C1), 58.22
(N-CH2-Ph), 51.33 (C5), 50.45 (C2), 41.62 (C4). In agreement with published data.
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Benzylamine (74 µl, 0.68 mmol, 1.3 equiv) was dissolved in acetonitrile (1.6 mL) and a
solution of aqueous NaHCO3 (164 mg in 1 mL H2O) was added. The resulting suspension
was cooled to 16 ◦C and ketone 244 (99 mg, 0.52 mmol, 1.0 equiv) in acetonitrile (1.6
mL) was slowly added over a period of 30 minutes. Upon addition of the ketone, the
reaction was stirred at reflux for 1.5 h. Evaporation of acetonitrile in vacuo was followed
by the addition of ethyl acetate (10 mL). The solution was stirred for 15 min, the layers
were separated and the aqueous layer was again extracted with ethyl acetate (2 x 10
mL). The organic layers were combined and washed with water (10 mL) and brine (10
mL). The organic phase was dried with anhydrous Na2SO4, filtered and the solvent was
evaporated in vacuo. Purification by column-chromatography (ethyl acetate:hexane 1:5
with 1% TEA) afforded product 255 (131 mg, 84%) as a pale yellow oil; Rf 0.32 (1:4
ethyl acetate:hexane); νmax (film) 2963, 2803, 1721, 1599, 1494, 1453, 1410, 1368, 1326,
1300, 1259, 1240, 1160, 1088, 1015, 836, 736; δH (400 MHz, CDCl3) 7.22-7.42 (9H, m, 9
x Ar-H), 3.80 (1H, d, J 13.5 Hz, 1 x N-CH2-Ph), 3.58 (1H, dd, J 10.8 Hz, 3.9 Hz, H-1),
3.19-3.24 (1H, m, 1 x H-5), 2.95 (1H, d, J 13.5 Hz, 1 x N-CH2-Ph), 2.61-2.69 (2H, m, 1 x
H-2, 1 x H-4), 2.52 (1H, ddd, J 14.5 Hz, 3.8 Hz, 2.3 Hz, 1 x H-2), 2.32-2.39 (2H, m, 1 x H-
5, 1 x H-4); δC (100.6 MHz, CDCl3) 208.13 (C=O), 141.20 (ipso ArII), 138.72 (ipso ArI),
133.59 (para ArII), 129.34, 128.78, 128.60, 128.51, 127.33 (para ArI), 67.68 (C1), 58.20
(N-CH2-Ph), 51.21 (C5), 50.20 (C2), 41.50 (C4); m/z (ESI+) 318 [M+H+H2O]
+, 300
[M+H]+, 282, 120, 91; Exact Mass Calcd for C18H18NO [M+H]
+requires m/z 300.1150
Found 300.1153 (NSI+)












Benzylamine (409 µl, 3.74 mmol, 1.3 equiv) was dissolved in acetonitrile (9 mL) and a
solution of aqueous NaHCO3 (907 mg in 6 mL H2O) was added. The resulting suspension
was cooled to 16 ◦C and ketone 245 (542 mg, 2.88 mmol, 1.0 equiv) in acetonitrile (9
mL) was slowly added over a period of 35 minutes. Upon addition of the ketone, the
reaction was stirred at reflux for 1.5 h. Evaporation of acetonitrile in vacuo was followed
by the addition of ethyl acetate (20 mL). The solution was stirred for 15 min, the layers
were separated and the aqueous layer was again extracted with ethyl acetate (2 x 20
mL). The organic layers were combined and washed with water (20 mL) and brine
(20 mL). The organic layer was dried with anhydrous Na2SO4, filtered and the solvent
was evaporated in vacuo. Purification by column-chromatography (ethyl acetate:hexane
1:3.2 with 1% TEA) afforded product 256 (712 mg, 84%) as a pale yellow oil; Rf 0.19
(1:5 ethyl acetate:hexane); νmax (film) 3029, 2800, 1720, 1611, 1585, 1512, 1495, 1454,
1367, 1325, 1303, 1248, 1173, 1115, 1032, 837, 816, 770, 738; δH (400 MHz, CDCl3)
7.35-7.39 (2H, m, ortho ArII-H), 7.21-7.33 (5H, m, 5 x ArI-H), 6.90-6.93 (2H, m, meta
ArII-H), 3.84 (1H, d, J 13.6 Hz, 1 x N-CH2-Ph), 3.81 (3H, s, -OCH3), 3.54 (1H, dd, J
10.9 Hz, 3.7 Hz, H-1), 3.21 (1H, ddd, J 11.1 Hz, 6.2 Hz, 2.4 Hz, 1 x H-5), 2.92 (1H, d, J
13.5 Hz, 1 x N-CH2-Ph), 2.61-2.72 (2H, m, 1 x H-2 and 1 x H-4), 2.52 (1H, ddd, J 14.6
Hz, 3.7 Hz, 2.5 Hz, 1 x H-2), 2.30-2.37 (2H, m, 1 x H-4 and 1 x H-5); δC (100.6 MHz,
CDCl3) 208.84 (C=O), 159.24 (para ArII), 139.21 (ipso ArI), 134.68 (ipso ArII), 128.64,
128.53, 128.41, 127.14 (para ArI), 114.41 (meta ArII), 67.76 (C1), 58.04 (N-CH2-Ph),
55.42 (-OCH3), 51.25 (C5), 50.51 (C2), 41.61 (C4); m/z (ESI+) 314 [M+H+H2O]
+, 296
[M+H]+, 177, 120, 91; Exact Mass Calcd for C20H26NO2 [M+H+CH3OH]
+requires m/z
328.1907 Found 328.1910 (NSI+).
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S -α-Phenylethylamine (4.92 g, 40.63 mmol, 1.3 equiv) was dissolved in acetonitrile (30
mL) and a solution of aqueous NaHCO3 (9.85 g in 20 mL H2O) was added. The resulting
suspension was cooled to 16 ◦C and crude ketone 238 (3.000 g, 31.25 mmol, 1.0 equiv)
in acetonitrile (30 mL) was slowly added over a period of 30 minutes. Upon addition
of the ketone, the reaction was stirred at reflux for 1 h. Evaporation of acetonitrile in
vacuo was followed by the addition of ethyl acetate (60 mL). The solution was stirred for
15 min, the layers were separated and the aqueous layer was again extracted with ethyl
acetate (2 x 60 mL). The organic layers were combined and washed with water (60 mL)
and brine (60 mL). The organic phase was dried with anhydrous Na2SO4, filtered and the
solvent was evaporated under reduced pressure. Purification by column-chromatography
(ethyl acetate:hexane 1:6 → 1:3) afforded product 258 (1.280 g, 19%) as a pale yellow
oil and product 259 (1.220 g, 18%) as a pale red solid;
Product 258, eluting first: [α]21D -47.7 (c 0.30, CHCl3); Rf 0.25 (1:4 ethyl
acetate:hexane); νmax (film) 3028, 2969, 2814, 1720, 1601, 1492, 1453, 1380, 1353, 1307,
1262, 1230, 1180, 1140, 766, 70; δH (400 MHz, CDCl3) 7.43-7.45 (2H, m, 2 x Ar-H),
7.31-7.35 (2H, m, 2 x Ar-H), 7.23-7.27 (1H, m, 1 x Ar-H), 4.01 (1H, q, J 6.7 Hz, -
CH(CH3)C6H5 ), 3.34-3.41 (1H, m, H-1), 2.75 (1H, ddd, J 12.5 Hz, 7.7 Hz, 4.9 Hz, 1 x
H-5), 2.61-2.70 (2H, m, 1 x H-5 and 1 x H-2), 2.29-2.37 (1H, m, 1 x H-4), 2.16-2.24 (2H,
m, 1 x H-4 and 1 x H-2), 1.33 (3H, d, J 6.8 Hz, -CH(CH3)C6H5 ), 1.14 (3H, d, J 6.4 Hz,
H-6); δC (100.6 MHz, CDCl3) 210.54 (C=O), 145.32 (ipso Ar), 128.46, 127.34, 126.99
(para Ar), 57.76 (CH(CH3)C6H5 ), 52.54 (C1), 48.89 (C2), 43.99 (C5), 41.46 (C4), 16.47
(C6), 16.33 (-CH(CH3)C6H5 ). In agreement with published literature.
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Product 259, eluting second: [α]20D -40.5 (c 0.15, CHCl3); mp 72-75
◦C; Rf 0.12
(1:4 ethyl acetate:hexane); νmax (solid) 3027, 2971, 2838, 1719, 1493, 1454, 1418, 1376,
1351, 1285, 1228, 1179, 1122, 1076, 1027, 768, 702; δH (400 MHz, CDCl3) 7.30-7.35 (4H,
m, 4 x Ar-H), 7.23-7.27 (1H, m, 1 x Ar-H), 3.92 (1H, q, J 6.7 Hz, -CH(CH3)C6H5 ),
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3.12-3.19 (1H, m, H-1), 2.90-3.00 (2H, m, 2 x H-5), 2.49-2.58 (2H, m, 1 x H-2 and 1 x
H-4), 2.28-2.35 (1H, m, 1 x H-4), 2.07-2.12 (1H, m, 1 x H-2), 1.42 (3H, d, J 6.7 Hz,
-CH(CH3)C6H5 ), 1.03 (3H, d, J 6.6 Hz, H-6); δC (100.6 MHz, CDCl3) 210.54 (C=O),
144.11 (ipso Ar), 128.55, 127.35, 127.22 (para Ar), 58.84 (CH(CH3)C6H5 ), 52.45 (C1),
48.37 (C2), 43.19 (C5), 41.20 (C4), 21.93 (-CH(CH3)C6H5 ), 14.78 (C6). In agreement
with published literature.174





















S -α-Phenylethylamine (496 mg, 4.09 mmol, 1.3 equiv) was dissolved in acetonitrile (9
mL) and a solution of aqueous NaHCO3 (1.01 g in 6 mL H2O) was added. The resulting
suspension was cooled to 16 ◦C and crude ketone 240 (400 mg, 3.22 mmol, 1.0 equiv)
in acetonitrile (9 mL) was slowly added over a period of 30 minutes. Upon addition of
the ketone, the reaction was stirred at reflux for 1.5 h. Evaporation of acetonitrile in
vacuo was followed by the addition of ethyl acetate (12 mL). The solution was stirred
for 20 min, the layers were separated and the organic layer was washed with water
(12 mL) and brine (12 mL). The organic layer was dried over anhydrous Na2SO4 and
filtered. Evaporation of the solvent and purification by column-chromatography (ethyl
acetate:hexane 1:5) afforded product 260 (123 mg, 16%) as a pale yellow oil and product
261 (86 mg, 11%) as pale yellow oil;
Product 260, eluting first: [α]22D -36.4 (c 0.52, CHCl3); Rf 0.42 (1:3 ethyl
acetate:hexane); νmax (film) 3026, 2959, 2931, 2872, 1716, 1601, 1492, 1454, 1351, 1282,
1219, 1178, 1082, 967, 770; δH (400 MHz, CDCl3) 7.40-7.43 (2H, m, 2 x Ar-H), 7.31
(2H, m, 2 x Ar-H), 7.23-7.26 (1H, m, 1 x Ar-H), 4.00 (1H, q, J 6.7 Hz, -CH(CH3)C6H5
), 3.17-3.22 (1H, m, H-1), 2.92-2.98 (1H, m, 1 x H-5), 2.83-2.89 (1H, m, 1 x H-5), 2.65
(1H, ddd, J 13.9 Hz, 5.5 Hz, 0.8 Hz, 1 x H-2), 2.36-2.44 (1H, m, 1 x H-4), 2.24 (1H,
ddd, J 14.0 Hz, 4.1 Hz, 2.0 Hz, 1 x H-2), 2.12-2.18 (1H, m, 1 x H-4), 1.45-1.53 (1H,
m, 1 x H-6), 1.25-1.37 (6H, m, 3 x -CH(CH3)C6H5 , 2 x H-7, 1 x H-6), 0.87 (3H, t, J
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7.1, H-8); δC (100.6 MHz, CDCl3) 210.89 (C=O), 145.80 (ipso Ar), 128.55 (ortho Ar),
127.30 (meta Ar), 127.12 (para Ar), 58.19 (-CH(CH3)C6H5 ), 57.00 (C1), 44.54 (C2),
43.72 (C5), 40.33 (C4), 32.56 (C6), 19.30 and 19.14 (C7 and -CH(CH3)C6H5 ), 14.34
(C8); m/z (ESI+) 264 [M+H+H2O]
+, 246 [M+H]+, 142, 105; Exact Mass Calcd for
C28H26NO [M+H+CH3OH]
+requires m/z 278.2115 Found 278.2118 (NSI+).
Product 261, eluting second: [α]21D -25.0 (c 1.08, CHCl3); Rf 0.23 (1:3 ethyl
acetate:hexane); νmax (film) 3027, 2960, 2932, 2872, 1713, 1602, 1492, 1454, 1352, 1281,
1219, 1174, 1083, 967, 770; δH (400 MHz, CDCl3) 7.23-7.42 (5H, m, 5 x Ar-H), 3.99 (1H,
q, J 6.5 Hz, -CH(CH3)C6H5 ), 3.27-3.32 (1H, m, H-1), 2.88-2.99 (2H, m, H-5), 2.49-2.61
(2H, m, 1 x H-2 and 1 x H-4), 2.11-2.19 (2H, m, 1 x H-2 and 1 x H-4), 1.47-1.58 (1H,
m, 1 x H-6), 1.40 (3H, d, J 6.5 Hz, 3 x -CH(CH3)C6H5 ); 1.20-1.37 (3H, m, 2 x H-7, 1 x
H-6), 0.88 (3H, t, J 7.0 Hz, H-8); δC (100.6 MHz, CDCl3) 210.79 (C=O), 145.57 (ipso
Ar), 128.65 (ortho Ar), 127.26 (meta & para Ar), 58.71 (-CH(CH3)C6H5 ), 56.18 (C1),
44.15 (C2), 43.51 (C5), 39.48 (C4), 32.34 (C6), 22.50 (-CH (CH3)C6H5 ), 19.50(C7),
14.11 (C8); m/z (ESI+) 264 [M+H+H2O]
+, 246 [M+H]+, 142, 105; Exact Mass Calcd
for C16H24NO [M+H]
+requires m/z 246.1852 Found 246.1855 (NSI+).















S -α-Phenylethylamine (291 mg, 2.40 mmol, 1.3 equiv) was dissolved in acetonitrile (6
mL) and a solution of aqueous NaHCO3 (599 mg in 4 mL H2O) was added. The resulting
suspension was cooled to 16 ◦C and ketone 239 (300 mg, 1.90 mmol, 1.0 equiv) in
acetonitrile (6 mL) was slowly added over a period of 40 minutes. Upon addition of
the ketone, the reaction was stirred at reflux for 1.5 h. Evaporation of acetonitrile in
vacuo was followed by the addition of ethyl acetate (12 mL). The solution was stirred
for 20 min, the layers were separated and the organic layer was washed with water
(12 mL) and brine (12 mL). The organic phase was dried over anhydrous Na2SO4 and
filtered. Evaporation of the solvent and purification by column-chromatography (ethyl
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acetate:hexane 1:5.5) afforded product 262 (249 mg, 47%) as a pale yellow solid and
product 263 (83 mg, 16%) as a pale yellow oil;
Product 262, eluting first: [α]21D -34.2 (c 0.42, CHCl3); mp 87-90
◦C; Rf 0.31 (17:3
hexane:ethyl acetate); νmax (solid) 3059, 2972, 2820, 1712, 1600, 1492, 1447, 1421, 1380,
1365, 1331, 1257, 1239, 1168, 1122, 1027, 1011, 805, 785; δH (400 MHz, CDCl3) 7.47-7.50
(4H, m, 4 x Ar-H), 7.22-7.40 (6H, m, 6 x Ar-H), 3.90-3.98 (2H, m, 1 x -CH(CH3)C6H5
and 1 x H-1), 2.88-2.93 (1H, m, 1 x H-5), 2.73 (1H, dd, J 14.4 Hz, 10.4 Hz, 1 x H-2), 2.49-
2.64 (3H, m, 1 x H-2 and 1 x H-4 and 1 x H-5), 2.29-2.33 (1H, m, 1 x H-4), 1.23 (3H, d,
J 6.8 Hz, -CH3); δC (100.6 MHz, CDCl3) 209.15 (C=O), 143.93 (ipso Ar), 142.30 (ipso
Ar), 129.13, 128.24, 127.96, 127.57, 127.49, 126.82, 64.90 (C1), 54.97 (CH(CH3)C6H5),
50.39 (C2), 44.16 (C5), 42.05 (C4), 9.52 (CH3); m/z (ESI+) 312 [M+H+CH3OH]
+, 280
[M+H]+, 176, 147, 129; Exact Mass Calcd for C20H42NO2 [M+H+CH3OH]
+ requires
m/z 312.1958 Found 312.1961 (NSI+)
Product 263, eluting second: [α]22D -95.1 (c 0.28, CHCl3); Rf 0.23 (17:3 hexane:ethyl
acetate); νmax (film) 3029, 2971, 2817, 1721, 1601, 1493, 1454, 1363, 1309, 1261, 1241,
1108, 1073, 1030, 759, 702; δH (400 MHz, CDCl3) 7.24-7.43 (8H, m, 8 x Ar-H), 7.06-7.09
(2H, m, 2 x Ar-H), 4.03 (1H, q, J 7.1 Hz, -CH(CH3)C6H5 ), 3.67 (1H, dd, J 9.4 Hz, 4.5
Hz, H-1), 3.34 (1H, ddd, J 12.0 Hz, 5.7 Hz, 3.8 Hz, 1 x H-5), 2.37-2.68 (4H, m, 2 x H-4
and 2 x H-2), 2.20-2.24 (1H, m, 1 x H-5), 1.44 (3H, d, J 7.2 Hz, CH3); δC (100.6 MHz,
CDCl3) 208.83 (C=O), 143.10 (ipso Ar), 139.01 (ipso Ar), 129.12, 128.46, 128.07, 127.67,
127.66, 127.36, 64.63 (C1), 56.63 (CH(CH3)C6H5), 50.56 (C2), 44.52 (C5), 41.84 (C4),
19.56 (CH3); m/z (ESI+) 312 [M+H+CH3OH]
+, 280 [M+H]+, 176, 147, 129; Exact
Mass Calcd for C19H22NO [M+H]
+requires m/z 280.1696 Found 280.1698 (NSI+).




















S -α-Phenylethylamine (345 µl, 2.68 mmol, 1.3 equiv) was dissolved in acetonitrile (6.5
mL) and a solution of aqueous NaHCO3 (649 mg in 4.3 mL H2O) was added. The
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resulting suspension was cooled to 16 ◦C and ketone 244 (396 mg, 2.06 mmol, 1.0 equiv)
in acetonitrile (6.5 mL) was slowly added over a period of 30 minutes. Upon addition
of the ketone, the reaction was stirred at reflux for 1.5 h. Evaporation of acetonitrile in
vacuo was followed by the addition of ethyl acetate (15 mL). The solution was stirred for
15 min, the layers were separated and the aqueous layer was again extracted with ethyl
acetate (2 x 15 mL). The organic layers were combined and washed with water (15 mL)
and brine (15 mL). The organic layer was dried with anhydrous Na2SO4, filtered and
the solvent was evaporated in vacuo. Purification by column-chromatography (ethyl
acetate:hexane 1:5.5 with 1.5% TEA) afforded product 264 (270 mg, 42%) as a pale
yellow solid and a mixture of product 264 and product 265 (170 mg, 26%) as a pale
yellow oil. NMR investigation indicated that the mixed fractions of diastereomers were
a 0.47:1 ratio of 264:265. Further purification of this diastereomeric mixture afforded
pure 265.
Product 264, eluting first: [α]24D -56.0 (c 0.38, CHCl3); mp 91-94
◦C; Rf 0.39 (1:4
ethyl acetate:hexane); νmax (solid) 2989, 2813, 1719, 1600, 1487, 1447, 1412, 1381, 1366,
1299, 1260, 1239, 1166, 1123, 1088, 1014, 835; δH (400 MHz, CDCl3) 7.23-7.46 (9H, m,
9 x Ar-H), 3.89-3.95 (2H, m, -CH(CH3)C6H5 , H-1), 2.90 (1H, ddd, J 11.6 Hz, 5.7 Hz,
3.4 Hz, 1 x H-5), 2.47-2.69 (4H, m, 2 x H-2, 1 x H-4, 1 x H-5), 2.32 (1H, ddd, J 14.0
Hz, 5.4 Hz, 2.9 Hz, 1 x H-4), 1.23 (3H, d, J 6.8 Hz, -CH3); δC (100.6 MHz, CDCl3)
208.61 (C=O), 143.62 (ipso ArI), 140.87 (ipso ArII), 133.60 (para ArII), 129.35, 128.88,
128.34, 127.41, 126.98 (para ArI), 64.07 (C1), 55.16 (-CH(CH3)C6H5 ), 49.98 (C2), 44.02
(C5), 41.86 (C4), 9.83 (-CH3); m/z (ESI+) 332 [M+H+H2O]
+, 314 [M+H]+, 210, 134,
105; Exact Mass Calcd for C19H20ClNO [M+H+CH3OH]
+ requires m/z 346.1568 Found
346.1572 (NSI+).
Product 265, eluting second: [α]23D -116.5 (c 0.13, CHCl3); Rf 0.30 (1:4 ethyl
acetate:hexane); νmax (film) 2972, 2815, 1720, 1600, 1487, 1453, 1411, 1370, 1278, 1261,
1240, 1167, 1111, 1088, 1014, 834, 768, 734; δH (400 MHz, CDCl3) 7.23-7.44 (7H, m, 7
x Ar-H), 7.04-7-06 (2H, m, ortho ArI-H), 3.97 (1H, q, J 7.1 Hz, -CH(CH3)C6H5 ), 3.67
(1H, dd, J 8.5 Hz, 5.4 Hz, H-1), 3.33 (1H, ddd, J 12.0 Hz, 5.7 Hz, 4.0 Hz, 1 x H-5),
2.37-2.51 (3H, m, 2 x H-2 and 1 x H-4), 2.25 (1H, td, J 11.8 Hz, 3.3 Hz, 1 x H-5), 1.44
(3H, d, J 7.1 Hz, -CH3); δC (100.6 MHz, CDCl3) 208.35 (C=O), 141.65 (ipso ArII),
138.88 (ipso ArI), 133.27 (para ArII), 129.31, 128.98, 128.36, 128.16, 127.49 (para ArI),
63.77 (C1), 56.87 (-CH(CH3)C6H5 ), 50.17(C2), 44.39 (C5), 41.70 (C4), 19.63 (-CH3);
m/z (ESI+) 332 [M+H+H2O]
+, 314 [M+H]+, 210, 134, 105; Exact Mass Calcd for
C19H21ClNO [M+H]
+requires m/z 314.1306 Found 314.1309 (NSI+).
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R-2-(4-Methoxyphenyl)-1-(S -1-phenylethyl)piperidin-4-one 266 and



















S -α-Phenylethylamine (365 µl, 2.83 mmol, 1.3 equiv) was dissolved in acetonitrile (6 mL)
and a solution of aqueous NaHCO3 (687 mg in 4 mL H2O) was added. The resulting
suspension was cooled to 16 ◦C and ketone 245 (410 mg, 2.18 mmol, 1.0 equiv) in
acetonitrile (6 mL) was slowly added over a period of 35 minutes. Upon addition of the
ketone, the reaction was stirred at reflux for 1 h. Evaporation of acetonitrile in vacuo
was followed by the addition of ethyl acetate (12 mL). The solution was stirred for 15
min, the layers were separated and the aqueous layer was again extracted with ethyl
acetate (2 x 12 mL). The organic layers were combined and washed with water (12 mL)
and brine (12 mL). The organic layer was dried with anhydrous Na2SO4, filtered and
the solvent was evaporated in vacuo. Purification by column-chromatography (ethyl
acetate:hexane 1:5.5 with 1.5% TEA) afforded product 266 (284 mg, 42%) as a pale
yellow solid and a mixture of product 266 and product 267 (99 mg, 15%) as a pale
yellow oil. NMR investigation indicated that the mixed fractions of diastereomers were
a 0.34:1 ratio of 266:267. Further purification of this diastereomeric mixture afforded
pure 267 as a pale yellow oil.
Product 266, eluting first: [α]21D -90.9 (c 0.22, CHCl3); mp 76-79
◦C; Rf 0.24 (1:6
ethyl acetate:hexane); νmax (solid) 2968, 2835, 1717, 1611, 1584, 1512, 1446, 1380, 1366,
1302, 1250, 1174, 1031, 835, 773, 724, 699; δH (400 MHz, CDCl3) 7.45-7.47 (2H, m, meta
ArI-H), 7.38-7.41 (2H, m, ortho ArII-H), 7.31-7.34 (2H, m, ortho ArI-H), 7.21-7.25 (1H,
m, para ArI-H), 6.89-6.93 (2H, m, meta ArII-H), 3.95 (1H, q, J 6.7 Hz, -CH(CH3)C6H5
), 3.86 (1H, dd, J 10.3 Hz, 3.7 Hz, H-1), 3.80 (3H, s, -OCH3), 2.87-2.92 (1H, m, 1 x H-5),
2.70 (1H, dd, J 14.2 Hz, 10.6 Hz, 1 x H-2), 2.47-2.58 (3H, m, 1 x H-2 and 1 x H-4 and 1
x H-5), 2.27-2.32 (1H, m, 1 x H-4), 1.22 (3H, d, J 6.8 Hz, -CH(CH3)C6H5 ); δC (100.6
MHz, CDCl3) 209.34 (C=O), 159.25 (para ArII), 144.06 (ipso ArI), 134.33 (ipso ArII),
128.61 (ortho ArII), 128.22 (ortho ArI), 127.47 (meta ArI), 126.77 (para ArI), 114.45
(meta ArII), 64.21 (C1), 55.41 (-OCH3), 54.85 (-CH(CH3)C6H5 ), 50.51 (C2), 44.13
(C5), 42.06 (C4), 9.57 (-CH3); m/z (ESI+) 328 [M+H+H2O]
+, 310 [M+H]+, 206, 177,
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134, 105; Exact Mass Calcd for C21H28NO2 [M+H+CH3OH]
+requires m/z 342.2064
Found 342.2067 (NSI+).
Product 267, eluting second: [α]22D -131.2 (c 0.32, CHCl3); Rf 0.16 (1:6 ethyl
acetate:hexane); νmax (film) 3029, 2970, 2835, 1719, 1611, 1585, 1511, 1454, 1365, 1302,
1249, 1173, 1033, 835, 771, 704; δH (400 MHz, CDCl3) 7.22-7.35 (5H, m, ortho ArII-H
and meta ArI-H and para ArI-H), 7.07-7.09 (2H, m, ortho ArI-H), 6.94-6.98 (2H, m,
meta ArII-H), 4.04 (1H, q, J 7.1 Hz, -CH(CH3)C6H5 ), 3.85 (3H, s, -OCH3), 3.63 (1H,
dd, J 9.1 and 4.5 Hz, H-1), 3,32 (1H, ddd, J 12.0 Hz, 5.7 Hz, 3.9 Hz, 1 x H-5), 2.36-2.66
(4H, m, 2 x H-2 and 2 x H-4), 2.21 (1H, td, J 11.5 Hz, 3.3 Hz, 1 x H-5), 1.43 (3H, d,
J 7.1 Hz, -CH(CH3)C6H5 ); δC (100.6 MHz, CDCl3) 209.01 (C=O), 159.01 (para ArII),
139.25 (ipso ArI), 135.00 (ipso ArII), 128.74 (ortho ArII), 128.42 (ortho ArI), 128.04
(meta ArI), 127.29 (para ArI), 114.40 (meta ArII), 63.92 (C1), 56.42 (-CH(CH3)C6H5
), 55.42 (-OCH3), 50.65 (C2), 44.51 (C5), 41.85 (C4), 19.64 (-CH3); m/z (ESI+) 342
[M+H+CH3OH]
+, 310 [M+H]+, 206, 177, 134, 105; Exact Mass Calcd for C20H24NO2





To a suspension of 4 A˚ molecular sieves (800 mg) in dichloromethane (7 mL) was added
benzylamine (107 mg, 1.00 mmol, 1.0 equiv). Manganese dioxide (2.17 g, 25.0 mmol, 25.0
equiv) was added portionwise and the mixture stirred at 40 ◦C for 24 h. The reaction
mixture was filtered through a pad of Celite and washed with hot (60 ◦C) methanol
(250 mL). Concentration under reduced pressure and recrystallisation (hexane) gave
benzamide 276 (119 mg, 98%) as a white solid;
To a suspension of 4 A˚ molecular sieves (10.0 g) in dichloromethane (130 mL) was added
benzylamine (2.00 g, 18.7 mmol, 1.0 equiv). Manganese dioxide (40.57 g, 466.6 mmol,
25.0 equiv) was added portionwise and the mixture stirred at 40 ◦C for 24 h. The
reaction mixture was filtered through a pad of Celite and washed with hot (60 ◦C)
methanol (600 mL). Concentration under reduced pressure and recrystallisation (hexane)
gave benzamide 276 (2.18 g, 96%) as a white solid; mp 125-127 ◦C; Rf 0.13 (1:1 ethyl
acetate:hexane); νmax (solid) 3360 (N-H), 3162 (N-H), 3062, 1651 (C=O), 1618, 1575,
1448, 1296, 1178, 1141, 1120, 1024, 917; δH (400 MHz, DMSO-d6) 7.99 (1H, s, -CONH2),
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7.88 (2H, d, J 8.4 Hz, ortho Ph-H), 7.52 (1H, t, J 7.3 Hz, para Ph-H), 7.45 (2 H, t, J
7.4 Hz, meta Ph-H), 7.37 (1 H, s, -CONH2); δC (100.6 MHz, DMSO-d6) 167.91 (C=O),






To a suspension of 4 A˚ molecular sieves (800 mg) in dichloromethane (7 mL) was added
4-methyl-benzylamine (121 mg, 1.00 mmol, 1.0 equiv). Manganese dioxide (2.17 g, 25.0
mmol, 25.0 equiv) was added portionwise and the mixture stirred at 40 ◦C for 24 h.
The reaction mixture was filtered through a pad of Celite and washed with hot (60 ◦C)
methanol (250 mL). Concentration under reduced pressure afforded 4-methylbenzamide
298 (132 mg, 98%) as a white solid; mp 159-160 ◦C; Rf 0.13 (1:1 ethyl acetate:hexane);
νmax (solid) 3337 (N-H), 3157 (N-H), 2929, 1666 (C=O), 1613, 1568, 1411, 1395, 1189,
1144, 1123, 1021; δH (400 MHz, DMSO-d6) 7.89 (1H, s, -CONH2), 7.77 (2 H, d, J 8.1
Hz, ortho Ar-H), 7.24 (3H, d, J 8.0 Hz, meta Ar-H and -CONH2), 2.34 (3H, s, CH3);
δC (100.6 MHz, DMSO-d6) 167.78 (C=O), 141.07 (para Ar), 131.47 (ipso Ar), 128.74






To a suspension of 4 A˚ molecular sieves (800 mg) in dichloromethane (7 mL) was added
4-trifluoromethyl-benzylamine (175 mg, 1.00 mmol, 1.0 equiv). Manganese dioxide (2.17
g, 25.0 mmol, 25.0 equiv) was added portionwise and the mixture stirred at 40 ◦C for 24
h. The reaction mixture was filtered through a pad of Celite and washed with hot (60 ◦C)
methanol (250 mL). The filtrate was concentrated under reduced pressure and the crude
product was washed with a small amount of hexane (5 mL). 4-Trifluoromethylbenzamide
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300 was obtained as a white solid (165 mg, 0.87 mmol) in a yield of 87%; mp 182-184 ◦C;
Rf 0.18 (1:1 ethyl acetate:hexane); νmax (solid) 3375 (N-H), 3177 (N-H), 1655 (C=O),
1627, 1579, 1516, 1418, 1322, 1067, 1016 δH (400 MHz, DMSO-d6) 8.21 (1H, s, -CONH2),
8.06 (2H, d, J 8.1 Hz, ortho Ar-H), 7.83 (2H, d, J 8.2 Hz, meta Ar-H), 7.63 (1H, s,
-CONH2); δC (100.6 MHz, DMSO-d6) 166.73 (C=O), 138.11 (ipso Ar), 131.18 (q,
2JCF
32 Hz, para Ar), 128.37 (ortho Ar), 125.31 (q, 3JCF 3.2 Hz, meta Ar), 124.01(q,
1JCF
272 Hz, -CF3);













To a suspension of 4 A˚ molecular sieves (800 mg) in dichloromethane (7 mL) was added
2-(aminomethyl)-thiophene (113 mg, 1.00 mmol, 1.0 equiv). Manganese dioxide (2.17
g, 25.0 mmol, 25.0 equiv) was added portionwise and the mixture stirred at 40 ◦C for
24 h. The reaction mixture was filtered through a pad of Celite and washed with hot
(60 ◦C) methanol (250 mL). Concentration under reduced pressure afforded thiophene-
2-carboxamide 302 (125 mg, 98%) as a white solid; mp 176-178 ◦C; Rf 0.12 (1:1 ethyl
acetate:hexane); νmax (solid) 3356 (N-H), 3164 (N-H), 1650 (C=O), 1601, 1524, 1429,
1392, 1242, 1123, 1096, 1041, 858; δH (400 MHz, DMSO-d6) 7.98 (1H, s, -CONH2),
7.75-7.73 (2H, m, H-3 and H-5), 7.38 (1H, s, -CONH2), 7.12 (1H, t, J 4.1 Hz, H-4); δC
(100.6 MHz, DMSO-d6) 162.90 (C=O), 140.35 (C2), 131.01 (C3), 128.70 (C5), 127.93






To a suspension of 4 A˚ molecular sieves (800 mg) in dichloromethane (7 mL) was added
4-methoxy-benzylamine (137 mg, 1.00 mmol, 1.0 equiv). Manganese dioxide (2.17 g,
25.0 mmol, 25.0 equiv) was added portionwise and the mixture stirred at 40 ◦C for
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24 h. The reaction mixture was filtered through a pad of Celite and washed with hot
(60 ◦C) methanol (250 mL). The solvent was removed under reduced pressure and the
crude was purified by column-chromatography (ethyl acetate:hexane, 1:1 → 4:1). 4-
Methoxybenzamide 304 (140 mg, 93%) was obtained as a white solid; mp 165-167 ◦C;
Rf 0.08 (1:1 ethyl acetate:hexane); νmax (solid) 3387 (N-H), 3159 (N-H), 2843, 1641
(C=O), 1615, 1572, 1515, 1457, 1421, 1391, 1308, 1249, 1190, 1179, 1145, 1114, 1023,
848; δH (400 MHz, DMSO-d6) 7.84 (2H, d, J 8.7 Hz, ortho Ar-H), 7.84 (1H, s, -CONH2),
7.18 (1H, s, -CONH2), 6.97 (2H, d, J 8.7 Hz, meta Ar-H), 3.79 (3H, s, -OCH3); δC (100.6
MHz, DMSO-d6) 167.47 (C=O), 161.61 (para Ar), 129.39 (ortho Ar), 126.51 (ipso Ar),













To a suspension of 4 A˚ molecular sieves (800 mg) in dichloromethane (7 mL) was added
3-methoxy-benzylamine (137 mg, 1.00 mmol, 1.0 equiv). Manganese dioxide (2.17 g,
25.0 mmol, 25.0 equiv) was added portionwise and the mixture stirred at 40 ◦C for
24 h. The reaction mixture was filtered through a pad of Celite and washed with hot
(60 ◦C) methanol (250 mL). The solvent was removed under reduced pressure and the
crude was purified by column-chromatography (ethyl acetate:hexane, 1:1 → 4:1). 3-
Methoxybenzamide 306 (125 mg, 83%) was obtained as a white solid; mp 131-133 ◦C;
Rf 0.16 (1:1 ethyl acetate:hexane); νmax (solid) 3128, 1664 (C=O), 1627, 1581, 1463,
1429, 1330, 1247, 1131, 1030, 902, 877; δH (400 MHz, DMSO-d6) 7.96 (1H, s, -CONH2),
7.46-7.33 (4H, m, 3 x Ar-H and -CONH2), 7.08 (1H, ddd, J 8.1 Hz, 2.6 Hz, 0.8 Hz, H-6),
3.79 (3H, s, -OCH3); δC (100.6 MHz, DMSO-d6) 167.64 (C=O), 159.14 (C1), 135.73
(C3), 129.33 (C5), 119.69 (C4), 117.07 (C6), 112.63 (C2), 55.23 (-OCH3). In agreement
with published data.242
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To a suspension of 4 A˚ molecular sieves (800 mg) in dichloromethane (7 mL) was added
2-methoxy-benzylamine (137 mg, 1.00 mmol, 1.0 equiv). Manganese dioxide (2.17 g,
25.0 mmol, 25.0 equiv) was added portionwise and the mixture stirred at 40 ◦C for
24 h. The reaction mixture was filtered through a pad of Celite and washed with
hot (60 ◦C) methanol (250 mL). The solvent was removed under reduced pressure
and the crude was purified by column-chromatography (ethyl acetate:hexane, 1:1 →
3:1). 2-Methoxybenzamide 427 (104 mg, 69%) was obtained as a white solid and 2-
methoxybenzonitrile 427 (37 mg, 28%) was obtained as a colorless oil;
2-Methoxybenzamide 308: mp 126-128 ◦C; Rf 0.15 (1:1 ethyl acetate:hexane); νmax
(solid) 3410 (N-H), 3190 (N-H), 3013, 2980, 2948, 2840, 1623 (C=O), 1597, 1573, 1488,
1462, 1434, 1394, 1274, 1240, 1179, 1106, 1020; δH (400 MHz, DMSO-d6) 7.79 (1H, dd,
J 7.7 Hz, 1.8 Hz, H-3), 7.63 (1H, s, -CONH2), 7.52 (1H, s, -CONH2), 7.47 (1H, ddd,
J 8.4 Hz, 7.4 Hz, 1.9 Hz, H-5), 7.12 (1H, d, J 8.2 Hz, H-6), 7.02 (1H, td, J 7.6 Hz,
0.9 Hz, H-4), 3.88 (3H, s, -OCH3); δC (100.6 MHz, DMSO-d6) 166.34 (C=O), 157.24
(C1), 132.48 (C5), 130.74 (C3), 122.73 (C4), 120.41 (C2), 111.99 (C6), 55.82 (-OCH3).
In agreement with published data.240,245
2-Methoxybenzonitrile 427: Rf 0.64 (1:1 ethyl acetate:hexane); νmax (film) 2975, 2948,
2843, 2228 (CN), 1688, 1599, 1494, 1465, 1290, 1262, 1021, 758; δH (400 MHz, CDCl3)
7.72-7.25 (2H, m, H-3 and H-5), 7.16-6.64 (2H, m, H-4 and H-6), 3.87 (3H, m, -OCH3);
δC (100.6 MHz, CDCl3) 161.25 (C1), 134.39 (C5), 133.79 (C3), 120.77 (C4), 116.52 (C6),
111.27 (CN), 101.83 (C2), 56.00 (-OCH3). In agreement with published data.
246,247






To a suspension of 4 A˚ molecular sieves (800 mg) in dichloromethane (7 mL) was added
4-trifluoromethoxy-benzylamine (191 mg, 1.00 mmol, 1.0 equiv). Manganese dioxide
(2.17 g, 25.0 mmol, 25.0 equiv) was added portionwise and the mixture stirred at 40
◦C for 24 h. The reaction mixture was filtered through a pad of Celite and washed
with hot (60 ◦C) methanol (250 mL). The solvent was removed under reduced pressure
and the crude was purified by column-chromatography (ethyl acetate:hexane, 1:1 →
3:1). 4-Trifluoromethoxybenzamide 310 (181 mg, 88%) was obtained as a white solid;
mp 152-154 ◦C; Rf 0.18 (1:1 ethyl acetate:hexane); νmax (solid) 3372 (N-H), 3172 (N-
H), 1652 (C=O), 1622, 1585, 1510, 1419, 1397, 1207, 1153, 1015, 926, 858; δH (400
MHz, DMSO-d6) 8.11 (1H, s, -CONH2), 8.00 (2H, d, J 8.7 Hz, ortho Ar-H), 7.51 (1H,
s, -CONH2), 7.45 (2H, d, J 8.3 Hz, meta Ar-H); δC (100.6 MHz, DMSO-d6) 166.59
(C=O), 150.26 (para Ar), 133.37 (ipso Ar), 129.75 (ortho Ar), 120.50 (meta Ar), 119.93
(q, -OCF3,
1JCF 255 Hz);







To a suspension of 4 A˚ molecular sieves (800 mg) in dichloromethane (7 mL) was added
4-chloro-benzylamine (142 mg, 1.00 mmol, 1.0 equiv). Manganese dioxide (2.17 g, 25.0
mmol, 25.0 equiv) was added portionwise and the mixture stirred at 40 ◦C for 24 h.
The reaction mixture was filtered through a pad of Celite and washed with hot (60 ◦C)
methanol (250 mL). Concentration under reduced pressure gave 4-chlorobenzamide 293
(154 mg, 99%) as a white solid;








To a suspension of 4 A˚ molecular sieves (800 mg) in dichloromethane (7 mL) was added
N -(4-Chlorobenzylidene)-1-(4-chlorophenyl)methanamine 295 (263 mg, 1.00 mmol, 1.0
equiv). Manganese dioxide (2.17 g, 25.0 mmol, 25 equiv) was added portionwise and
the mixture stirred at 40 ◦C for 24 h. The reaction mixture was filtered through a
pad of Celite and washed with hot (60 ◦C) methanol (250 mL). Concentration under
reduced pressure and recrystallisation (hexane) gave 4-chlorobenzamide 293 (148 mg,
95%) as a white solid. Concentration of the hexane filtrate under reduced pressure gave
4-chlorobenzaldehyde 296 (0.136 mg, 97%) as a white solid;
4-Chlorobenzamide 293: mp 176-177 ◦C; Rf 0.18 (1:1 ethyl acetate:hexane); νmax (solid)
3368 (N-H), 3177 (N-H), 1658 (C=O), 1620, 1568, 1493, 1407, 1388, 1089, 1013; δH (400
MHz, DMSO-d6) 8.06 (1H, s, -CONH2), 7.89 (2H, d, J 8.3 Hz, ortho Ar-H), 7.53 (2H, d,
J 9.6 Hz, meta Ar-H), 7.47 (1H, s, -CONH2); δC (100.6 MHz, DMSO-d6) 166.78 (C=O),
136.04 (para Ar), 133.00 (ipso Ar), 129.38 (meta Ar), 128.28 (ortho Ar). In agreement
with published data.249,250
4-Chlorobenzaldehyde 296: mp 43-46 ◦C; Rf 0.57 (1:2 ethyl acetate:hexane); νmax
(solid) 1690 (C=O), 1575, 1386, 1292, 1206, 1153, 1092, 1011, 838, 813; δH (400 MHz,
DMSO-d6) 10.00 (1H, s, CHO), 7.91-7.94 (2H, m, ortho Ar-H), 7.65-7.68 (2H, m, meta
Ar-H); δC (100.6 MHz, DMSO-d6) 192.15 (CHO), 139.40 (para Ar), 134.85 (ipso Ar),




To a suspension of 4 A˚ molecular sieves (3 g) in dichloromethane (30 mL) was added
4-chlorobenzaldehyde (1.66 g, 11.8 mmol, 1.0 equiv) and 4-chloro-benzylamine (1.67 g,
11.8 mmol, 1.0 equiv). The reaction was left to stir at 40 ◦C for 1.5 h. The molecular
sieves were filtered off and washed with some acetone. Concentration under reduced
pressure gave N -(4-chlorobenzylidene)-1-(4-chlorophenyl)methanamine 295 (3.051 mg,
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99%) as a white solid; mp 62-64 ◦C; Rf 0.56 (1:2 ethyl acetate:hexane); νmax (solid)
2817, 1642, 1593, 1568, 1489, 1428, 1404, 1372, 1090, 1047, 1013, 862; δH (400 MHz,
DMSO-d6) 8.50 (1H, s, Ar-CH=N-), 7.79 (2H, d, J 8.6 Hz, 1 x Ar-H), 7.52 (2H, d, J
8.4 Hz, 2 x Ar-H), 7.34-7.41 (4H, m, 2 x Ar-H), 4.76 (2H, s, N-CH2-Ar); δC (100.6 MHz,
DMSO-d6) 161.11, 138.55, 135.48, 134.80, 131.45, 129.72, 129.68, 128.86, 128.36, 62.90.












To a suspension of 4 A˚ molecular sieves (800 mg) in dichloromethane (7 mL) was added
3-chloro-benzylamine (142 mg, 1.00 mmol, 1.0 equiv). Manganese dioxide (2.17 g, 25.0
mmol, 25.0 equiv) was added portionwise and the mixture stirred at 40 ◦C for 24 h.
The reaction mixture was filtered through a pad of Celite and washed with hot (60
◦C) methanol (250 mL). Concentration under reduced pressure and recrystallisation
(hexane) gave 3-chlorobenzamide 312 (142 mg, 92%) as a white solid; mp 132-134 ◦C;
Rf 0.26 (1:1 ethyl acetate:hexane); νmax (solid) 3347 (N-H), 3167 (N-H), 1656 (C=O),
1620, 1561, 1426, 1387, 1122, 901; δH (400 MHz, DMSO-d6) 8.11 (1H, s, -CONH2),
7.91 (1H, s, H-2), 7.83 (1H, d, J 7.7 Hz, H-4), 7.59 (1H, d, J 8.0 Hz, H-6), 7.54 (1H, s,
-CONH2), 7.49 (1H, t, J 7.9 Hz, H-5); δC (100.6 MHz, DMSO-d6) 166.44 (C=O), 136.32












To a suspension of 4 A˚ molecular sieves (800 mg) in dichloromethane (7 mL) was added
2-chloro-benzylamine (142 mg, 1.00 mmol, 1.0 equiv). Manganese dioxide (2.17 g, 25.0
mmol, 25.0 equiv) was added portionwise and the mixture stirred at 40 ◦C for 24 h.
Chapter 3. Experimental 156
The reaction mixture was filtered through a pad of Celite and washed with hot (60
◦C) methanol (250 mL). The solvent was removed under reduced pressure and the
crude was purified by column-chromatography (ethyl acetate:hexane, 1:1 → 4:1). 2-
Chlorobenzamide 314 (128 mg, 83%) was obtained as a white solid; mp 139-141 ◦C;
Rf 0.19 (1:1 ethyl acetate:hexane); νmax (solid) 3357 (N-H), 3172 (N-H), 1638 (C=O),
1563, 1480, 1432, 1401, 1119, 1047, 953; δH (400 MHz, DMSO-d6) 7.87 (1H, s, -CONH2),
7.59 (1H, s, -CONH2), 7.47-7.35 (4H, m, 4 x Ar-H); δC (100.6 MHz, DMSO-d6) 168.17
(C=O), 137.17 (C), 130.56 (CH), 129.62 (C), 129.60 (CH), 128.66 (CH), 127.03 (CH).











(Methoxymethyl)triphenylphosphonium chloride (1.028 g, 3.00 mmol, 1.5 equiv) and
molecular sieves were placed in an oven-dried flask and added with absolute THF (6
mL) under an atmosphere of nitrogen. The mixture was cooled to -78 ◦C and a 2
M solution of lithium diisopropylamide in THF/heptane/ethylbenzene (1.500 mL, 3.00
mmol, 1.5 equiv) was added slowly. The mixture was stirred at -78 ◦C for 5 min and then
allowed to warm to room temperature while stirring for another 20 min. The reaction
mixture was cooled to -20 ◦C and a solution of 201 (379 mg, 2.00 mmol, 1.0 equiv) in
absolute THF (4 mL) was added slowly. The mixture was stirred at -20 ◦C for 15 min,
then allowed to warm to room temperature and stirred for 16 h. 1 M NH4Cl solution
(5 mL) and ethyl acetate (10 mL) were added and the solution was stirred vigorously
for 5 min. The phases were separated and the aqueous phase was again extracted with
ethyl acetate. The combined organic layers were washed with water and brine, dried
over MgSO4, filtered and the solvent was removed under reduced pressure. Purification
by column chromatography (hexane:ethyl acetate 1:1) afforded 318 (400 mg, 92%) as
a colourless oil; νmax (film) 2932, 2898, 2833, 2796, 1692, 1495, 1454, 1358, 1227, 1190,
1125, 1069, 987, 737; δH (400 MHz, CDCl3) 7.22-7.33 (5H, m, 5 x Ar-H), 5.78 (1H, s,
H-6), 3.54 (3H, s, -OCH3), 3.50 (2H, s, H-1), 2.39 (4H, t, J 5.6 Hz, 2 x H-2, 2 x H-5),
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2.30 (2H, t, J 5.5 Hz, 2 x H-3), 2.06 (2H, t, J 5.5 Hz, 2 x H-4); δC (100.6 MHz, CDCl3)
139.69 (C6), 138.63 (ipso Ar), 129.32 (ortho Ar), 128.27 (meta Ar), 127.04 (para Ar),
114.89 (C7), 63.37 (C1), 59.50 (-OCH3), 55.35 (C5), 54.17 (C2), 29.81 (C4), 25.28 (C3);
m/z (ESI+) 218 [M+H]+, 186, 91; Exact Mass Calcd for C14H20NO [M+H]
+requires









1.6 N HCl (1 mL) was added to a solution of 318 (100 mg, 0.46 mmol) in THF (1 mL)
and stirred at 45 ◦C for two hours. THF was evaporated under reduced pressure and
the residue was diluted with water (4 mL). The pH was adjusted to 10 by the addition
of an aqueous Na2CO3 solution. The aqueous phase was extracted with CH2Cl2 (3 x 6
mL) and the combined organic layers were washed with brine and dried over MgSO4.
The solvent was removed under reduced pressure and aldehyde 319 (87 mg, 95%) was
obtained as a colourless oil. The product could be used for the next step without the
need of further purification.
Method B:
Magnesium bromide etherate (1.867 g, 7.23 mmol, 2.0 equiv) was added to toluene (7.5
mL) and 4 A˚ molecular sieves and the system was put under an atmosphere of nitrogen
and heated to 40 ◦C. 323 (734 mg, 3.61 mmol, 1.0 equiv) in toluene (1.5 mL) was added
to the mixture and the reaction was stirred for 35 min. Water (10 mL) was added to
quench the reaction and the creamy mixture was stirred until it became clear. The
aqueous mixture was extracted with ethyl acetate (3 x 25 mL), washed with brine and
dried over Na2SO4. The solvent was reduced under reduced pressure and the crude was
subjected to destillation under reduced pressure at a temperature of 145-149 ◦C to give
product 319 (141 mg, 19%) as a colourless oil.
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Rf 0.13 (1:1 ethyl acetate:hexane); νmax (film) 3028, 2941, 2804, 2759, 1723, 1495, 1453,
1394, 1366, 1342, 1311, 1264, 1144, 967, 739; δH (400 MHz, CDCl3) 9.64 (1H, d, J 1.1
Hz, -CHO), 7.23-7.34 (m, 5 H, 5 x Ar-H), 3.50 (2H, s, -N-CH2-Ph), 2.82 (2H, dt, J
11.1 Hz, 3.6 Hz, 2 x H-1), 2.20-2.28 (1H, m, H-3), 2.11 (2H, dt, J 11.2 Hz, 2.7 Hz, 2 x
H-1), 1.85-1.91 (2H, m, 2 x H-2), 1.64-1.74 (2H, m, 2 x H-2); δC (100.6 MHz, CDCl3)
201.24 (C=O); 138.34 (ipso Ar), 129.23 (ortho Ar), 128.36 (meta Ar), 127.19 (para Ar),








A solution of 1-benzylpiperidin-4-one 201 (185 µl, 1.00 mmol, 1.0 equiv) in anhydrous
DMSO (8 mL) was added to a dry mixture of t-BuOK (224 mg, 2.00 mmol, 2.0 equiv)
and Me3S(O)
+I− (440 mg, 2.00 mmol, 2.0 equiv) under an atmosphere of nitrogen.
The resulting solution was stirred at 55 ◦C for 50 min. The mixture was added with
water (50 mL) and extracted with diethyl ether (3 x 20 mL). The combined organic
extracts were washed with brine (3 x 20 mL), dried over anhydrous MgSO4, filtered
and evaporated in vacuo to afford epoxide 323 (201 mg, 99%) as a colourless oil. 323
could be used for the next step without the need of further purification; Rf 0.18 (1:1
ethyl acetate:hexane); νmax (film) 3029, 2948, 2918, 2799, 1495, 1467, 1454, 1366, 1351,
1256, 1130, 1093, 1072, 1012, 920, 791, 739; δH (400 MHz, CDCl3) 7.23-7.36 (5H, m, 5 x
Ar-H), 3.56 (2H, s, -N-CH2-Ph), 2.65 (2H, s, O-CH2-), 2.53-2.62 (4H, m, H-1), 1.80-1.87
(2H, m, 2 x H-2), 1.52-1.58 (2H, m, 2 x H-2); δC (100.6 MHz, CDCl3) 138.57 (ipso Ar),
129.22 (ortho Ar), 128.37 (meta Ar), 127.18 (para Ar), 63.07 (-N-CH2-Ph) 57.57 (C3)
53.87 (O-CH2-), 52.03 (C1), 33.16 (C2). In agreement with published data.
196










A solution of 1-benzyl-2-methylpiperidin-4-one 241 (300 mg, 1.48 mmol, 1.0 equiv) in
anhydrous DMSO (12 mL) was added to a dry mixture of t-BuOK (330 mg, 2.95 mmol,
2.0 equiv) and Me3S(O)
+I− (649 mg, 2.95 mmol, 2.0 equiv) under an atmosphere of
nitrogen. The resulting solution was stirred at 55 ◦C for 60 min. The mixture was added
with water (75 mL) and extracted with diethyl ether (3 x 40 mL). The combined organic
extracts were washed with brine (3 x 30 mL), dried over anhydrous MgSO4, filtered
and evaporated in vacuo. Purification by column chromatography (ethyl acetate:hexane
1:2→ 1:1) afforded epoxide 330 as a mixture of inseparable stereoisomers (218 mg, 68%)
as a colourless oil; Rf 0.21 (1:1 ethyl acetate:hexane); νmax (film) 3029, 2918, 2799, 1599,
1494, 1452, 1377, 1328, 1290, 1150, 1066, 1011, 917, 777, 734; δH (400 MHz, CDCl3)
7.22-7.36 (5H, m, 5 x Ar-H), 4.07 (1H, d, J 13.5 Hz, 1 x -N-CH2-Ph), 3.26 (1H, d, J
13.5 Hz, 1 x -N-CH2-Ph), 2.80 (1H, td, J 11.7 Hz, 4.2 Hz, 1 x H-5), 2.70-2.75 (1H, m,
H-1), 2.65 (2H, s, H-7), 2.34 (1H, td, J 11.6 Hz, 3.3 Hz, 1 x H-5), 1.95 (1H, ddd, J 13.5
Hz, 11.3 Hz, 4.5 Hz, 1 x H-4), 1.85 (1H, dd, J 13.5 Hz, 10.1 Hz, 1 x H-2), 1.37-1.42
(1H, m, 1 x H-2), 1.24-1.30 (1H, m, 1 x H-4), 1.20 (3H, d, J 6.3 Hz, H-6); δC (100.6
MHz, CDCl3) 19.44 (C6), 32.78 (C4), 41.20 (C2), 49.26 (C5), 53.60 (C7), 54.73 (C1),
57.36 (C3), 57.77 (-N-CH2-Ph), 126.97 (para Ar), 128.33 (meta Ar), 129.13 (ortho Ar),
139.39 (ipso Ar); m/z (ESI+) 218 [M+H]+, 126, 91; Exact Mass Calcd for C14H19NO
[M+H]+requires m/z 218.1539 Found 218.1539 (NSI+).












A solution of 1-benzyl-2-phenylpiperidin-4-one 242 (142 mg, 0.54 mmol, 1.0 equiv) in
anhydrous DMSO (4 mL) was added to a dry mixture of t-BuOK (120 mg, 1.07 mmol,
2.0 equiv) and Me3S(O)
+I− (235 mg, 1.07 mmol, 2.0 equiv) under an atmosphere of
nitrogen. The resulting solution was stirred at 55 ◦C for 60 min. The mixture was added
with water (15 mL) and extracted with diethyl ether (3 x 10 mL). The combined organic
extracts were washed with brine (3 x 8 mL), dried over anhydrous MgSO4, filtered and
evaporated in vacuo. Purification by column chromatography (ethyl acetate:hexane 1:10
→ 1:8) afforded epoxide 331 as a mixture of inseparable stereoisomers (98 mg, 65%) as
a white solid; mp 81-84 ◦C; Rf 0.45 (1:5 ethyl acetate:hexane); νmax (solid) 2941, 2800,
1494, 1451, 1380, 1247, 1117, 1064, 990, 958, 919, 851, 810, 764; δH (400 MHz, CDCl3)
7.20-7.49 (10H, m, 10 x Ar-H), 3.82 (1H, d, J 13.5 Hz, 1 x H-1), 3.52 (1H, dd, J 11.7
Hz, 3.0 Hz, H-7), 2.97-3.01 (1H, m, 1 x H-2), 2.89 (1H, d, J 13.5 Hz, 1 x H-1), 2.68 (2H,
dd, J 13.1 Hz, 4.5 Hz, H-5), 2.20-2.39 (3H, m, 1 x H-2, 1 x H-3, 1 x H-6), 1.37-1.43 (1H,
m, 2 x H-6), 1.20 (1H, ddd, J 13.4 Hz, 5.0 Hz, 2.4 Hz, 1 x H-3); δC (100.6 MHz, CDCl3)
144.35 (ipso Ar-II), 139.70 (ipso Ar-I), 128.84, 128.77, 128.25, 127.58, 127.41, 126.84,
66.47 (C7), 59.18 (C1), 57.46 (C4), 53.24 (C5), 50.13 (C2), 43.24 (C6), 32.74 (C3); m/z
(ESI+) 280 [M+H]+, 188, 120, 91; Exact Mass Calcd for C19H21NO [M+H]
+requires
m/z 280.1696 Found 280.1697 (NSI+)
Chapter 3. Experimental 161



























A solution of R-2-methyl-1-(S -1-phenylethyl)piperidin-4-one 259 (67 mg, 0.31 mmol,
1.0 equiv) in anhydrous DMSO (2.5 mL) was added to a dry mixture of t-BuOK (69
mg, 0.62 mmol, 2.0 equiv) and Me3S(O)
+I− (136 mg, 0.62 mmol, 2.0 equiv) under an
atmosphere of nitrogen. The resulting solution was stirred at 55 ◦C for 60 min. The
mixture was added with water (10 mL) and extracted with diethyl ether (3 x 6 mL).
The combined organic extracts were washed with brine (3 x 5 mL), dried over anhydrous
MgSO4, filtered and evaporated in vacuo. Purification by column chromatography (ethyl
acetate:hexane 1:1→ 3:1) afforded 332 (8 mg, 11%) as a colourless oil and 333 (34 mg,
47%) as a colourless oil.
Compound 332, eluting first: [α]24D -71.4 (c 0.07, CHCl3); Rf 0.22 (3:2 ethyl
acetate:hexane); νmax (film) 3029, 2967, 2928, 2850, 1727, 1492, 1453, 1376, 1279, 1130,
1098, 1076, 1026, 924, 768, 736, 702; δH (400 MHz, CDCl3) 7.22-7.34 (5H, m, 5 x Ar-H),
4.02 (1H, q, J 6.8 Hz, H-7), 2.98 (1H, ddd, J 11.6 Hz, 7.8 Hz, 3.8 Hz, 1 x H-1), 2.62-2.70
(1H, m, H-5), 2.42-2.51 (3H, m, 1 x H-1, H-9), 1.60-1.79 (3H, m, 2 x H-2, 1 x H-4), 1.41-
1.46 (4H, m, 1 x H-4, H-8), 1.17 (3H, d, J 6.4 Hz, H-6); δC (100.6 MHz, CDCl3) 142.95
(ipso Ar), 128.23 (ortho Ar), 127.87 (meta Ar), 126.94 (para Ar), 57.94 (C7), 57.19 (C3),
52.89 (C9), 51.64 (C5), 42.23 (C1), 40.60 (C4), 33.49 (C2), 21.11 (C8), 15.87 (C6); m/z
(ESI+) 232 [M+H]+, 128, 105; Exact Mass Calcd for C15H21NO [M+H]
+requires m/z
232.16959 Found 232.17017 (ESI+)
Compound 333, eluting second: [α]23D -76.5 (c 0.24, CHCl3); Rf 0.15 (3:2 ethyl
acetate:hexane); νmax (film) 2971, 2940, 2816, 1728, 1601, 1495, 1453, 1365, 1289, 1280,
1145, 1099, 1076, 1041, 1028, 919, 762, 751, 702; δH (400 MHz, CDCl3) 7.21-7.33 (5H,
m, 5 x Ar-H), 4.08 (1H, q, J 6.9 Hz, H-7), 2.90 (1H, ddd, J 11.1 Hz, 6.6 Hz, 4.0 Hz,
1 x H-1), 2.71-2.79 (1H, m, H-5), 2.64 (1H, d, J 4.7 Hz, 1 x H-9), 2.60 (1H, d, J 4.7
Hz, 1 x H-9), 2.48-2.55 (1H, m, 1 x H-1), 1.76 (1H, ddd, J 12.8 Hz, 8.6 Hz, 3.9 Hz, 1 x
H-2), 1.55-1.63 (3H, m, 1 x H-2, 2 x H-4), 1.43 (3H, d, J 6.9 Hz, H-8), 1.13 (3H, d, J
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6.4 Hz, H-6); δC (100.6 MHz, CDCl3) 142.41 (ipso Ar), 128.23 (ortho Ar), 127.91 (meta
Ar), 126.97 (para Ar), 57.60 (C7), 57.06 (C3), 54.23 (C9), 51.39 (C5), 42.75 (C1), 41.05
(C4), 33.46 (C2), 20.78 (C8), 16.80 (C6); m/z (ESI+) 232 [M+H]+, 128, 105; Exact
Mass Calcd for C15H21NO [M+H]
+requires m/z 232.1696 Found 232.1697 (NSI+)
S,Z -4-(Methoxymethylene)-2-methyl-1-(S -1-phenylethyl)piperidine 352
























(Methoxymethyl)triphenylphosphonium chloride (1.419 g, 4.14 mmol, 1.5 equiv) and
molecular sieves were placed in an oven-dried flask and added with absolute THF (8
mL) under an atmosphere of nitrogen. The mixture was cooled to -78 ◦C and a 2
M solution of lithium diisopropylamide in THF/heptane/ethylbenzene (2.07 mL, 4.14
mmol, 1.5 equiv) was added slowly. The mixture was stirred at -78 ◦C for 5 min and then
allowed to warm to room temperature while stirring for another 20 min. The reaction
mixture was cooled to -20 ◦C and a solution of 258 (600 mg, 2.76 mmol, 1.0 equiv) in
absolute THF (7 mL) was added slowly. The mixture was stirred at -20 ◦C for 15 min,
then allowed to warm to room temperature and stirred for 16 h. 1 M NH4Cl solution (12
mL) and ethyl acetate (25 mL) was added and the solution was stirred vigorously for 5
min. The phases were separated and the aqueous phase was again extracted with ethyl
acetate. The combined organic layers were washed with water and brine, dried over
MgSO4, filtered and the solvent was removed under reduced pressure. Purification by
column chromatography (hexane:ethyl acetate 10:1) afforded 352 and 353 as acolourless
oil (607 mg, 2.48 mmol) in a combined yield of 90%. Several pure fractions of 352 and
353 could be obtained and were used for spectral analysis. The other fractions contained
a mixture of the two diastereoisomers. NMR investigation of the crude residue indicated
that the mixture of diastereoisomers was a 1.21:1 ratio of 352:353.
Compound 352, eluting first: [α]24D -51.4 (c 0.18, CHCl3); Rf 0.19 (1:10 ethyl
acetate:hexane); νmax (film) 2968, 2931, 2833, 1689, 1601, 1492, 1454, 1370, 1315, 1228,
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1210, 1126, 1029, 977, 766; δH (400 MHz, CDCl3) 7.42-7.44 (2H, m, 2 x ortho Ar-H),
7.29-7.32 (2H, m, 2 x meta Ar-H), 7.19-7.22 (1H, m, para Ar-H), 5.80 (1H, s, H-9), 3.94
(1H, q, J 6.7 Hz, H-2), 3.53 (3H, s, H-10), 2.93-3.00 (1H, m, H-7), 2.47 (1H, dd, J 13.4
Hz, 3.8 Hz, 1 x H-6), 2.37 (1H, ddd, J 11.3 Hz, 7.1 Hz, 4.1 Hz, 1 x H-3), 2.22 (1H, ddd,
J 11.3 Hz, 7.2 Hz, 4.0 Hz, 1 x H-3), 2.11 (1H, dd, J 13.4 Hz, 6.8 Hz, 1 x H-6), 1.87-1.93
(1H, m, 1 x H-4), 1.79-1.85 (1H, m, 1 x H-4), 1.26 (3H, d, J 6.7 Hz, 3 x H-1), 1.09 (3H,
d, J 6.3 Hz, 3 x H-8); δC (100.6 MHz, CDCl3) 146.23 (ipso Ar), 139.97 (C9), 128.17
(ortho Ar), 127.64 (meta Ar), 126.47 (para Ar), 114.97 (C5), 59.48 (C10), 57.68 (C2),
51.53 (C7), 46.07 (C3), 33.36 (C6), 30.06 (C4), 15.54 (C8), 15.09 (C1); m/z (ESI+) 246
[M+H]+, 142; Exact Mass Calcd for C16H24NO [M+H]
+requires m/z 246.1852 Found
246.1854 (NSI+).
Compound 353, eluting second: [α]24D -29.2 (c 0.15, CHCl3); Rf 0.13 (1:10 ethyl
acetate:hexane); νmax (film) 2968, 2931, 2825, 1692, 1601, 1492, 1453, 1371, 1311, 1265,
1230, 1211, 1186, 1125, 1028, 766; δH (400 MHz, CDCl3) 7.42-7.44 (2H, m, 2 x ortho
Ar-H), 7.29-7.34 (2H, m, 2 x meta Ar-H), 7.20-7.24 (1H, m, para Ar-H), 5.75 (1H, s, H-
9), 3.91 (1H, q, J 6.7 Hz, H-2), 3.53 (3H, s, 3 x H-10), 2.92-3.00 (1H, m, H-7), 2.36 (1H,
ddd, J 11.5 Hz, 7.3 Hz, 4.3 Hz, 1 x H-3), 2.20-2.25 (2H, m, 1 x H-3, 1 x H-6), 2.11-2.17
(1H, m, 1 x H-4), 2.02-2.08 (1H, m, 1 x H-4), 1.85 (1H, dd, J 13.2 Hz, 6.5 Hz, 1 x H-6),
1.26 (3H, d, J 6.7 Hz, 3 x H-1), 1.06 (3H, d, J 6.4 Hz, 3 x H-8); δC (100.6 MHz, CDCl3)
146.24 (ipso Ar), 139.77 (C9), 128.20 (ortho Ar), 127.61 (meta Ar), 126.49 (para Ar),
114.69 (C5), 59.51 (C10), 57.83 (C2), 52.18 (C7), 44.65 (C3), 37.76 (C6), 25.50 (C4),
15.42 (C1), 15.18 (C8); m/z (ESI+) 246 [M+H]+, 142; Exact Mass Calcd for C16H24NO
[M+H]+requires m/z 246.18524 Found 246.18577 (ESI+).
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R,E -4-(Methoxymethylene)-2-methyl-1-(S -1-phenylethyl)piperidine 354

























(Methoxymethyl)triphenylphosphonium chloride (473 mg, 1.38 mmol, 1.5 equiv) and
molecular sieves were placed in an oven-dried flask and added with absolute THF (3
mL) under an atmosphere of nitrogen. The mixture was cooled to -78 ◦C and a 2 M
solution of lithium diisopropylamide in THF/heptane/ethylbenzene (690 µl, 1.38 mmol,
1.5 equiv) was added slowly. The mixture was stirred at -78 ◦C for 5 min and then
allowed to warm to room temperature while stirring for another 20 min. The reaction
mixture was cooled to -20 ◦C and a solution of 259 (200 mg, 0.92 mmol, 1.0 equiv) in
absolute THF (2 mL) was added slowly. The mixture was stirred at -20 ◦C for 15 min,
then allowed to warm to room temperature and stirred for 16 h. 1 M NH4Cl solution
(5 mL) and ethyl acetate (10 mL) were added and the solution was stirred vigorously
for 5 min. The phases were separated and the aqueous phase was again extracted with
ethyl acetate. The combined organic layers were washed with water and brine, dried
over MgSO4, filtered and the solvent was removed under reduced pressure. Purification
by column chromatography (hexane:ethyl acetate 1.3:1) afforded 354 and 355 as a
colourless oil (170 mg, 0.69 mmol) in a combined yield of 75%. Several pure fractions of
354 and 355 could be obtained and were used for spectral analysis, the other fractions
contained a mixture of the two diastereoisomers. NMR investigation of the crude residue
indicated that the mixture of diastereoisomers was a 1:1.23 ratio of 354:355.
Product 354, eluting first: [α]24D -58.4 (c 0.29, CHCl3); Rf 0.29 (1:1 ethyl
acetate:hexane); νmax (film) 2970, 2931, 2828, 1693, 1492, 1453, 1371, 1230, 1211, 1125,
768; δH (400 MHz, CDCl3) 7.20-7.32 (5H, m, Ar-H), 5.67 (1H, s, H-9), 3.90 (1H, q, J
6.8 Hz, H-2), 3.51 (3H, s, H-10), 2.69 (1H, ddd, J 11.6 Hz, 7.4 Hz, 4.7 Hz, 1 x H-3), 2.56
(1H, dq, J 12.2 Hz, 6.1 Hz, H-7), 2.39-2.44 (1H, m, 1 x H-3), 2.28-2.32 (2H, m, 2 x H-4),
2.12 (1H, dd, J 13.3 Hz, 4.1 Hz, 1 x H-6), 1.73 (1H, dd, J 13.2 Hz, 6.0 Hz, 1 x H-6), 1.38
(1H, d, 3 H, J 6.8 Hz, H-1), 1.00 (1H, d, 3 H, J 6.3 Hz, H-8); δC (100.6 MHz, CDCl3)
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143.63 (ipso Ar), 139.79 (C9), 128.15 (ortho Ar), 127.87 (meta Ar), 126.75 (para Ar),
113.89 (C5), 59.48 (C10), 58.59 (C2), 52.43 (C7), 43.87 (C3), 37.56 (C6), 25.63 (C4),
21.29 (C1), 14.43 (C8); m/z (ESI+) 246 [M+H]+, 142; Exact Mass Calcd for C16H24NO
[M+H]+requires m/z 246.1852 Found 246.1854 (NSI+).
Product 355, eluting second: [α]24D -126.05 (c 0.12, CHCl3); Rf 0.23 (1:1 ethyl
acetate:hexane); νmax (film) 2969, 2929, 2833, 1692, 1492, 1453, 1372, 1229, 1193, 1124,
768; δH (400 MHz, CDCl3) 7.20-7.33 (5H, m, Ar-H), 5.79 (1H, s, H-9), 3.95 (1H, q, J
6.8 Hz, H-2), 3.49 (s, 3 H, H-10), 2.73 (1H, ddd, J 11.4 Hz, 7.7 Hz, 4.0 Hz, 1 x H-3),
2.52-2.59 (1H, m, 1 x H-7), 2.37 (1H, ddd, J 11.1 Hz, 6.7 Hz, 4.2 Hz, 1 x H-3), 2.29
(1H, dd, J 13.5 Hz, 3.5 Hz, 1 x H-6), 1.98-2.13 (3H, m, 1 x H-6, 2 x H-4), 1.38 (3H, d,
J 6.8 Hz, H-1), 1.04 (3H, d, J 6.3 Hz, H-8); δC (100.6 MHz, CDCl3) 143.39 (ipso Ar),
140.04 (C9), 128.15 (ortho Ar), 127.91 (meta Ar), 126.78 (para Ar), 114.28 (C5), 59.43
(C10), 58.31 (C2), 51.93 (C7), 45.37 (C3), 33.18 (C6), 30.17 (C4), 21.15 (C1), 15.03
(C8); m/z (ESI+) 246 [M+H]+, 142; Exact Mass Calcd for C16H24NO [M+H]
+requires
m/z 246.18524 Found 246.18566 (ESI+).
R,E -4-(Methoxymethylene)-2-phenyl-1-(S -1-phenylethyl)piperidine 356



























(Methoxymethyl)triphenylphosphonium chloride (1.028 g, 3.00 mmol, 1.5 equiv) and
molecular sieves were placed in an oven-dried flask and added with absolute THF (6
mL) under an atmosphere of nitrogen. The mixture was cooled to -70 ◦C and a 2
M solution of lithium diisopropylamide in THF/heptane/ethylbenzene (1.500 mL, 3.00
mmol, 1.5 equiv) was added slowly. The mixture was stirred at -70 ◦C for 5 min and then
allowed to warm to room temperature while stirring for another 20 min. The reaction
mixture was cooled to -20 ◦C and a solution of 262 (558 mg, 2.00 mmol, 1.0 equiv) in
absolute THF (4 mL) was added slowly. The mixture was stirred at -20 ◦C for 15 min,
then allowed to warm to room temperature and stirred for 16 h. 1 M NH4Cl solution
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(8 mL) and ethyl acetate (15 mL) were added and the solution was stirred vigorously
for 5 min. The phases were separated and the aqueous phase was again extracted with
ethyl acetate (2 x 15 mL). The combined organic layers were washed with water and
brine, dried over MgSO4, filtered and the solvent was removed under reduced pressure.
Purification by column chromatography (ethyl acetate:hexane 1:36 → 1:28) afforded
356 (128 mg, 21%) as a colourless oil, a mixture of 356 and 357 (392 mg, 64%) as a
colourless oil and 357 (72 mg, 12%) as a colourless oil. NMR investigation of the crude
residue indicated that the mixture of diastereoisomers was a 1.03:1 ratio of 356:357.
Product 356, eluting first: [α]23D -69.8 (c 0.94, CHCl3); Rf 0.31 (1:20 ethyl
acetate:hexane); νmax (film) 3060, 3027, 2967, 2931, 2901, 2814, 1692, 1493, 1452, 1372,
1228, 1211, 1126, 1029, 761, 732; δH (400 MHz, CDCl3) 7.46-7.50 (4H, m, 2 x meta ArI-
H, 2 x meta ArII-H), 7.29-7.36 (4H, m, 2 x ortho ArI-H, 2 x ortho ArII-H), 7.18-7.27
(2H, m, para ArI-H, para ArII-H), 5.80 (1H, s, H-9), 3.85 (1H, q, J 6.8 Hz, H-2), 3.55
(3H, s, H-10), 3.47 (1H, dd, J 10.7 Hz, 3.2 Hz, H-7), 2.60-2.66 (2H, m, 1 x H-3, 1 x
H-4), 2.28-2.34 (1H, m, 1 x H-6), 2.19 (1H, td, J 11.6 Hz, J 3.0 Hz, 1 x H-3), 2.10-2.14
(1H, m, 1 x H-6), 1.86 (1H, td, J 13.1 Hz, 4.9 Hz, 1 x H-4), 1.16 (3H, d, J 6.8 Hz, H-
1); δC (100.6 MHz, CDCl3) 144.71 (ipso ArI), 144.41 (ipso ArII), 139.55 (C9), 128.73,
127.96, 127.69, 127.60, 127.28 (para ArI), 126.29 (para ArII), 115.95 (C5), 67.01 (C7),
59.58 (C10), 54.96 (C2), 45.16 (C3), 40.69 (C6), 25.83 (C4), 8.50 (C1); m/z (ESI+)
308 [M+H]+, 204, 172; Exact Mass Calcd for C21H26NO [M+H]
+requires m/z 308.2009
Found 308.2009 (NSI+)
Product 357, eluting second: [α]24D -149.6 (c 0.12, CHCl3); Rf 0.28 (1:20 ethyl
acetate:hexane); νmax (film) 2931, 2833, 1692, 1600, 1492, 1451, 1378, 1245, 1225, 1204,
1127, 1029, 975, 774, 758; 7.46-7.52 (4H, m, 2 x meta ArI-H, 2 x meta ArII-H), 7.28-7.36
(4H, m, 2 x ortho ArI-H, 2 x ortho ArII-H), 7.18-7.27 (2H, m, para ArI-H, para ArII-H),
5.81 (1H, t, J 1.6 Hz, H-9), 3.87 1H, q, J 6.8 Hz, H-2), 3.54 (3H, s, H-10), 3.49 (1H,
dd, J 10.9 Hz, 3.3 Hz, H-7), 2.86 (1H, ddd, J 13.6 Hz, 2.8 Hz, 2.0 Hz, 1 x H-6), 2.65
(1H, ddd, J 10.5 Hz, 3.9 Hz, 2.9 Hz, 1 x H-3), 2.19 (1H, ”dt”, J 11.8 Hz, 2.6 Hz, 1
x H-3), 2.04 -2.12 (2H, m, 1 x H-6, 1 x H-4), 1.88-1.93 (1H, m, 1 x H-4), 1.17 (3H, d,
J 6.8 Hz, H-1); δC (100.6 MHz, CDCl3) 144.81 (ipso ArI), 144.51 (ipso ArII), 128.65,
127.94, 127.75, 127.62, 127.18 (para ArI), 126.27 (para ArII), 115.72 (C5), 65.41 (C7),
59.52 (C10), 54.98 (C2), 46.37 (C3), 35.81 (C6), 30.11 (C4), 8.63 (C1); m/z (ESI+)
308 [M+H]+, 204, 172; Exact Mass Calcd for C21H26NO [M+H]
+requires m/z 308.2009
Found 308.2010 (NSI+)
Chapter 3. Experimental 167
S,E -4-(Methoxymethylene)-2-phenyl-1-(S -1-phenylethyl)piperidine 358



























(Methoxymethyl)triphenylphosphonium chloride (922 mg, 2.69 mmol, 1.5 equiv) and
molecular sieves were placed in an oven-dried flask and added with absolute THF (6
mL) under an atmosphere of nitrogen. The mixture was cooled to -78 ◦C and a 2
M solution of lithium diisopropylamide in THF/heptane/ethylbenzene (1.345 mL, 2.69
mmol, 1.5 equiv) was added slowly. The mixture was stirred at -78 ◦C for 5 min and then
allowed to warm to room temperature while stirring for another 20 min. The reaction
mixture was cooled to -20 ◦C and a solution of 263 (500 mg, 1.79 mmol, 1.0 equiv) in
absolute THF (4 mL) was added slowly. The mixture was stirred at -20 ◦C for 15 min,
then allowed to warm to room temperature and stirred for 16 h. 1 M NH4Cl solution
(8 mL) and ethyl acetate (15 mL) were added and the solution was stirred vigorously
for 5 min. The phases were separated and the aqueous phase was again extracted with
ethyl acetate (2 x 15 mL). The combined organic layers were washed with water and
brine, dried over MgSO4, filtered and the solvent was removed under reduced pressure.
Purification by column chromatography (ethyl acetate:hexane 1:28→ 1:10) afforded 358
(20 mg, 4%) as colourless oil, a mixture of 358 and 359 (304 mg, 55%, ratio of 358:359
1.62:1) as a colourless oil and 359 (104 mg, 19%) as a colourless oil. NMR investigation
of the crude residue indicated that the mixture of diastereoisomers was a 1.06:1 ratio of
359:358.
Product 358, eluting first: [α]23D -116.4 (c 0.19, CHCl3); Rf 0.42 (1:8 ethyl
acetate:hexane); νmax (film) 2823, 1692, 1492, 1453, 1227, 1122, 944, 822, 759, 701;
δH (400 MHz, CDCl3) 7.19-7.45 (8H, m, 2 x ortho ArI, 2 x meta ArI, 2 x meta ArII, 1
x para ArI, 1 x para ArII), 7.00-7.02 (2H, m, 2 x ortho Ar-II), 5.66 (1H, s, H-9), 3.96
(1H, q, J 7.1 Hz, H-2), 3.47 (3H, s, 3 x H-10), 3.17 (1H, ddd, J 10.9 Hz, 4.4 Hz, 2.9 Hz,
1 x H-3), 3.11 (1H, dd, J 10.5 Hz, 3.5 Hz, H-7), 2.67-2.72 (1H, m, 1 x H-4), 2.09-2.16
(1H, m, 1 x H-6), 1.96-2.04 (2H, m, 1 x H-6, 1 x H-4), 1.75 (1H, td, J 12.2 Hz, 2.9 Hz,
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1 x H-3), 1.39 (3H, s, J 7.2 Hz, 3 x H-1); δC (100.6 MHz, CDCl3) 145.33 (ipso ArII),
139.30 (C9), 139.04 (ipso ArI), 128.93 (ortho ArII), 128.75 (ortho ArI), 127.86 (meta
ArII), 127.64 (meta ArI), 127.03 (para ArII), 126.85 (para ArI), 115.42 (C5), 67.20 (C7),
59.46 (C10), 56.76 (C2), 45.87(C3), 41.47 (C6), 25.93 (C4), 18.98 (C1); m/z (ESI+) 308
[M+H]+, 204, 172; Exact Mass Calcd for C21H26NO [M+H]
+requires m/z 308.20089
Found 308.20020 (ESI+)
Product 359, eluting second: [α]24D -148.2 (c 0.16, CHCl3); Rf 0.36 (1:8 ethyl
acetate:hexane); νmax (film) 2833, 1692, 1492, 1453, 1225, 1196, 1124, 912, 838, 757,
700; δH (400 MHz, CDCl3) 7.19-7.48 (8H, m, 2 x ortho ArII, 2 x meta ArI, 2 x meta
ArII, 1 x para ArI, 1 x para ArII), 7.02 (2 H, d, J 7.2 Hz, 2 x ortho ArI), 5.69 (1H, s,
H-9), 3.99 (1H, q, J 7.1 Hz, H-2), 3.45 (3H, s, 3 x H-10), 3.13-3.20 (2H, m, 1 x H-3,
H-7), 2.70-2.75 (1H, m, 1 x H-6), 2.20 (1H, ddd, J 12.8 Hz, 4.1 Hz, 2.3 Hz, 1 x H-4),
1.98-2.03 (1H, m, 1 x H-4), 1.89-1.95 (1H, m, 1 x H-6), 1.74 (1H, td, J 11.6 Hz, 2.9 Hz,
1 x H-3), 1.39 (3H, d, J 7.1 Hz, 3 x H-1); δC (100.6 MHz, CDCl3) 145.41 (ipso ArII),
139.24 (C9), 139.13 (ipso ArI), 128.90 (ortho ArII), 128.69 (ortho ArI), 127.90 (meta
ArII), 127.63 (meta ArI), 126.93 (para ArII), 126.85 (para ArI), 115.19 (C5), 65.63 (C7),
59.40 (C10), 56.67 (C2), 47.08 (C3), 36.59 (C6), 30.15 (C4), 18.98 (C1); m/z (ESI+)
308 [M+H]+, 204, 172; Exact Mass Calcd for C21H26NO [M+H]
+requires m/z 308.20089
Found 308.20013 (ESI+)
2S,4R-2-Methyl-1-(S -1-phenylethyl)piperidine-4-carbaldehyde 362 and



















1.6 N HCl (2.4 mL) was added to a solution of a diastereomeric mixture of 352 and
353 (ratio of 352:353 was 1:1.70) (274 mg, 1.12 mmol) in THF (2.4 mL) and stirred at
45 ◦C for two hours. THF was evaporated under reduced pressure and the residue was
diluted with water (10 mL). The pH was adjusted to 10 by the addition of an aqueous
Na2CO3 solution. The aqueous phase was extracted with DCM (3 x 15 mL) and the
combined organic layers were washed with brine and dried over MgSO4. The solvent
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was removed under reduced pressure and crude aldehydes 362 and 363 were obtained
as a colourless oil (253 mg, 97%). The products could be used for the next step without
the need of further purification.
NMR investigation indicates that the mixture of diastereoisomers is a 1:1.29 ratio of
362:363. NOe analysis suggests that compound 363 is the major product and compound
362 is the minor compound (labelled as M ).
Products 362 and 363 as a mixture: Product 362 is labelled as M . Rf 0.08 (1:3
ethyl acetate:hexane); νmax (film) 2968, 2935, 2803, 1724, 1601, 1493, 1446, 1376, 1331,
1286, 1267, 1194, 1145, 1073, 912, 782, 765; δH (400 MHz, CDCl3) 9.65 (1H, d, J 1.2
Hz, H-9M ), 9.59 (1H, d, J 1.6 Hz, H-9), 7.44-7.46 (2H, m, 2 x Ar-H), 7.28-7.37 (6H,
m, 2 x Ar-H, 4 x Ar-HM ), 7.20-7.24 (2H, m, para Ar-H, para Ar-HM ), 4.35 (1H, q, J
6.8 Hz, H-2), 3.71 (1H, q, J 6.6 Hz, H-2M ), 3.29-3.37 (1H, m, H-7M ), 2.64 (1H, dqd, J
12.4 Hz, 6.2 Hz, 2.6 Hz, H-7), 2.45-2.56 (2H, m, 1 x H-3, 1 x H-5M ), 2.22 -2.40 (3H, m,
2 x H-3M ), 1 x H-5), 2.12 (1H,“td”, J 11.7 Hz, 2.5 Hz, 1 x H-3), 1.87-1.97 (2H, m, 1
x H-6, 1 x H-6M ), 1.54-1.76 (4H, m, 1 x H-6M , 1 x H-4, 2 x H-4M ), 1.31-1.45 (2H, m,
1 x H-6, 1 x H-4), 1.24-1.27 (9H, m, 3 x H-1, 3 x H-1M , 3 x H-8), 1.09 (3H, d, J 6.6
Hz, 3 x H-8M ); δC (100.6 MHz, CDCl3) 205.15 (C9M ), 204.18 (C9), 146.41 (ipso ArM ),
144.49 (ipso Ar), 128.36 (Ar), 128.04 (Ar), 127.86 (Ar), 127.39 (Ar), 126.72 (para ArM ),
126.46 (para Ar), 59.43 (C2M ), 54.35 (C2), 52.85 (C7), 49.64 (C5), 48.25 (C7M ), 44.45
(C5M ), 44.00 (C3), 42.48 (C3M ), 35.05 (C6), 32.18 (C6M ), 26.15 (C4), 25.51 (C4M ),
20.70 (C8), 18.43 (C1M ), 12.38 (C8M ), 8.55 (C1); m/z (ESI+) 264 [M+H+CH3OH]
+,
232 [M+H]+, 128, 105; Exact Mass Calcd for C15H22NO [M+H]
+requires m/z 232.1696
Found 232.17028 (ESI+)
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2R,4R-2-Methyl-1-(S -1-phenylethyl)piperidine-4-carbaldehyde 364 and




















1.6 N HCl (850 µl) was added to a solution of a diastereomeric mixture of 354 and 355
(ratio of 354:355 was 1:1.16) (94 mg, 0.38 mmol) in THF (850 µl) and stirred at 45 ◦C
for two hours. THF was evaporated under reduced pressure and the residue was diluted
with water (4 mL). The pH was adjusted to 10 by the addition of an aqueous Na2CO3
solution. The aqueous phase was extracted with DCM (3 x 6 mL) and the combined
organic layers were washed with brine and dried over MgSO4. The solvent was removed
under reduced pressure and crude aldehydes 364 and 365 were obtained as a colourless
oil (87 mg, 100%). The products could be used for the next step without the need of
further purification.
NMR investigation indicates that the mixture of diastereoisomers is a 1:1.85 ratio of
365:364. NOe analysis suggests that compound 364 is the major product and compound
365 is the minor compound (labelled as M ).
Products 364 and 365 as a mixture: Product 365 is labelled as M . Rf 0.10 (2:1
ethyl acetate:hexane); νmax (film) 3027, 2971, 2932, 2805, 2741, 1724, 1493, 1452, 1376,
1278, 1070, 762, 703; δH (400 MHz, CDCl3) 9.60 (1H, d, J 1.36 Hz, H-9M ), 9.55 (1H,
d, J 1.42 Hz, H-9), 7.20-7.35 (10H, m, 5 x Ar-H, 5 x Ar-HM ), 4.33 (1H, q, J 7.1 Hz,
H-2), 3.72 (1H, q, J 6.5 Hz, H-2M ), 3.15 (1H, dt, J 11.5 Hz, 3.7 Hz, 1 x H-3), 2.87-2.94
(1H, m, H-7M ), 2.80 (1H, dt, J 11.5 Hz, 4.3 Hz, 1 x H-3M ), 2.57 (1H, dt, J 11.7 Hz,
3.0 Hz, 1 x H-3M ), 2.42-2.50 (m, 1 H, H-5M ), 2.21 (1H, dqd, J 12.0 Hz, 6.0 Hz, 2.9
Hz, H-7), 2.08 (1H, ttd, J 12.2 Hz, 3.9 Hz, 1.5 Hz, H-5), 1.70-1.91 (5H, m, 1 x H-4, 1
x H-6, 1 x H-3, 2 x H-4M , 1 x H-6M ), 1.43-1.62 (5H, m, 1 x H-6M , 1 x H-4, 3 x H-1),
1.24-1.41 (7H, m, 1 x H-6, 3 x H-8, 3 x H-1M ), 0.97 (3H, d, J 6.6 Hz, H-8M ); δC (100.6
MHz, CDCl3) 204.97(C9M ), 203.86 (C9), 144.90 (ipso ArM ), 139.48 (ipso Ar), 128.46
(Ar), 128.40 (Ar), 127.94 (Ar), 127.42 (Ar), 127.04 (Ar), 126.89 (Ar), 59.67 (C2M ),
55.86 (C2), 52.93 (C7), 48.93 (C7M , C5), 44.95 (C3), 43.89 (C5M ), 41.03 (C3M ), 34.93
(C6), 32.14 (C6M ), 26.20 (C4), 25.76 (C4M ), 22.03 (C1M ), 21.13 (C8), 19.09 (C1), 11.30
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(C8M ); m/z (ESI+) 264 [M+H+CH3OH]
+, 232 [M+H]+, 128, 105; Exact Mass Calcd
for C15H22NO [M+H]
+requires m/z 232.1696 Found 232.1696 (NSI+)
2R,4R-2-Phenyl-1-S -1-phenylethyl)piperidine-4-carbaldehyde 366 and
























1.6 N HCl (2.8 mL) was added to a solution of a diastereomeric mixture of 356 and 357
(ratio of 356:357 was 1:1.32) (365 mg, 1.19 mmol) in THF (2.8 mL) and stirred at 45
◦C for three hours. THF was evaporated under reduced pressure and the residue was
diluted with water (10 mL). The pH was adjusted to 10 by the addition of an aqueous
Na2CO3 solution. The aqueous phase was extracted with DCM (3 x 15 mL) and the
combined organic layers were washed with brine and dried over MgSO4. The solvent
was removed under reduced pressure and crude aldehydes 366 and 367 were obtained
as a colourless oil (349 mg, 100%). The products could be used for the next step without
the need of further purification.
NMR investigation indicates that the mixture of diastereoisomers is a 1:1.33 ratio
of 366:367. NOe analysis indicates that compound 367 is the major product and
compound 366 is the minor compound (labelled as M ).
Products 366 and 367 as a mixture: Product 366 is labelled as M . Rf 0.13 (1:20
ethyl acetate:hexane); νmax (film) 2968, 2938, 2808, 2712, 1723, 1601, 1492, 1446, 1384,
1365, 1266, 1204, 1129, 1071, 1025, 953, 910, 760; δH (400 MHz, CDCl3) 9.82 (1H, s, H-
9M ), 9.61 (1H, d, J 1.5 Hz, H-9), 7.18-7.51 (20H, m, 10 x Ar-H, 10 x Ar-HM ), 3.89 (1H,
q, J 6.8 Hz, H-2), 3.83 (1H, q, J 6.9 Hz, H-2M ), 3.58-3.63 (2H, m, 1 x H-7, 1 x H-7M ),
2.72 (1H, dt, J 11.6 Hz, 3.4 Hz, 1 x H-3), 2.60-2.63 (1H, m, H-5M ), 2.50 (1H, dt, J 12.0
Hz, 3.6 Hz, 1 x H-3M ), 2.23-2.43 (4H, m, 1 x H-5, 1 x H-3, 1 x H-6M , 1 x H-3M ), 2.09-2.15
(1H, m, 1 x H-4M ), 1.95-2.08 (2H, m, 1 x H-6, 1 x H-6M ), 1.79-1.89 (2H, m, 1 x H-4, 1
x H-4M ), 1.67-1.76 (1H, m, 1 x H-6), 1.48-1.58 (1H, m, 1 x H-4), 1.20 (3H, d, J 6.8 Hz,
H-1), 1.13 (3H, d, J 6.8 Hz, H-1M ); δC (100.6 MHz, CDCl3) 205.17 (C8M ), 203.58 (C8),
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144.44 (Cquart.M ), 144.19 (Cquart.), 144.10 (Cquart.M ), 143.81(Cquart.), 128.89, 128.81,
128.02, 128.00, 127.64, 127.59, 127.55, 127.39, 126.44, 126.40, 64.48 (C7), 61.89 (C7M ),
55.19 (C2M ), 54.82 (C2), 49.86 (C5), 46.16 (C5M ), 44.01 (C3), 41.86 (C3M ), 36.13
(C6), 34.73 (C6M ), 26.05 (C4), 24.97(C4M ), 8.88 (C1M ), 8.20 (C1); m/z (ESI+) 326
[M+H+CH3OH]
+, 294 [M+H]+, 190; Exact Mass Calcd for C20H24NO [M+H]
+requires
m/z 294.1852 Found 294.1850 (NSI+).
2S,4R-2-phenyl-1-S -1-Phenylethyl)piperidine-4-carbaldehyde 368 and
























1.6 N HCl (3 mL) was added to a solution of a diastereomeric mixture of 358 and 359
(ratio of 358:359 was 1:1.10) (395 mg, 1.29 mmol) in THF (3 mL) and stirred at 45 ◦C
for two hours. THF was evaporated under reduced pressure and the residue was diluted
with water (10 mL). The pH was adjusted to 10 by the addition of an aqueous Na2CO3
solution. The aqueous phase was extracted with DCM (3 x 20 mL) and the combined
organic layers were washed with brine and dried over MgSO4. The solvent was removed
under reduced pressure and crude aldehydes 368 and 369 were obtained as a colourless
oil (379 mg, 100%). The products could be used for the next step without the need of
further purification.
NMR investigation indicates that the mixture of diastereoisomers is a 2.04:1 ratio
of 368:369. NOe analysis indicates that compound 368 is the major product and
compound 369 is the minor compound (labelled as M ).
Products 368 and 369 as a mixture: Product 369 is labelled as M . Rf 0.16 (1:8
ethyl acetate:hexane); νmax (film) 2809, 1720, 1492, 1453, 1374, 959, 911, 759, 734, 701;
δH (400 MHz, CDCl3) 9.62 (1H, s, H-8M ), 9.53 (1H, s, H-8), 7.18-7.46 (16 H, m, 2 x meta
ArI, 1 x para ArI, 2 x ortho ArII, 2 x meta ArII, 1 x para ArII, 2 x meta ArIM , 1 x para
ArIM , 2 x ortho ArIIM , 2 x meta ArIIM , 1 x para ArIIM ), 7.03 (2H, d, J 7.8 Hz, 2 x
ortho ArI), 6.98 (2H, d, J 7.7 Hz, 2 x ortho ArIM ), 3.99 (1H, q, J 7.0 Hz, H-2), 3.93 (1H,
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q, J 7.0 Hz, H-2M ), 3.24-3.31 (2H, m, 1 x H-3, 1 x H-7M ), 3.20 (1H, dd, J 11.1 Hz, 2.3
Hz, H-7), 3.01 (1H, dt, J 11.8 Hz, 3.5 Hz, 1 x H-3M ), 2.46-2.50 (1H, m, H-5M ), 2.10-2.22
(3H, m, H-5, 1 x H-4M , 1 x H-6M ), 1.80-1.97 (6H, m, 1 x H-4M , 1 x H-6M , 1 x H-3M , 1
x H-3, 1 x H-4, 1 x H-6), 1.44-1.66 (2H, m, 1 x H-4, 1 x H-6), 1.38 (3H, d, J 7.2 Hz, 3 x
H-1), 1.35 (3H, d, J 7.1 Hz, 3 x H-1M ); δC (100.6 MHz, CDCl3) 204.81 (C8M ), 203.38
(C8), 144.97 (ipso ArIM ), 144.85 (ipso ArI), 139.13 (ipso ArIIM ), 138.33 (ipso ArII),
128.95, 128.93, 128.83, 128.63, 127.83, 127.79, 127.73, 127.35, 127.14, 127.08, 127.04,
64.73 (C7), 62.12 (C7M ), 56.87 (C2M ), 56.56 (C2), 49.35 (C5), 45.65 (C5M ), 44.68
(C3), 42.78 (C3M ), 37.14 (C6), 35.36 (C6M ), 26.14 (C4), 25.15 (C4M ), 19.14 (C1M ),
18.66 (C1); m/z (ESI+) 326 [M+H+CH3OH]
+, 294 [M+H]+, 190; Exact Mass Calcd
for C20H24NO [M+H]
























5,6-Dimethoxy-1-indanone (71 mg, 0.37 mmol, 1.0 equiv) was added to a solution of
319 (75 mg, 0.37 mmol, 1.0 equiv) in methanol (2 mL) and the system was put under
an atmosphere of nitrogen. The mixture was heated to 80 ◦C and a sodium methoxide
solution (28% in methanol, 77 µl, 0.44 mmol, 1.2 equiv) was added. Stirring under reflux
was continued for 75 min, then the reaction was allowed to cool to room temperature.
The solvent was evaporated under reduced pressure and the residue was dissolved in
CH2Cl2 (5 mL). Water (3 mL) was added and the phases were separated. The aqueous
phase was extracted again with CH2Cl2 (2 x 6 mL), the organic phases were combined
and washed with brine and dried over MgSO4. The solvent was evaporated under reduced
pressure and purification by column chromatography (ethyl acetate:methanol 19:1.5)
afforded product 370 (117 mg, 84%) as a white solid; mp 169-171 ◦C; Rf 0.16 (100%
ethyl acetate); νmax (solid) 1688, 1646, 1602, 1586, 1498, 1458, 1309, 1255, 1240, 1214,
1134, 1119, 1021, 1000, 981, 855, 843, 803, 766; δH (400 MHz, CDCl3) 7.23-7.33 (6H, m,
H-8, 2 x ortho Ph-H, 2 x meta Ph-H, para Ph-H), 6.89 (1H, s, H-5), 6.66 (1H, d, J 9.6
Hz, H-10), 3.97 (3H, s, H3CO-C6), 3.92 (3H, s, H3CO-C7), 3.58-3.59 (2H, m, H-3), 3.53
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(2H, s, H-14), 2.92-2.95 (2H, m, 1 x H-13, 1 x H-13’), 2.28-2.38 (1H, m, H-11), 2.04-2.10
(2H, m, 1 x H-13, 1 x H-13’), 1.58-1.71 (4H, m, 4 x H-12); δC (100.6 MHz, CDCl3)
192.61(C=O), 155.32 (C6), 149.52 (C7), 144.53 (C9), 139.81 (C10), 138.07 (ipso Ph),
135.66 (C4), 131.87 (C2), 129.26 (ortho Ph), 128.22 (meta Ph), 127.07 (para Ph), 107.24
(C5), 105.05 (C8), 63.47 (C14), 56.26 (C6-OCH3), 56.16 (C7-OCH3), 53.04 (C13), 37.24
(C11), 31.17 (C12), 29.51 (C3). In agreement with published data.254
E -5,6-Dimethoxy-2-((2S,4S -2-methyl-1-(S -1-phenylethyl)piperidin-4-yl)-












































5,6-Dimethoxy-1-indanone (349 mg, 1.82 mmol, 1.0 equiv) was added to a solution of a
mixture of 362 and 363 (420 mg, 1.82 mmol, 1.0 equiv, ratio of 362:363 was 1:1.42)
in methanol (10 mL) and the system was put under an atmosphere of nitrogen. The
mixture was heated to 80 ◦C and a sodium methoxide solution (28% in methanol, 382 µl,
2.18 mmol, 1.2 equiv) was added. Stirring under reflux was continued for 90 min, then
the reaction was allowed to cool to room temperature. The solvent was evaporated
under reduced pressure and the residue was dissolved in CH2Cl2 (25 mL). Water (15
mL) was added and the phases were separated. The aqueous phase was extracted again
with CH2Cl2 (2 x 20 mL), the organic phases were combined and washed with brine and
dried over MgSO4. The solvent was evaporated under reduced pressure and purification
by column chromatography (ethyl acetate:hexane 3:2 → 100% ethyl acetate) afforded
product 371 (368 mg, 50%) as white crystals, a mixture of 371 and 372 (129 mg, 18%)
as white crystals and 372 (144 mg, 19%) as pale yellow crystals.
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NMR analysis of the crude residue indicated that the mixture of diastereomers was a
1.63:1 ratio of 371:372. NOe analysis of the purified products indicated the correct
stereochemistry.
Product 371, eluting first: [α]21D 11.2 (c 0.22, CHCl3); mp 84-87
◦C; Rf 0.30 (3:1
ethyl acetate:hexane); νmax (solid) 2911, 1694, 1652, 1606, 1591, 1502, 1427, 1367, 1307,
1251, 1214, 1130, 1071, 997, 802, 761, 720, 697; δH (400 MHz, CDCl3) 7.47-7.49 (2H, m,
ortho Ar-H), 7.20-7.35 (4H, m, 2 x meta Ar-H, para Ar-H, H-8), 6.90 (1H, s, H-5), 6.60
(1H, dt, J 9.6 Hz, 1.8 Hz, H-10), 4.38 (1H, q, J 6.8 Hz), 3.97 (3H, s, H3CO-C6), 3.92
(3H, s, H3CO-C7), 3.58 (2H, s, H-3), 2.61-2.69 (1H, m, H-13), 2.49 (1H, dt, J 11.4 Hz,
3.3 Hz, 1 x H-14), 2.35-2.39 (1H, m, H-11), 2.17 (1H, dt, J 11.7 Hz, 2.2 Hz, 1 x H-14),
1.68 -1.73 (1H, m, 1 x H-12), 1.50-1.56 (1H, m, 1 x H-15), 1.32-1.45 (2H, m, 1 x H-15,
1 x H-12), 1.21-1.29 (6H, m, 3 x H-17, 3 x H-18); δC (100.6 MHz, CDCl3) 192.82 (C1),
155.35 (C6), 149.58 (C7), 144.65 & 144.55 (C9 & ipso Ar), 140.33 (C10), 135.36 (Cquart.),
132.03 (Cquart.), 128.01 & 127.96 (ortho Ar & meta Ar), 126.41 (para Ar), 107.35 (C5),
105.12 (C8), 56.37 (C6-OCH3), 56.27 (C7-OCH3), 54.29 (C16), 53.23 (C13), 44.39 (C14),
41.11 (C12), 38.68 (C11), 31.87(C15), 29.62 (C3), 20.91 (C18), 8.15 (C17); m/z (ESI+)
406 [M+H]+, 302; Exact Mass Calcd for C26H32NO3 [M+H]
+requires m/z 406.23767
Found 406.23728 (ESI+); HPLC tR1= 14.1 min, tR2 16.9 min, tR3 31.2 min.
Product 372, eluting second: [α]20D -95.0 (c 0.50, CHCl3); mp 66-69
◦C; Rf 0.16 (3:1
ethyl acetate:hexane); νmax (solid) 2927, 1693, 1648, 1604, 1587, 1499, 1454, 1369, 1302,
1253, 1216, 1124, 1084, 996, 913, 801, 763, 727, 700; δH (400 MHz, CDCl3) 7.19-7.38
(6H, m, 5 x Ar-H, 1 x H-8), 6.90 (1H, s, H-5), 6.68 (1H, dt, J 9.4 Hz, 1.7 Hz, H-10),
3.96 (3H, s, H3CO-C6), 3.92 (3H, s, H3CO-C7), 3.59-3.64 (3H, m, 2 x H-3, 1 x H-16),
3.44-3.51 (1H, m, H-13), 2.59-2.69 (1H, m, H-11), 2.46 (1H, dt, J 12.2 Hz, 4.0 Hz, 1 x
H-14), 2.33 (1H, dt, J 11.7 Hz, 3.0 Hz, 1 x H-14), 1.80-1.87 (1H, m, 1 x H-12), 1.58-
1.63 (1H, m, 1 x H-12), 1.50-1.55 (1H, m, 1 x H-15), 1.38-1.48 (1H, m, 1 x H-15), 1.30
(3H, d, J 6.6 Hz, H-17), 1.11 (3H, d, J 6.6 Hz, H-18); δC (100.6 MHz, CDCl3) 192.80
(C1), 155.38 (C6), 149.60 (C7), 144.65 (ipso Ar, overlapping C9), 140.56 (C10), 135.61
(Cquart.), 132.04 (Cquart.), 128.43 (ortho Ar), 127.39 (meta Ar), 126.76 (para Ar), 107.35
(C5), 105.15 (C8), 60.57 (C16), 56.38 (C6-OCH3), 56.29 (C7-OCH3), 47.94 (C13), 42.96
(C14), 37.59 (C12), 32.35 (C11), 31.28 (C15), 29.62 (C3), 20.28 (C17), 10.99 (C18);
m/z (ESI+) 406 [M+H]+, 302; Exact Mass Calcd for C26H32NO3 [M+H]
+requires m/z
406.23767 Found 406.23770 (ESI+)
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E -5,6-Dimethoxy-2-((2R,4S -2-methyl-1-(S -1-phenylethyl)piperidin-4-yl)-











































5,6-Dimethoxy-1-indanone (340 mg, 1.77 mmol, 1.0 equiv) was added to a solution of
a mixture of 364 and 365 (410 mg, 1.77 mmol, 1.0 equiv, ratio of 364:365 was 2:1)
in methanol (10 mL) and the system was put under an atmosphere of nitrogen. The
mixture was heated to 80 ◦C and a sodium methoxide solution (28% in methanol, 372 µl,
2.12 mmol, 1.2 equiv) was added. Stirring under reflux was continued for 90 min, then
the reaction was allowed to cool to room temperature. The solvent was evaporated
under reduced pressure and the residue was dissolved in CH2Cl2 (25 mL). Water (15
mL) was added and the phases were separated. The aqueous phase was extracted again
with CH2Cl2 (2 x 20 mL), the organic phases were combined and washed with brine and
dried over MgSO4. The solvent was evaporated under reduced pressure and purification
by column chromatography (ethyl acetate:hexane 6:1 → 100% ethyl acetate) afforded
product 373 (64 mg, 9%) as pale yellow crystals, a mixture of 373 and 374 (121 mg,
17%, 373:374 1.36:1) as white crystals and a mixture of 373 and 374 (274 mg, 38%,
373:374 1:5.39) as white crystals.
NMR analysis of the crude residue indicated that the mixture of diastereomers was a
1:1.68 ratio of 373:374. NOe analysis of the purified products indicated the correct
stereochemistry.
Product 373, eluting first: [α]22D -177.6 (c 0.11, CHCl3); mp 66-68
◦C; Rf 0.28
(19:1.5 ethyl acetate:methanol); νmax (solid) 1693, 1648, 1605, 1587, 1500, 1454, 1303,
1253, 1217, 1127, 1080, 996, 801, 763; δH (400 MHz, CDCl3) 7.21-7.37 (6H, m, H-8,
ortho Ar-H, meta Ar-H, para Ar-H), 6.90 (1H, s, H-5), 6.63 (1H, dt, J 9.5 Hz, 2.0 Hz,
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H-10), 3.97 (3H, s, H3CO-C6), 3.92 (3H, s, H3CO-C7), 3.58-3.67 (3H, m, H-16, 2 x H-3),
2.93-2.99 (2H, m, H-13, 1 x H-14), 2.52-2.66 (2H, m, H-11, 1 x H-14), 1.64-1.73 (3H, 2 x
H-15, 1 x H-12), 1.37-1.51 (1H, m, 1 x H-12), 1.32 (3H, d, J 5.8 Hz, H-17), 0.98 (3H, d, J
5.9 Hz, H-18); δC (100.6 MHz, CDCl3) 192.76 (C=O), 155.36 (C6), 149.58 (C7), 145.66
(C9), 144.63 (ipso Ar), 140.69 (C10), 135.55 (C2), 132.02 (C4), 128.45 (meta Ar), 127.40
(ortho Ar), 126.84 (para Ar), 107.34 (C5), 105.13 (C8), 60.36 (C16), 56.37 & 56.28 (C6-
OCH3, C7-OCH3), 48.86 (C13), 41.36 (C14), 37.74 (C12), 31.99 (C11), 31.73 (C15),
29.61 (C3), 22.57 (C17), 10.16 (C18); m/z (ESI+) 406 [M+H]+, 302; Exact Mass Calcd
for C26H32NO3 [M+H]
+requires m/z 406.2377 Found 406.2376 (NSI+)
Product 374, eluting second: [α]22D -62.5 (c 0.19, CHCl3); mp 76-78
◦C; Rf 0.23
(19:1.5 ethyl acetate:methanol); νmax (film) 1693, 1648, 1605, 1588, 1499, 1454, 1302,
1254, 1216, 1129, 1080, 996, 748, 702, 665; δH (400 MHz, CDCl3) 7.23-7.37 (6H, m, H-8,
meta Ar-H, ortho Ar-H, para Ar-H), 6.84 (1H, s, H-5), 6.56 (1H, dt, J 9.7 Hz, 2.0 Hz,
H-10), 4.39 (1H, q, J 6.7 Hz, H-16), 3.95 (3H, s, H3CO-C6), 3.91 (3H, s, H3CO-C7),
3.47 (2H, d, J 1.9 Hz, H-3), 3.15 (1H, app d, J 11.3 Hz, 1 x H-14), 2.14-2.23 (2H,
m, H.13, H-11), 1.86 (1H, app t, J 11.8 Hz, 1 x H-14), 1.37-1.71 (7H, m, 2 x H-12, 2
x H-15, H-17), 1.30 (3H, d, J 5.8 Hz, H-18); δC (100.6 MHz, CDCl3) 192.71 (C=O),
155.34 (C6), 149.55 (C7), 144.61 (C9), 144.59 (ipso Ar), 139.89 (C10), 135.53 (C2),
131.95 (C4), 128.74 (meta Ar), 127.86 (ortho Ar), 127.04 (para Ar), 107.30 (C5), 105.08
(C8), 56.37 & 56.26 (C6-OCH3, C7-OCH3), 55.72 (C16), 53.31 (C13), 45.29 (C14), 40.91
(C15), 38.01 (C11), 31.85 (C12), 29.59 (C3), 21.36 (C18), 19.00 (C17); m/z (ESI+) 406
[M+H]+, 302; Exact Mass Calcd for C26H32NO3 [M+H]
+requires m/z 406.23767 Found
406.23771 (ESI+)
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E -5,6-Dimethoxy-2-((2R,4S -2-phenyl-1-(S -1-phenylethyl)piperidin-4-yl)-














































5,6-Dimethoxy-1-indanone (206 mg, 1.07 mmol, 1.0 equiv) was added to a solution of a
mixture of 366 and 367 (314 mg, 1.07 mmol, 1.0 equiv, ratio of 366:367 was 1:1.33)
in methanol (5 mL) and the system was put under an atmosphere of nitrogen. The
mixture was heated to 80 ◦C and a sodium methoxide solution (28% in methanol,
225 µl, 1.28 mmol, 1.2 equiv) was added. Stirring under reflux was continued for
2 h, then the reaction was allowed to cool to room temperature. The solvent was
evaporated under reduced pressure and the residue was dissolved in CH2Cl2 (25 mL).
Water (15 mL) was added and the phases were separated. The aqueous phase was
extracted again with CH2Cl2 (2 x 20 mL), the organic phases were combined and washed
with brine and dried over MgSO4. The solvent was evaporated under reduced pressure
and purification by column chromatography (ethyl acetate:hexane 1:3 with 1% TEA)
afforded the inseparable mixture of 375 and 388 (317 mg, 64%) as white crystals;
Products 375 and 388 as a mixture: Rf 0.18 (1:1 ethyl acetate:hexane); νmax (solid)
2930, 1694, 1650, 1604, 1586, 1499, 1453, 1302, 1254, 1214, 1127, 1076, 1029, 998, 801,
759, 699; δH (400 MHz, CDCl3) 7.44-7.49 (4H, m, 2 x meta ArI-H, 2 x meta ArII-H),
7.19-7.36 (7H, m, 2 x ortho ArI-H, 2 x ortho ArII-H, para ArI-H, para ArII-H, H-8),
6.90 (1H, s, H-5), 6.62 (1H, dt, J 9.4 Hz, 1.8 Hz, H-10), 3.97 (3H, s, H3CO-C6), 3.86-
3.95 (4H, m, H3CO-C7, H-16), 3.56-3.66 (3H, m, 2 x H-3, 1 x H-13), 2.67 (1H, “dt”,
J 11.5 Hz, 3.3 Hz, 1 x H-14), 2.44-2.54 (1H, m, H-11), 2.36 (1H,“td”, J 11.7 Hz, 2.4
Hz, 1 x H-14), 1.83-1.89 (1H, m, 1 x H-12), 1.72-1.78 (1H, m, 1 x H-12), 1.65-1.69 (1H,
m, 1 x H-15), 1.51-1.61 (1H, m, 1 x H-15), 1.21-1.26 (3H, m, H-17); δC (100.6 MHz,
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CDCl3) 192.68 (C1), 155.38 (C6), 149.59 (C7), 144.60 & 144.33 & 144.13 (ipso ArI,
ipso ArII, C9), 139.65 (C10), 135.60 (C2), 131.97(C4), 128.81, 127.99, 127.64, 127.61,
127.39, 126.37, 107.33 (C5), 105.12 (C8), 64.86 (C13), 56.37 & 56.25 (C6-OCH3, C7-
OCH3), 54.85 (C16), 44.33 (C14), 41.89 (C12), 38.79 (C11), 31.79 (C15), 29.64 (C3),
8.10 (C17); m/z (ESI+) 468 [M+H]+, 381, 363, 293; Exact Mass Calcd for C31H34NO3
[M+H]+requires m/z 468.2533 Found 468.2527 (NSI+); HPLC tR1= 15.8 min, tR2 19.5
min, tR3 38.2 min.
E -5,6-Dimethoxy-2-((2S,4S -2-phenyl-1-(S -1-phenylethyl)piperidin-4-yl)-














































5,6-Dimethoxy-1-indanone (236 mg, 1.23 mmol, 1.0 equiv) was added to a solution of a
mixture of 368 and 369 (360 mg, 1.23 mmol, 1.0 equiv, ratio of 368:369 was 2.04:1) in
methanol (5 mL) and the system was put under an atmosphere of nitrogen. The mixture
was heated to 80 ◦C and a sodium methoxide solution (28% in methanol, 258 µl, 1.47
mmol, 1.2 equiv) was added. Stirring under reflux was continued for 2 h, then the
reaction was allowed to cool to room temperature. The solvent was evaporated under
reduced pressure and the residue was dissolved in CH2Cl2 (25 mL). Water (15 mL)
was added and the phases were separated. The aqueous phase was extracted again with
CH2Cl2 (2 x 20 mL), the organic phases were combined and washed with brine and dried
over MgSO4. The solvent was evaporated under reduced pressure and purification by
column chromatography (ethyl acetate:hexane 1:3 → 1:1) afforded inseparable product
377 and 393 (335 mg, 59%) as white crystals;
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Products 377 and 393 as a mixture: Rf 0.30 (1:2 ethyl acetate:hexane); νmax (solid)
2928, 1695, 1649, 1605, 1587, 1499, 1453, 1303, 1253, 1215, 1129, 1976, 802, 760, 702;
δH (400 MHz, CDCl3) 7.26-7.46 (9H, m, H-8, 2 x ortho Ar-II, 4 x meta Ar, 2 x para
Ar), 7.06-7.08 (2H, m, 2 x ortho Ar-I), 6.85 (1H, s, H-5), 6.56 (1H,“dt”, J 9.5 Hz, 1.8
Hz, H-10), 4.02 (1H, q, J 7.2 Hz, H-16), 3.96 (3H, s, H3CO-C6), 3.91 (3H, s, H3CO-C7),
3.49-3.50 (2H, d, J 1.5 Hz, H-3), 3.22-3.27 (2H, m, 1 x H-14, 1 x H-13), 2.22-2.32 (1H,
m, H-11), 1.90 (1H,“dt”, J 11.8 Hz, 2.3 Hz, 1 x H-14), 1.63-1.80 (3H, m, 2 x H-15, 1 x
H-12), 1.52-1.62 (1H, m, 1 x H-12), 1.41 (3H, d, J 7.2 Hz, 3 x H.17); δC (100.6 MHz,
CDCl3) 192.56 (C1), 155.44 (C6), 149.66 (C7), 145.10 (ipso ArII), 144.55 (C9), 139.51
(C10), 138.54 (ipso ArI), 135.65 (C2), 131.99 (C4), 129.08 (ortho Ar), 128.87 (ortho Ar),
127.72 (meta Ar), 127.65 (meta Ar), 127.15 (para Ar), 126.98 (para Ar), 107.38 (C5),
105.20 (C8), 65.14 (C13), 56.62 (C16), 56.35 & 56.25 (C6-OCH3, C7-OCH3), 45.05
(C14), 42.90 (C12), 38.28 (C11), 31.89 (C15), 29.62 (C3), 18.64 (C17); m/z (ESI+)
468 [M+H]+, 381, 363, 293; Exact Mass Calcd for C31H34NO3 [M+H]
+requires m/z
























A solution of 370 (52 mg, 0.19 mmol) in THF (4 mL) was hydrogenated over palladium
10% on activated charcoal (5.2 mg) for 6 h at ambient temperature and pressure. The
reaction mixture was filtered through Celite and washed with CH2Cl2 (10 mL). The
solvent was removed under reduced pressure and purification by column chromatography
(CHCL3:MeOH 30:1) afforded 379 (62 mg, 84%) as an off-white solid; mp 83-85
◦C; Rf
0.20 (18:1.7 ethyl acetate:methanol); νmax (solid) 2919, 1692, 1590, 1499, 1438, 1365,
1311, 1262, 1219, 1120, 1036, 973, 862, 803, 786; δH (400 MHz, CDCl3) 7.21-7.32 (5H,
m, 5 x Ar-H), 7.16 (1H, s, H-8), 6.84 (1H, s, H-5), 3.95 (3H, s, H3CO-C6), 3.89 (3H,
s, H3CO-C7), 3.50 (2H, s, H-14), 3.22 (1H, dd, J 17.6 Hz, 8.1 Hz, 1 x H-3), 2.87-2.91
(2H, m, 1 x H-13, 1 x H-13’), 2.66-2.71 (2H, m, 1 x H-3, H-2), 1.87-2.00 (3H, 1 x H-13,
1 x H-13’, 1 x H-10), 1.63-1.75 (2H, m, 1 x H-12, 1 x H-12’), 1.43-1.54 (1H, m, H-11),
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1.24-1.41 (3H, m, 1 x H-12, 1 x H-12’, 1 x H-10); δC (100.6 MHz, CDCl3) 207.95 (C1),
155.54 (C6), 149.51 (C7), 148.88 (C4), 138.50 (ipso Ar), 129.41 (C9), 129.35 (ortho
Ar), 128.23 (meta Ar), 127.02 (para Ar), 107.44 (C5), 104.46 (C8), 63.54 (C14), 56.31
& 56.19 (C6-OCH3, C7-OCH3), 53.88 & 53.86 (C13, C13’), 45.56 (C2), 38.81 (C10),
34.56 (C11), 33.44 (C3), 33.11 & 31.88 (C12, C12’); Exact Mass Calcd for C24H29NO3
[M+H]+requires m/z 380.2220 Found 380.2220 (NSI+). In agreement with published
data.255
R-5,6-Dimethoxy-2-((2S,4S -2-methyl-1-(S -1-phenylethyl)piperidin-4-yl)-















































A solution of 371 (150 mg, 0.37 mmol) in THF (15 mL) was hydrogenated over palladium
10% on activated charcoal (25 mg) for 8 h at ambient temperature and pressure. The
reaction mixture was filtered through Celite and washed with CH2Cl2 (40 mL). The
solvent was removed under reduced pressure and purification by column chromatography
(ethyl acetate:hexane 2:1 → 100% ethyl acetate) afforded an inseparable mixture of
product 380 and product 381 (103 mg, 68%) as a pale yellow solid.
Products 380 and 381 as a mixture: Rf 0.32 (8:1 ethyl acetate:methanol); νmax
(solid) 2919, 1693, 1590, 1499, 1454, 1420, 1307, 1262, 1221, 1119, 1034, 764, 721, 698;
δH (400 MHz, CDCl3) 7.46-7.48 (4H, m, 4 x ortho Ar-H), 7.30-7.33 (4H, m, 4 x meta
Ar-H), 7.19-7.23 (2H, m, 2 x para Ar-H), 7.16 (2 H, s, 2 x H-8), 6.84-6.85 (2H, m, 2
x H-5), 4.35 (2H, q, J 6.1 Hz, 2 x H-16), 3.96 (6H, s, 6 x H3CO-C6), 3.90 (6H, s, 6 x
H3CO-C7), 3.23 (2H, dd, J 17.5 Hz, 8.1 Hz, 2 x H H-3), 2.65-2.71 (4H, m, 2 x HH -3, 2
x H-2), 2.53-2.61 (2H, m, 2 x H-13), 2.42-2.47 (2H, m, 2 x H H-14), 2.06-2.12 (2H, m, 2
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x HH -14), 1.82-1.90 (2H, m, 2 x H H-10), 1.68-1.78 (2H, m, 2 x H H-12), 1.48-1.59 (4H,
m, 2 x H H-15, 2 x H-11), 1.02-1.31 (18H, m, 2 x HH -10, 6 x H-17, 6 x H-18, 2 x HH -12,
2 x HH -15); δC (100.6 MHz, CDCl3) 208.13 & 208.12 (C1), 155.51 (C6), 149.49 (C7),
148.97 & 148.96 (C4), 144.89 (ipso Ar), 129.47 & 129.44 (C9), 127.95 & 127.92 (ortho
& meta Ar), 126.27 (para Ar), 56.34 & 56.22 (C6-OCH3, C7-OCH3), 54.26 (C16), 53.54
(C13), 45.68 & 45.52 (C2), 44.88 (C14), 43.48 & 42.35 (C12), 39.20 & 39.12 (C10), 35.66
& 35.57 (C11), 33.72 & 32.45 (C15), 33.54 (C3), 21.16 & 21.14 (C18), 8.15 & 8.12 (C17);
m/z (ESI+) 408 [M+H]+, 304; Exact Mass Calcd for C26H34NO3 [M+H]
+requires m/z
408.25332 Found 408.25278 (ESI+); HPLC tR1= 14.2 min, tR2 17.0 min, tR3 31.3 min.
R-5,6-Dimethoxy-2-((2S,4R-2-methyl-1-(S -1-phenylethyl)piperidin-4-yl)-















































A solution of 372 (72 mg, 0.18 mmol) in THF (7 mL) was hydrogenated over palladium
10% on activated charcoal (10 mg) for 8 h at ambient temperature and pressure. The
reaction mixture was filtered through Celite and washed with CH2Cl2 (30 mL). The
solvent was removed under reduced pressure and purification by column chromatography
(100% ethyl acetate → ethyl acetate:methanol 10:1) afforded an inseparable mixture of
product 382 and product 383 (26 mg, 35%) as a pale yellow sticky solid.
Products 382 and 383 as a mixture: Rf 0.20 (9:1 ethyl acetate:methanol); νmax
(film) 2921, 1693, 1606, 1591, 1500, 1454, 1310, 1263, 1122, 1039, 751, 701, 649; δH (400
MHz, CDCl3) 7.35-7.41 (4H, m, 4 x ortho Ar-H), 7.28-7.32 (4H, m, 4 x meta Ar-H),
7.20-7.23 (2H, m, 2 x para Ar-H), 7.16 (2H, s, 2 x H-8), 6.85 (2H, “ds”, 2 x H-5), 3.95
(6H, s, 6 x H3CO-C6), 3.90 (6H, s, 6 x H3CO-C7), 3.45-3.63 (4H, m, 2 x H-16, 2 x H-13),
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3.19-3.26 (2H, m, 2 x H H-3), 2.65-2.73 (4H, m, 2 x HH -3, 2 x H-2), 2.42-2.52 (2H, m,
2 x H H-14), 2.28-2.36 (2H, m, 2 x HH -14), 1.78-1.92 (4H, m, 2 x H-11, 2 x H H-10),
1.48-1.65 (6H, m, 4 x H-12, 2 x H H-15), 1.07-1.33 (16H, m, 6 x H-17, 2 x HH -10, 2 x
HH -15, 6 x H-18); δC (100.6 MHz, CDCl3) 208.04 (C1), 155.54 & 155.53 (C6), 149.50
(C7), 148.93 (C4), 147.03 (ipso Ar), 129.43 & 129.39 (C9), 128.50 (meta Ar), 127.48
(ortho Ar), 126.93 (para Ar), 107.44 (C5), 104.43 & 104.42 (C8), 61.15 (C16), 56.34
& 56.21 (C6-OCH3, C7-OCH3), 48.68 (C13), 45.64 & 45.39 (C2), 43.87 (C14), 38.95 &
38.89 (C10), 37.77 (C12), 33.54 & 33.48 (C3), 31.42 (C15), 28.97 & 28.67 (C11), 20.94
(C17), 10.64 (C18); m/z (ESI+) 408 [M+H]+, 304; Exact Mass Calcd for C26H34NO3
[M+H]+requires m/z 408.25332 Found 408.25349 (ESI+); HPLC tR1= 14.4 min, tR2
17.4 min, tR3 32.2 min.
R-5,6-Dimethoxy-2-((2R,4S -2-methyl-1-(S -1-phenylethyl)piperidin-4-yl)-














































A solution of 373 (72 mg, 0.18 mmol) in THF (8 mL) was hydrogenated over palladium
10% on activated charcoal (14 mg) for 9 h at ambient temperature and pressure. The
reaction mixture was filtered through Celite and washed with CH2Cl2 (30 mL). The
solvent was removed under reduced pressure and purification by column chromatography
(ethyl acetate:hexane 8:1→ 100% ethyl acetate→ ethyl acetate:methanol 10:1) afforded
an inseparable mixture of product 384 and product 385 (31 mg, 42%) as a pale yellow
sticky solid.
Products 384 and 385 as a mixture: Rf 0.09 (100% ethyl acetate); νmax (film)
2921, 1692, 1606, 1591, 1499, 1454,1311, 1263, 1121, 1037, 913, 767, 728, 702, 646; δH
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(400 MHz, CDCl3) 7.41-7.43 (2H, m, 2 x meta Ar-H), 7.32 (2H, t, J 7.4 Hz, 2 x ortho
Ar-H), 7.22-7.26 (1H, m, para Ar-H), 7.15 (1H, s, H-8), 6.84-6.85 (1H, ‘m’, H-5), 3.95
(3H, s, H3CO-C6), 3.89 (3H, s, H3CO-C7), 3.67-3.72 (1H, m, H-16), 3.23 (1H, dd, J
17.4 Hz, 8.0 Hz, 1 x H-3), 3.01-3.11 (2H, 1 x H-14, H-13), 2.54-2.71 (3H, m, 1 x H-3,
H-2, 1 x H-14), 1.76-1.88 (3H, 1 x H-10, 1 x H-15, H-11), 1.23-1.57 (7H, 1 x H-15, 2 x
H-12, H-18, 1 x H-10), 0.98-1.00 (3H, m, 3 x H-18); δC (100.6 MHz, CDCl3) 207.93 &
207.91 (C1), 155.58 (C6), 149.54 (C7), 148.91 (C4), 142.64 (ipso Ar) 129.40 & 129.37
(C9), 128.61 (ortho Ar), 127.60 (meta Ar), 127.22 (para Ar), 107.46 (C5), 104.43 (C8),
61.12 (C16), 56.33 (C6-OCH3), 56.20 (C7-OCH3), 50.08 (C13), 45.46 & 45.34 (C2),
42.40 (C14), 38.91 & 38.84 (C10), 37.73 (C12), 33.63 & 33.54 (C3), 31.57 (C15), 28.25
& 28.14 (C11), 22.02 (C17), 10.49 (C18); m/z (ESI+) 408 [M+H]+, 304; Exact Mass
Calcd for C26H34NO3 [M+H]
+requires m/z 408.25332 Found 408.25396 (ESI+); HPLC
tR1= 14.5 min, tR2 17.6 min, tR3 32.7 min.
R-5,6-Dimethoxy-2-((2R,4R-2-methyl-1-(S -1-phenylethyl)piperidin-4-yl)-














































A solution 374 (85 mg, 0.21 mmol) in THF (10 mL) was hydrogenated over palladium
10% on activated charcoal (16 mg) for 7 h at ambient temperature and pressure. The
reaction mixture was filtered through Celite and washed with CH2Cl2 (40 mL). The
solvent was removed under reduced pressure and purification by column chromatography
(ethyl acetate:hexane 3:1 → 100% ethyl acetate) afforded the inseparable mixture of
product 386 and product 387 (57 mg, 67%) as a pale yellow foamy solid.
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Products 386 and 387 as a mixture: Rf 0.25 (9:1 ethyl acetate:methanol); νmax
(film) 2918, 1693, 1605, 1590, 1499, 1453,1307, 1262, 1119, 1035, 762, 733, 702, 651; δH
(400 MHz, CDCl3) 7.23-7.36 (10H, m, 4 x ortho Ar-H, 4 x meta Ar-H, 2 x para Ar-H),
7.14 (2H, s, 2 x H-8), 6.81 (2H, s, 2 x H-5), 4.39 (2H, q, J 7.1 Hz, 2 x H-16), 3.94 (6H, s,
6 x H3CO-C6), 3.89 (6H, s, 6 x 6 x H3CO-C7), 3.12-3.19 (4H, m, 2 x H H-14, 2 x H H-3),
2.58-2.68 (4H, m, 2 x H-2, 2 x HH -3), 2.14-2.17 (2H, m, 2 x H-13), 1.58-1.87 (8H, m, 2 x
HH -14, 2 x H H-10, 2 x H H-12, 2 x H H-15), 1.50 (6H, d, J 7.0 Hz, 6 x H-17), 1.10-1.37
(14 H, 2 x H-11, 6 x H-18, 2 x HH -10, 2 x HH -15, 2 x HH -12); δC (100.6 MHz, CDCl3)
207.83 & 207.79 (C1), 155.40 (C6), 149.37 (C7), 148.74 (C4), 138.96 (ipso Ar), 129.29 &
129.27 (C9), 128.68 (meta Ar), 127.71 (ortho Ar), 126.94 (ipso Ar), 107.32 (C5), 104.33
(C8), 56.21 & 56.09, (C6-OCH3, C7-OCH3), 55.72 & 55.69 (C16), 53.71 (C13), 45.71
(C14), 45.35 & 45.26 (C2), 42.98 & 41.88 (C12), 38.85 & 38.77 (C10), 34.68 (C11), 33.33
(C3, overlapping 1 x C15), 32.09 (1 x C15), 21.34 & 21.29 (C18), 18.88 & 18.87 (C17);
m/z (ESI+) 408 [M+H]+, 304; Exact Mass Calcd for C26H34NO3 [M+H]
+requires m/z
408.25332 Found 408.25274 (ESI+); HPLC tR1= 14.5 min, tR2 17.6 min, tR3 32.9 min.
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R-5,6-Dimethoxy-2-((2R,4S -2-phenyl-1-(S -1-phenylethyl)-piperidin-4-yl)-
methyl)-2,3-dihydro-1H -inden-1-one 389 and R-5,6-dimethoxy-2-((2R,4R-
2-phenyl-1-(S -1-phenylethyl)-piperidin-4-yl)-methyl)-2,3-dihydro-1H -inden-
1-one 391 and S -5,6-dimethoxy-2-((2R,4S -2-phenyl-1-(S -1-phenylethyl)-































































































A solution of a mixture of 375 and 388 (139 mg, 0.30 mmol) in THF (13 mL) was
hydrogenated over palladium 10% on activated charcoal (14 mg) for 10 h at ambient
temperature and pressure. The reaction mixture was filtered through Celite and washed
with CH2Cl2 (40 mL). The solvent was removed under reduced pressure and purification
by column chromatography (ethyl acetate:hexane 1:3.5) afforded an inseparable mixture
of products 389, 391, 390, and 392 (108 mg, 77%) as a foamy white solid;
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Product 389, 391, 390 and 392 as a mixture: Rf 0.47 (1:1 ethyl acetate:hexane);
νmax (solid) 2910, 1693, 1606, 1591, 1499, 1453,1309, 1262, 1120, 1032, 909, 762, 728,
690; δH (400 MHz, CDCl3) 7.44-7.50 (4H, m, 4 x Ar-H), 7.16-7.36 (7H, m, 7 x Ar-H),
6.84-6.85 (1H, m, H-5), 3.94-3.95 (3H, m, H3CO-C6), 3.89 (3H, s, H3CO-C7), 3.84-3.92
(1H, m, H-16), 3.55-3.61 (1H, m, H-13), 3.19-3.26 (1H, m, 1 x H-3), 2.59-2.73 (3H, m,
H-2, 1 x H-3, 1 x H-14), 2.26-2.32 (1H, m, 1 x H-14), 1.86-1.94 (2H, m, 1 x H-10, 1 x
H-12), 1.60-1.74 (2H, m, H-11, 1 x H-15), 1.41-1.53 (1H, m, 1 x H-15), 1.20-1.38 (5H,
m, 1 x H-10, 1 x H-15, H-17); δC (100.6 MHz, CDCl3) 207.89 & 207.85 (C1), 155.51
& 155.50 (C6), 149.48 (C7), 148.86 & 148.83 (C4), 144.95 & 144.90 (ipso ArII), 144.64
(ipso ArI), 129.38 (C9), 128.69 (Ar), 127.89 (Ar), 127.63 (Ar), 127.55 (Ar), 127.17 (Ar),
127.13 (Ar), 126.20 (Ar), 107.43 & 107.41 (C5), 104.43 (C8), 65.18 (C13), 56.29 & 56.16
(C6-OCH3, C7-OCH3), 54.79 (C16), 45.45 & 45.38 (C2), 44.69 & 44.67 (C14), 44.42 &
43.31 (C12), 39.12 & 39.03 (C10), 35.85 & 35.63 (C11), 33.69 & 33.43 (C3), 33.38 & 32.32
(C15), 8.12 (C17); m/z (ESI+) 470 [M+H]+, 366; Exact Mass Calcd for C31H36NO3
[M+H]+requires m/z 470.26897 Found 470.26805 (ESI+); HPLC tR1= 15.7 min, tR2
19.4 min, tR3 37.8 min.
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R-5,6-Dimethoxy-2-((2S,4S -2-phenyl-1-(S -1-phenylethyl)-piperidin-4-yl)-
methyl)-2,3-dihydro-1H -inden-1-one 394 and R-5,6-dimethoxy-2-((2S,4R-
2-phenyl-1-(S -1-phenylethyl)-piperidin-4-yl)-methyl)-2,3-dihydro-1H -inden-
1-one 396 and S -5,6-dimethoxy-2-((2S,4S -2-phenyl-1-(S -1-phenylethyl)-































































































A solution of a mixture of 377 and 393 (200 mg, 0.43 mmol) in THF (16 mL) was
hydrogenated over palladium 10% on activated charcoal (26 mg) for 8 h at ambient
temperature and pressure. The reaction mixture was filtered through Celite and washed
with CH2Cl2 (100 mL). The solvent was removed under reduced pressure and purification
by column chromatography (chloroform:methanol 4:0.1) afforded an inseparable mixture
of products 394, 396, 395, and 397 (171 mg, 84%) as a colourless solid;
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Products 394, 396, 395 and 397 as a mixture: Rf 0.31 (1:2 ethyl acetate:hexane);
νmax (film) 2923, 1693, 1591, 1500, 1453, 1311, 1263, 1216, 1119, 1033, 844, 759, 735,
701; δH (400 MHz, CDCl3) 7.37-7.45 (4H, m, 4 x Ar-H), 7.22-7.32 (4H, m, 4 x Ar-H),
7.13 (1H, s, H-8), 7.03-7.05 (2H, m, 2 x ortho ArI-H), 6.79-6.81 (1H, m, H-5), 3.97 (1H,
q, J 7.2 Hz, H-16), 3.93-3.94 (3H, s, H3CO-C6), 3.88 (3H, s, H3CO-C7), 3.10-3.21 (3H,
m, 1 x H-14, H-13, 1 x H-3), 2.55-2.67 (2H, m, H-2, 1 x H-3), 1.66-1.86 (4H, m, 1 x H-14,
1 x H-10, 1 x H-15, 1 x H-12), 1.26-1.45 (6H, m, H-11, 3 x H-17, 1 x H-15, 1 x H-12),
1.12-1.21 (1H, m, 1 x H-10); δC (100.6 MHz, CDCl3) 207.82 & 207.73 (C1), 155.58 &
155.55 (C6), 149.55 (C7), 148.83 & 148.78 (C4), 145.86 & 145.84 (ipso ArII), 138.66
(ipso ArI), 129.43 (C9), 129.06, 128.78, 127.75, 127.57, 126.95, 126.91, 126.88, 107.49 &
107.47 (C5), 104.52 (C8), 65.56 (C13), 56.62 & 56.60 (C16), 56.31 & 56.20 (C6-OCH3,
C7-OCH3), 45.51 & 45.48 (C14, C12), 45.43 & 45.34 (C2), 44.34 (C12’), 38.97 & 38.89
(C10), 35.32 & 35.05 (C11), 33.57 (C3), 33.30 & 32.32 (C15), 18.73 & 18.70 (C17);
m/z (ESI+) 470 [M+H]+, 366; Exact Mass Calcd for C31H36NO3 [M+H]
+requires m/z







Methyl iodide (4.126 mL, 66.28 mmol, 2.5 equiv) was added to a stirring solution of
1-methyl-4-piperidone (3.261 mL, 26.51 mmol, 1.0 equiv) in acetone (140 mL) at 25 ◦C.
After stirring for 2 h, the precipitate was isolated by filtration and subsequent washing
with acetone (40 mL). Product 399 (6.713 g, 99%) was obtained as a pale yellow solid;
mp 185-189 ◦C (decomposition) ; νmax (solid) 1726, 1476, 1386, 1333, 1295, 1169, 1025,
909, 773, 757; δH (400 MHz, DMSO-d6) 3.76 (4H, t, J 6.6 Hz, 2 x β-CH2), 3.29 (6H, s, 2
x -CH3), 2.71 (4H, t, J 6.6 Hz, 2 x α-CH2); δC (100.6 MHz, DMSO-d6) 201.66 (C=O),
60.02 (β-CH2), 50.90 (α-CH2), 35.13 (CH3) In agreement with published data.
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S -α-Phenylethylamine (2.128 mL, 16.50 mmol, 1.0 equiv) was added to a solution of
ethanol (25 mL), potassium carbonate (4.790 g, 34.66 mmol, 2.65 equiv) and water (12
mL) and the resulting mixture was heated to 95 ◦C. 399 (4.210 g, 16.50 mmol, 1.0
equiv) in water (14 mL) was added dropwise to the mixture. The mixture was heated
at reflux for another 30 min and then cooled to room temperature. The ethanol was
removed under reduced pressure and the aqueous residue was extracted with ether (3 x
100 mL). The combined organic layers were dried over magnesium sulfate, the solvent
was evaporated under reduced pressure and purification by column chromatography
(ethyl acetate:hexane 1:1) afforded product 400 (2.327 g, 69%) as a yellow oil; Rf 0.29
(1:1 ethyl acetate:hexane); [α]23D -29.3 (c 0.72, CHCl3); νmax (film) 3028, 2971, 2908,
2806, 2756, 1718, 1493, 1454, 1412, 1386, 1342, 1316, 1284, 1220, 1131, 1080, 1011, 767,
703; δH (400 MHz, CDCl3) 7.24-7.37 (5H, m, 5 x Ar-H), 3.62 (1H, q, J 6.7 Hz, N-CH<),
2.69-2.80 (4H, m, 2 x β-CH2), 2.42 (4H, t, J 6.2 Hz, 2 x α-CH2), 1.42 (3H, d, J 6.7
Hz, -CH3); δC (100.6 MHz, CDCl3) 209.84 (C=O), 143.58 (ipso Ar), 128.47 (meta Ar),
127.48 (ortho Ar), 127.27 (para Ar), 63.53 (N-CH<), 50.14 (β-CH2), 41.68 (α-CH2),
19.50 (CH3). In agreement with published data.
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R-5,6-Dimethoxy-2-((1-(S -1-phenylethyl)piperidin-4-yl)methyl)-2,3-dihydro-














































A solution of 410 (300 mg, 0.77 mmol) in THF (29 mL) was hydrogenated over palladium
10% on activated charcoal (48 mg) for 8 h at ambient temperature and pressure. The
reaction mixture was filtered through Celite and washed with CH2Cl2 (100 mL). The
solvent was removed under reduced pressure and purification by column chromatography
(100% ethyl acetate→ ethyl acetate:methanol 10:0.5) afforded product 401 and product
402 (176 mg, 58%) as a colourless sticky solid.
Products 401 and 402 as a mixture: Rf 0.23 (19:2.5 ethyl acetate:methanol); νmax
(film) 2920, 1693, 1606, 1591, 1499, 1453,1312, 1262, 1121, 1036, 912, 763, 728, 701,
647; δH (400 MHz, CDCl3) 7.22-7.34 (5H, 5 x Ar-H), 7.15 (1H, s, H-8), 6.83 (1H, s,
H-5), 3.95 (3H, s, H3CO-C6), 3.89 (1H, s, H3CO-C6), 3.47-3.53 (1H, m, H-14), 3.20 (1H,
dd, J 17.6 Hz, 8.1 Hz, 1 x H-3), 3.07-3.11 (1H, m, 1 x H H-13), 2.84-2.90 (1H, m, 1 x
H H-13), 2.64-2.71 (2H, 1 x H-3, H-2), 1.95-2.03 (1H, m, 1 x HH -13), 1.84-1.93 (2H, m, 1
x HH -13, 1 x H-10), 1.60-1.77 (2H, m, 2 x H H-12), 1.23-1.46 (7H, m, 1 x H-11, 3 x H-15,
1 x H-10, 2 x HH -12); δC (100.6 MHz, CDCl3) 207.91 (C1), 155.57 (C6), 149.55 (C7),
148.87 (C4), 143.07 (ipso Ar), 129.44 (C9), 128.27 (meta Ar), 128.04 (ortho Ar), 127.11
(para Ar), 107.47 (C5), 104.50 (C8), 65.02 (C14), 56.34 (C6-OCH3), 56.22 (C7-OCH3),
51.15 & 51.13 (C13), 50.50 (C13), 45.54 & 45.53 (C2), 38.77 (C10), 34.57 (C11), 33.49
& 33.47 (C3), 33.01 (C12), 31.95 & 31.89 (C12), 19.46 & 19.43 (C15); m/z (ESI+) 394
[M+H]+, 290; Exact Mass Calcd for C25H32NO3 [M+H]
+requires m/z 394.23767 Found
394.23764 (ESI+); HPLC tR1= 14.1 min, tR2 16.9 min, tR3 31.3 min.












(Methoxymethyl)triphenylphosphonium chloride (2.785 g, 8.12 mmol, 1.5 equiv) and
molecular sieves were placed in an oven-dried flask and added with absolute THF (17
mL) under an atmosphere of nitrogen. The mixture was cooled to -78 ◦C and a 2
M solution of lithium diisopropylamide in THF/heptane/ethylbenzene (4.06 mL, 8.12
mmol, 1.5 equiv) was added slowly. The mixture was stirred at -78 ◦C for 5 min and
then allowed to warm to rt while stirring for another 20 min. The reaction mixture
was cooled to -20 ◦C and a solution of 400 (1.100 g, 5.42 mmol, 1.0 equiv) in absolute
THF (12 mL) was added slowly. The mixture was stirred at -20 ◦C for 15 min, then
allowed to warm to room temperature and stirred for 16 h. 1 M NH4Cl solution (25
mL) and ethyl acetate (50 mL) was added and the solution was stirred vigorously for
5 min. The phases were separated and the aqueous phase was again extracted with
ethyl acetate. The combined organic layers were washed with water and brine, dried
over MgSO4, filtered and the solvent was removed under reduced pressure. Purification
by column chromatography (hexane:ethyl acetate 3:2) afforded 408 as a colourless oil
(1.165 g, 93%); [α]23D -42.6 (c 1.21, CHCl3); Rf 0.25 (1.5:1 ethyl acetate:hexane); νmax
(film) 1691, 1452, 1223, 1190, 1121, 1075, 837, 758, 735, 700; δH (400 MHz, CDCl3)
7.23-7.37 (5H, m, 5 x Ar-H), 5.77 (1H, s, H-6), 3.54 (3H, s, -OCH3), 3.49 (1H, q, J 6.9
Hz, H-1), 2.36-2.48 (4H, m, 2 x H-2, 2 x H-5), 2.31 (2H, t, J 5.8 Hz, 2 x H-3), 2.06 (2H,
t, J 5.6 Hz, 2 x H-4), 1.41 (3H, d, J 6.8 Hz, H-8); δC (100.6 MHz, CDCl3) 143.74 (ipso
Ar), 139.42 (C6), 128.18 & 127.85 (meta & ortho Ar), 126.87 (para Ar), 115.30 (C7),
64.60 (C1), 59.43 (-OCH3), 52.38 (C5), 51.14 (C2), 30.04 (C4), 25.53 (C3), 19.28 (C8);
m/z (ESI+) 232 [M+H]+, 128; Exact Mass Calcd for C15H22NO [M+H]
+requires m/z
232.16959 Found 232.16937 (ESI+)













1.6 N HCl (9 mL) was added to a solution of 408 (1.000 g, 4.33 mmol) in THF (9
mL) and stirred at 45 ◦C for 2.5 hours. THF was evaporated under reduced pressure
and the residue was diluted with water (20 mL). The pH was adjusted to 10 by the
addition of an aqueous Na2CO3 solution. The aqueous phase was extracted with DCM
(3 x 40 mL) and the combined organic layers were washed with brine and dried over
MgSO4. The solvent was removed under reduced pressure and crude aldehyde 409 was
obtained as a colourless oil (863 mg, 92%). The product could be used for the next step
without the need of further purification; [α]24D -71.8 (c 0.20, CHCl3); Rf 0.23 (1.5:1 ethyl
acetate:hexane); νmax (film) 1723, 1492, 1450, 1373, 1147, 1132, 941, 769, 758, 701; δH
(400 MHz, CDCl3) 9.62 (1H, s, H-5), 7.22-7.35 (5H, 5 x Ar-H), 3.45 (1H, q, J 6.7 Hz,
H-1), 2.93-2.96 (1H, m, 1 x H H-2), 2.73-2.79 (1H, m, 1 x H H-2), 2.15-2.22 (1H, m, H-4),
2.03-2.13 (2H, m, 2 x HH -2), 1.83-1.91 (2H, m, 2 x H H-3), 1.58-1.75 (2H, m, 2 x HH -3),
1.38 (3H, d, J 6.8 Hz, H-6); δC (100.6 MHz, CDCl3) 204.25 (C5), 143.56 (ipso Ar),
128.35 (meta Ar), 127.78 (ortho Ar), 127.10 (para Ar), 64.84 (C1), 49.75 (C2), 49.56
(C2’), 48.24 (C4), 25.75 (C3), 19.31 (C6); m/z (ESI+) 236 [M+H+H2O]
+, 218 [M+H]+,
132, 114, 105; Exact Mass Calcd for C14H20NO [M+H]
+requires m/z 218.15394 Found
218.15448 (ESI+).

























5,6-Dimethoxy-1-indanone (679 mg, 3.53 mmol, 1.0 equiv) was added to a solution of
409 (767 mg, 3.53 mmol, 1.0 equiv) in methanol (18 mL) and the system was put
under an atmosphere of nitrogen. The mixture was heated to 80 ◦C and a sodium
methoxide solution (28% in methanol, 740 µl, 4.24 mmol, 1.2 equiv) was added. Stirring
under reflux was continued for 75 min, then the reaction was allowed to cool to room
temperature. The solvent was evaporated under reduced pressure and purification by
column chromatography (100% ethyl acetate → ethyl acetate:methanol 19:1.5) afforded
product 410 (926 mg, 67%) as a white foamy solid; [α]23D -53.5 (c 0.35, CHCl3); mp
76-79 ◦C; Rf 0.26 (19:1.5 ethyl acetate:methanol); νmax (solid) 1693, 1648, 1605, 1587,
1499, 1453, 1424, 1303, 1253, 1216, 1126, 1075, 984, 802, 762, 731, 701; δH (400 MHz,
CDCl3) 7.22-7.34 (6H, m, 2 x meta Ar-H, 2 x ipso Ar-H, para Ar-H, H-8), 6.88 (1H,
s, H-5), 6.64 (1H, dt, J 9.5 Hz, 1.6 Hz, H-10), 3.96 (3H, s, H3CO-C6), 3.91 (3H, s,
H3CO-C7), 3.55 (2H, “d”, J 1.4 Hz, H-3), 3.46 (1H, q, J 6.6 Hz, H-14), 3.06-3.10 (1H,
m, 1 x H H-13), 2.84-2.89 (1H, m, 1 x H H-13), 2.22-2.32 (1H, m, H-11), 2.02-2.08 (1H,
m, 1 x HH -13), 1.93-1.98 (1H, m, 1 x HH -13), 1.50-1.74 (4H, m, 4 x H-12), 1.40 (3
H, J 6.8 Hz, H-15); δC (100.6 MHz, CDCl3) 192.70 (C1), 155.40 (C6), 149.60 (C7),
144.62 (C9), 143.36 (ipso Ar), 139.98 (C10), 135.70 (C4), 131.97 (C2), 128.28 (meta
Ar), 127.90 (ortho Ar), 127.05 (para Ar), 107.34 (C5), 105.13 (C8), 65.09 (C14), 56.35
& 56.25 (C6-OCH3 & C7-OCH3), 50.41 & 50.06 (C13 & C13’), 37.53 (C11), 31.49 (C12
& C12’), 29.60 (C3), 19.49 (C15); m/z (ESI+) 392 [M+H]+, 288; Exact Mass Calcd for
C25H30NO3 [M+H]
+requires m/z 392.2220 Found 392.2216 (NSI+); HPLC tR1= 14.1
min, tR2 16.9 min, tR3 31.2 min.
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3.2.1 Acetylcholinesterase Inhibition Assay
The inhibitory activity of compounds 380+381, 382+383, 384+385, 386+387,
401+402, 389-392 and 394-397 towards AChE (enzyme commission (EC) number
3.1.1.7, type VI-S from Electrophorus electricus (electric eel)) was measured using
a protocol based on Ellman’s reagent.125 The 96-well plate format of this assay, as
described by Mohamed,218 was further adjusted to result in the following protocol.
The control compound donepezil (Bertin Pharma, Cayman, France) and the test
compounds were dissolved in methanol to obtain stock solutions of 10 mM. 12
further dilutions were made of each compound using methanol, resulting in final assay
concentrations of 0.001-100 µM. To obtain a 1.5 mM solution, 29.73 mg 5,5’-dithiobis(2-
nitrobenzoic acid) (DTNB, Ellman’s reagent, Alfa Aesar) were dissolved in 50 mL of 50
mM tris(hydroxymethyl)aminomethane (TRIS)-HCl buffer (pH=8.0) containing 0.1 M
NaCl and 0.02 M MgCl2 · 6 H2O. A 259 U/mL stock solution of AChE in buffer (50 mM
TRIS-HCl, pH=8.0, 0.1% w/v bovine serum albumin (BSA)) was prepared and aliquots
of 21 µL were frozen in Eppendorf tubes and stored at -20 ◦C. Before running the assay,
one of these aliquots was diluted with buffer (50 mM TRIS-HCl, pH=8.0, 0.1% w/v BSA)
to obtain 25 mL of a solution with an enzyme concentration of 0.22 U/mL. A 15 mM
solution of acetylthiocholine iodide (ATCI, Sigma-Aldrich) was prepared by dissolving
108.45 mg in ultrapure water (25 mL). All these solutions were prepared freshly directly
before the assay was run.
In 96-well plates, 160 µL of the 1.5 mM DTNB solution were first added, followed
by 10 µL of the different concentrations of test compounds. Then the 0.22 U/mL
enzyme solution was added (50 µL) and incubated at room temperature for 7 min.
The background absorbance was measured at a wavelength of 412 nm on a POLARstar
OPTIMA (BMG Labtech) microplate reader. The addition of 30 µL of the 15 mM ATCI
solution initiated the enzymatic reaction and the time that passed between the beginning
of the pipetting and the first measurement (t=0) was noted and kept consistently at 2
min. Further kinetic measurements were made at different time intervals (t= 1, 2, 3, 4,
5 min) after a short episode of shaking (10 s).
Each experiment was carried out in triplicates. Various control incubations containing
10 µL methanol were run alongside the test compounds on each plate. The IC50 values
were calculated using GraphPad Prism software (version 6.01) applying a nonlinear
regression analysis (sigmoidal dose-response fit with a variable slope).
Chapter 4
Appendix
4.1 HPLC Chromatograms of Biologically Tested Donepezil
Analogues
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